_pmid,_doi,_publicationTitle,resourceName,resourceType,observationType,details,foundIn,contextSnippet,confidence
PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,129T2/SvEmsJ::C57Bl/6NTac Nf1+/+ and Nf1+/- mice,animal_model,Biomarker,"Nf1+/- mice (n=33) exhibited reduced dopamine transient frequency compared to Nf1+/+ littermates (n=19) (unpaired t-test; t50=3.06, p=0.004)",Results,"Peak analysis of baseline dLight1.2 recordings revealed that Nf1+/- mice (n = 33) exhibit reduced transient frequency (unpaired t-test; t50 = 3.06, p=0.004)",0.95
PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,129T2/SvEmsJ::C57Bl/6NTac Nf1+/+ and Nf1+/- mice,animal_model,Biomarker,"Nf1+/- putative dopaminergic neurons (n=18) showed lower spontaneous firing rates compared to Nf1+/+ neurons (n=12) (unpaired t-test; t28=2.58, p<0.05)",Results,"Spontaneous firing rates (right) were lower (unpaired t-test; t28 = 2.58, p=0.0w) in Nf1+/- putative dopaminergic neurons (n = 18) compared to Nf1+/+ neurons (n = 12)",0.95
PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,129T2/SvEmsJ::C57Bl/6NTac Nf1+/+ and Nf1+/- mice,animal_model,Biomarker,"Nf1+/- neurons (n=29) had increased rheobase (171.7±7.779 pA) compared to Nf1+/+ (n=21, 124.1±8.65 pA) (unpaired t-test; t48=4.05, p<0.001)",Results,"Rheobase (right; unpaired t-test; t48 = 4.05, p<0.001) but not action potential threshold was increased in Nf1+/- (n = 29) putative dopaminergic neurons compared to Nf1+/+ (n = 21)",0.95
PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,129T2/SvEmsJ::C57Bl/6NTac Nf1+/+ and Nf1+/- mice,animal_model,Biomarker,"Nf1+/- putative dopaminergic neurons (n=29) had increased input resistance (235.7±16.32 MΩ) and decreased capacitance (41.27±2.026 pF) compared to Nf1+/+ neurons (n=21, 172.4±10.94 MΩ, 47.35±2.032 pF)",Results,"Nf1+/- putative dopaminergic neurons (n = 29) had increased input resistance (Rm; left; unpaired t-test; t48 = 2.97, p=0.005) and decreased capacitance (Cm; right; t48 = 2.54, p=0.01)",0.95
PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,129T2/SvEmsJ::C57Bl/6NTac Nf1+/+ and Nf1+/- mice,animal_model,Biomarker,"VTA dopaminergic soma cross-sectional area was reduced in Nf1+/- mice (n=2586 somata) compared to Nf1+/+ (n=2344 somata) (two-sample Kolmogorov-Smirnov test; D=0.18, p<0.001)",Results,"The cumulative probability distribution of the cross sectional area of manually traced Nf1+/+ (n = 2344) and Nf1+/- (n = 2586) VTA dopaminergic neuron somata (two-sample Kolmogorov-Smirnov test; D = 0.18, p<0.001)",0.95
PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,129T2/SvEmsJ::C57Bl/6NTac Nf1+/+ and Nf1+/- mice,animal_model,Biomarker,"Nf1+/- putative dopaminergic neurons displayed increased sIPSC frequency but not sIPSC amplitude, sEPSC frequency, or sEPSC amplitude compared to Nf1+/+ neurons",Results,"Nf1+/- putative dopaminergic neurons displayed increased sIPSC frequency but not sIPSC amplitude, sEPSC frequency, or sEPSC amplitude compared to Nf1+/+ neurons",0.9
PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,129T2/SvEmsJ::C57Bl/6NTac Nf1+/+ and Nf1+/- mice,animal_model,Behavioral,"Nf1+/- mice exhibited larger dLight1.2 responses to CS presentation on first day of testing compared to Nf1+/+ littermates (unpaired t-test; t20=2.34, p=0.03)",Results,"Nf1+/- mice displayed enhanced dLight1.2 responses to CS presentation on the first day of testing (Figure 4J, inset) compared to Nf1+/+ littermates",0.9
PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,129T2/SvEmsJ::C57Bl/6NTac Nf1+/+ and Nf1+/- mice,animal_model,Behavioral,Nf1+/- mice had greater peak responses to light (p<0.001) but not tone onset (p>0.99) compared to Nf1+/+ mice (n=10 each group),Results,"Nf1+/- mice had greater peak responses to light (p<0.001) but not tone onset (p>0.99) compared to Nf1+/+ mice (n+/+ = 10, n+/- = 10)",0.95
PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,Nf1 f/neo ; hGFAP-Cre mice,animal_model,Efficacy,"All Nf1 f/neo ; hGFAP-Cre mice developed OPGs (6/6) with increased optic nerve volumes (0.079 mm³), proliferative indices (5.9% Ki67+ cells), microglia (11.8% Iba1+ cells), and T cells (7 CD3+ cells)",Results,all Nf1 f/neo ; hGFAP-Cre mice (Nf1-OPG)...developed OPGs (6/6) with increased optic nerve volumes (0.079 mm³)...proliferative indices (5.9% Ki67+ cells),0.95
PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,Nf1 flox/flox ; Hoxb7-Cre mice,animal_model,Efficacy,Nf1 f/f ; Hoxb7-Cre mice developed pNFs (7/13) and exhibited enlarged DRGs,Results,"Nf1 f/neo ; Hoxb7-Cre mice (11/16), and Nf1 f/f ; Hoxb7-Cre mice (7/13), Nf1 f/1809 ; Hoxb7-Cre mice did not develop pNFs",0.9
PMID:28465357,10.1101/gad.298703.117,Identification of hair shaft progenitors that create a niche for hair pigmentation.,DhhCre,genetic_reagent,Efficacy,"Scf(flox/gfp);DhhCre mice showed no hair color changes for up to 6 months (n=8), demonstrating hair pigmentation does not depend on SCF expression in Schwann cells",Results,"In mice lacking SCF in Schwann cells (Scf flox/gfp;DhhCre), we did not observe any hair color changes for up to 6 mo (Fig. 2 A). n = 8.",0.9
PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,MCF7,cell_line,Efficacy,NF1-deficient MCF7 cells (NF1-45) proliferate faster in 2D culture compared to NF1-WT controls,Results,"Compared to NF1-WT controls (NF1-EV and Nf1-WT), NF1-deficient cells proliferate faster in 2D",0.85
PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,MCF7,cell_line,Efficacy,"NF1-45 MCF7 cells developed larger 3D spherical colonies compared to NF1-EV control, indicating greater tumor potential",Results,"When compared to the NF1-EV control, NF1-45 developed larger 3D spherical colonies, indicating greater tumor potential",0.85
PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,MCF7,cell_line,Biomarker,NF1 deficiency in MCF7 cells resulted in decreased expression of the neurofibromin 250 kDa isoform,Results,"In the MCF7 cells, NF1 deficiency resulted in decreased expression of the neurofibromin 250 kDa isoform",0.9
PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,MCF7,cell_line,Biomarker,NF1-45 MCF7 cells had decreased active and total ERα activation at baseline and following estradiol stimulation,Results,we saw that NF1-45 cells had decreased active and total ERα activation at baseline and following estradiol (E2) stimulation,0.9
PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,MCF7,cell_line,Biomarker,"NF1 deficiency in MCF7 cells dramatically increased active T202/Y204-phosphorylated ERK, indicative of increased RAS-pathway signaling",Results,"we found that NF1 deficiency dramatically increased active T202/Y204-phosphorylated ERK, which is indicative of increased RAS-pathway signaling",0.9
PMID:20200958,10.1002/jbmr.42,Local low-dose lovastatin delivery improves the bone-healing defect caused by Nf1 loss of function in osteoblasts.,Nf1 flox/flox calvaria osteoblasts,cell_line,Mechanistic,Increased ERK1/2 phosphorylation following cre-recombinase adenovirus infection,Results,"Following cre-recombinase adrenovirus infection, ERK1/2 phosphorylation status was increased compared with GFP mock-transfected controls, indicating effective adenovirus-mediated recombination...",0.9
PMID:20200958,10.1002/jbmr.42,Local low-dose lovastatin delivery improves the bone-healing defect caused by Nf1 loss of function in osteoblasts.,Nf1 flox/flox calvaria osteoblasts,cell_line,Efficacy,Lovastatin treatment (20 µM for 12 hours) consistently decreased ERK1/2 activation in Nf1−/− osteoblasts,Results,Lovastatin treatment (20 µM for 12 hours) consistently decreased ERK1/2 activation in Nf1−/− osteoblasts compared with vehicle-treated controls.,0.95
PMID:20200958,10.1002/jbmr.42,Local low-dose lovastatin delivery improves the bone-healing defect caused by Nf1 loss of function in osteoblasts.,2.3-kb α1(I) collagen-cre Nf1 flox/flox mice,animal_model,Safety,No differences in body weight observed between groups at study endpoint,Results,"...animals were able to ambulate and thrive adequately, and no differences in body weight were observed between groups at the endpoint of the study...",0.9
PMID:38201517,10.3390/cancers16010089,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.,S462TY,cell_line,Efficacy,"Colony formation suppressed by prodrug FTIs 1 and 2 at ≥0.3 μM, with effects greatly enhanced by combinational treatment with lovastatin",Results,"Both prodrugs, in the absence of lovastatin, suppressed colony formation by the NF1 MPNST cell line S462TY when used at ≥0.3 μM...the suppressive effects of the two FTIs were greatly enhanced by combinational treatment with lovastatin",0.95
PMID:38201517,10.3390/cancers16010089,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.,S462TY,cell_line,Efficacy,"IG2 showed no effect on colony formation up to 7 μM alone, but potentiation observed with concentrations as low as 0.5 μM when co-treated with lovastatin",Results,"By itself, IG 2 had no effect on S462TY colony formation up to 7 μM...Co-treatment with lovastatin markedly enhanced IG 2 suppression of colony formation. This potentiation was observed with concentrations of IG 2 as low as 0.5 μM",0.95
PMID:38201517,10.3390/cancers16010089,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.,S462TY,cell_line,Efficacy,Concentrations of lovastatin as low as 250 nM reproducibly enhanced IG2 suppression of colony formation,Results,Concentrations of lovastatin as low as 250 nM reproducibly enhanced IG 2 suppression of colony formation,0.95
PMID:38201517,10.3390/cancers16010089,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.,S462TY,cell_line,Efficacy,"Lovastatin (0.5 μM) and IG2 (5 μM) had only minor effects on proliferation or viability individually, but co-treatment resulted in concentration-dependent decreases in cell number",Results,"Lovastatin and IG 2 at concentrations of 0.5 μM and 5 μM, respectively, had only minor effects on proliferation or viability...However, co-treatment with 0.5 μM lovastatin and varied concentrations of IG 2 resulted in concentration-dependent decreases in cell number",0.95
PMID:38201517,10.3390/cancers16010089,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.,S462TY,cell_line,Mechanistic,Combining IG2 with concentrations of lovastatin as low as 0.1 μM caused concentration-dependent activation of DEVDase (procaspase-3/7 activation),Results,"However, combining IG 2 with concentrations of lovastatin as low as 0.1 μM caused a concentration-dependent activation of DEVDase that paralleled reductions in colony formation",0.95
PMID:38201517,10.3390/cancers16010089,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.,S462TY,cell_line,Efficacy,Synergy observed at all 4 concentrations of IG2 with each of the 3 lovastatin concentrations in MTT assay,Results,Synergy was observed at all 4 concentrations of IG 2 with each of the 3 lovastatin concentrations,0.95
PMID:38201517,10.3390/cancers16010089,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.,S462TY,cell_line,Mechanistic,"5 μM IG2 accumulated non-prenylated RAB5A and RAP1A within 4 h of treatment, while 0.5 or 1.0 μM had no effect",Results,Cultures exposed to 5 μM of IG 2 (but not 0.5 or 1.0 μM) accumulated non-prenylated RAB5A...and non-prenylated RAP1A...These accumulations occurred within 4 h of treatment,0.95
PMID:38201517,10.3390/cancers16010089,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.,S462TY,cell_line,Mechanistic,"0.25 μM lovastatin caused accumulation of non-prenylated RAB5A within 4 h, with 0.5 μM accelerating accumulation and also stimulating non-prenylated RAP1A",Results,Accumulations of non-prenylated RAB5A were also observed within 4 h of treatment with 0.25 μM of lovastatin...Treatment with a higher concentration of lovastatin (0.5 μM) accelerated the accumulation...also stimulated the accumulation of non-prenylated RAP1A,0.95
PMID:38201517,10.3390/cancers16010089,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.,S462TY,cell_line,Mechanistic,"Co-treatment with 0.25 μM lovastatin and 1.0 μM IG2 caused dramatic accumulations of non-prenylated N-RAS within 4 h, while neither agent alone affected N-RAS prenylation at these concentrations",Results,"when S462TY cultures were co-treated with concentrations of lovastatin (0.25 μM) and IG 2 (1.0 μM) that singularly had no effect on N-RAS prenylation, dramatic accumulations of non-prenylated RAS were observed within 4 h of co-treatment",0.95
PMID:38201517,10.3390/cancers16010089,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.,ST88-14,cell_line,Efficacy,Co-treatment with concentrations of lovastatin or IG2 that had little to no effect individually resulted in cooperative inhibition of colony formation,Results,Co-treatment of ST88-14 cells with concentrations of lovastatin or IG 2 that had little to no effect individually resulted in a cooperative inhibition of colony formation,0.9
PMID:38201517,10.3390/cancers16010089,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.,ST88-14,cell_line,Efficacy,"MTT assays showed cooperative inhibition of growth/viability by lovastatin plus IG2 co-treatment, with synergistic interaction confirmed by CI versus Fa plots",Results,MTT assays also show a cooperative inhibition of growth/viability by lovastatin plus IG 2 co-treatment...CI versus Fa plots of MTT-derived data indicated that lovastatin and IG 2 worked synergistically,0.95
PMID:38201517,10.3390/cancers16010089,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.,iSC,cell_line,Efficacy,"Neither 0.5 μM lovastatin nor concentrations of IG2 up to 5 μM affected colony formation, and no synergistic suppression observed with co-treatment",Results,Neither 0.5 μM of lovastatin nor concentrations of IG 2 up to 5 μM affected iSC colony formation...we observed no synergistic suppression of iSC colony formation following co-treatment with lovastatin and IG 2,0.95
PMID:38201517,10.3390/cancers16010089,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.,MCF10A,cell_line,Efficacy,"Concentrations of IG2 could be reached that were cytostatic/cytotoxic in MTT assay, but co-treatment with lovastatin did not enhance the effects",Results,although concentrations of IG 2 could be reached that were cytostatic/cytotoxic (as scored in an MTT assay) to cultures of normal human breast MCF10A epithelial cells...co-treatment with lovastatin did not enhance the effects of IG 2,0.9
PMID:38201517,10.3390/cancers16010089,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.,A549,cell_line,Efficacy,"Lovastatin strongly synergized with IG2 to suppress growth of A549 cells, a non-small cell lung carcinoma cell line with mutated K-Ras",Discussion,"in a preclinical study, we found that lovastatin strongly synergized with IG 2 to suppress the growth of A549 cells, a non-small cell lung carcinoma cell line with mutated K-Ras as a driver",0.9
PMID:32781282,10.1016/j.trsl.2020.08.001,Nf1 heterozygous mice recapitulate the anthropometric and metabolic features of human neurofibromatosis type 1.,Nf1+/- mice,animal_model,Biomarker,Percent fat mass significantly reduced and lean mass modestly increased compared to WT mice,Results,The percent fat mass is significantly reduced and lean mass is modestly increased in Nf1 +/− mice when compared with littermate WT mice,0.9
PMID:32781282,10.1016/j.trsl.2020.08.001,Nf1 heterozygous mice recapitulate the anthropometric and metabolic features of human neurofibromatosis type 1.,Nf1+/- mice,animal_model,Behavioral,Less active than WT mice despite consuming similar quantities of food and water,Results,"Interestingly, Nf1 +/− mice were less active than WT mice despite consuming similar quantities of food and water",0.9
PMID:32781282,10.1016/j.trsl.2020.08.001,Nf1 heterozygous mice recapitulate the anthropometric and metabolic features of human neurofibromatosis type 1.,Nf1+/- mice,animal_model,Biomarker,Heat production lower compared to WT mice,Results,"Further, heat production, a metabolic side product, was lower in Nf1 +/− mice when compared with WT mice",0.9
PMID:32781282,10.1016/j.trsl.2020.08.001,Nf1 heterozygous mice recapitulate the anthropometric and metabolic features of human neurofibromatosis type 1.,Nf1+/- mice,animal_model,Biomarker,Consumed significantly less oxygen than WT mice while CO2 production was similar,Results,Nf1 +/− mice consumed significantly less oxygen than WT mice while CO 2 production was similar between genotypes,0.9
PMID:32781282,10.1016/j.trsl.2020.08.001,Nf1 heterozygous mice recapitulate the anthropometric and metabolic features of human neurofibromatosis type 1.,Nf1+/- mice,animal_model,Biomarker,"RER significantly higher than WT mice, suggesting more dependence on carbohydrates rather than fatty acids as fuel source",Results,The RER for Nf1 +/− mice is significantly higher than WT mice and suggests that Nf1 +/− mice are more dependent on carbohydrates rather than fatty acids as a fuel source,0.9
PMID:32781282,10.1016/j.trsl.2020.08.001,Nf1 heterozygous mice recapitulate the anthropometric and metabolic features of human neurofibromatosis type 1.,Nf1+/- mice,animal_model,Biomarker,Visceral fat mass reduced nearly 3-fold compared to WT mice,Results,"In comparison to WT mice, visceral fat mass was reduced nearly 3-fold in littermate Nf1 +/− mice",0.9
PMID:32781282,10.1016/j.trsl.2020.08.001,Nf1 heterozygous mice recapitulate the anthropometric and metabolic features of human neurofibromatosis type 1.,Nf1+/- mice,animal_model,Biomarker,Increased adipocyte density but reduced cross-sectional area in visceral fat depots compared to WT mice,Results,"Quantification of hematoxylin and eosin-stained visceral fat depots identified increased density, but reduced cross-sectional area for adipocytes isolated from Nf1 +/− mice",0.9
PMID:32781282,10.1016/j.trsl.2020.08.001,Nf1 heterozygous mice recapitulate the anthropometric and metabolic features of human neurofibromatosis type 1.,Nf1+/- mice,animal_model,Biomarker,Cell density in subcutaneous fat increased over two-fold while cross-sectional area reduced two-fold compared to WT mice,Results,the cell density in subcutaneous fat depots from Nf1 +/− mice was increased over two-fold while cross-sectional area was reduced two-fold when compared with WT mice,0.9
PMID:32781282,10.1016/j.trsl.2020.08.001,Nf1 heterozygous mice recapitulate the anthropometric and metabolic features of human neurofibromatosis type 1.,Nf1+/- mice,animal_model,Biomarker,"Brown adipose mass reduced (4.1 ± 1.6 mg/g vs. 7.1 ± 1.7 mg/g, p = 0.006) compared to WT mice",Results,"Brown adipose mass was also reduced in Nf1 +/− mice when compared with WT mice (4.1 ± 1.6 mg/g vs. 7.1 ± 1.7 mg/g, p = 0.006)",0.9
PMID:32781282,10.1016/j.trsl.2020.08.001,Nf1 heterozygous mice recapitulate the anthropometric and metabolic features of human neurofibromatosis type 1.,Nf1+/- mice,animal_model,Biomarker,Lipid deposition significantly reduced in livers but nearly 3-fold higher in skeletal muscle compared to WT mice,Results,Lipid deposition was significantly reduced in livers isolated from Nf1 +/− mice but lipid content was nearly 3-fold higher in skeletal muscle from Nf1 +/− mice,0.9
PMID:32781282,10.1016/j.trsl.2020.08.001,Nf1 heterozygous mice recapitulate the anthropometric and metabolic features of human neurofibromatosis type 1.,Nf1+/- mice,animal_model,Biomarker,"HDL concentration significantly increased, triglyceride levels increased, LDL reduced nearly 2-fold compared to WT mice",Results,"High-density lipoprotein (HDL) concentration was significantly increased as was triglyceride levels, while low-density lipoprotein (LDL) was reduced nearly 2-fold in Nf1 +/− mice",0.9
PMID:32781282,10.1016/j.trsl.2020.08.001,Nf1 heterozygous mice recapitulate the anthropometric and metabolic features of human neurofibromatosis type 1.,Nf1+/- mice,animal_model,Biomarker,Total cholesterol-to-HDL ratio reduced compared to WT mice,Results,The total cholesterol-to-HDL ratio was also reduced in Nf1 +/− mice when compared with WT mice,0.9
PMID:32781282,10.1016/j.trsl.2020.08.001,Nf1 heterozygous mice recapitulate the anthropometric and metabolic features of human neurofibromatosis type 1.,Nf1+/- mice,animal_model,Biomarker,Significantly lower circulating leptin levels compared to WT mice,Results,"Similar to persons with NF1, Nf1 +/− mice have significantly lower circulating leptin levels when compared with littermate WT mice",0.9
PMID:32781282,10.1016/j.trsl.2020.08.001,Nf1 heterozygous mice recapitulate the anthropometric and metabolic features of human neurofibromatosis type 1.,Nf1+/- mice,animal_model,Biomarker,HgbA1c modestly lower (4.45% ± 0.15% vs. 4.62% ± 0.13%; p = 0.02) compared to WT mice,Results,"Initial blood glucose values after the 24 hour fast did not differ between groups, but HgbA1c was modestly lower in Nf1 +/− mice (4.62% ± 0.13% vs. 4.45% ± 0.15%; p -value = 0.02)",0.9
PMID:32781282,10.1016/j.trsl.2020.08.001,Nf1 heterozygous mice recapitulate the anthropometric and metabolic features of human neurofibromatosis type 1.,Nf1+/- mice,animal_model,Biomarker,Lower peak blood glucose values and recovered more quickly in glucose tolerance test compared to WT mice,Results,"In response to a glucose load, Nf1 +/− mice had lower peak blood glucose values and recovered more quickly when compared with WT mice",0.9
PMID:32781282,10.1016/j.trsl.2020.08.001,Nf1 heterozygous mice recapitulate the anthropometric and metabolic features of human neurofibromatosis type 1.,Nf1+/- mice,animal_model,Biomarker,Dramatically lower starting blood glucose concentrations after 5-hour fast and slower recovery period from 45-90 minutes in insulin tolerance test,Results,"after a brief fast of 5 hours, Nf1 +/− mice had dramatically lower starting blood glucose concentrations when compared to WT mice...Nf1 +/− mice exhibited a much slower recovery period from 45–90 minutes",0.9
PMID:32781282,10.1016/j.trsl.2020.08.001,Nf1 heterozygous mice recapitulate the anthropometric and metabolic features of human neurofibromatosis type 1.,Nf1+/- mice,animal_model,Safety,30% increase in body weight vs. 50% increase in WT mice on high-glucose diet for 16 weeks,Results,WT mice had gained an average of 50% increase in body weight as compared to an average of 30% increase in body weight for the Nf1 +/− cohort,0.9
PMID:32781282,10.1016/j.trsl.2020.08.001,Nf1 heterozygous mice recapitulate the anthropometric and metabolic features of human neurofibromatosis type 1.,Nf1+/- mice,animal_model,Biomarker,"Did not develop hyperglycemia after 16 weeks of 30% glucose drinking water, had nearly identical blood glucose values at beginning and end",Results,"Strikingly, Nf1 +/− mice did not develop hyperglycemia after 16 weeks of a 30% glucose drinking water solution and had nearly identical blood glucose values at the beginning and end of the study",0.9
PMID:38811427,10.1186/s41687-024-00732-w,Quality of life in individuals with neurofibromatosis type 1 associated cutaneous neurofibromas: validation of the Dutch cNF-Skindex.,cNF-Skindex,clinical_assessment_tool,Behavioral,Mean total cNF-Skindex score was 40.7 (SD 27.1) with median 36.0 (IQR 15.0-65.0) and score range 3-94,Results,"The mean total cNF-Skindex score was 40.7 (Table 2). Nine participants had a total cNF-Skindex score that placed them in severity stratum 1 (nonbothersome cNF, 15%), 28 were in stratum 2 (moderately bothersome cNF, 48%) and 22 patients were in stratum 3 (very bothersome cNF, 37%).",0.95
PMID:38811427,10.1186/s41687-024-00732-w,Quality of life in individuals with neurofibromatosis type 1 associated cutaneous neurofibromas: validation of the Dutch cNF-Skindex.,cNF-Skindex,clinical_assessment_tool,Other,"High internal consistency with Cronbach's alpha above 0.90 for total score (0.96) and all subdomains (Functioning: 0.93, Emotions: 0.93, Symptoms: 0.91)",Results,"The Cronbach's alpha of the total score and the subdomains were all above 0.90, indicating high internal consistency.",0.95
PMID:38811427,10.1186/s41687-024-00732-w,Quality of life in individuals with neurofibromatosis type 1 associated cutaneous neurofibromas: validation of the Dutch cNF-Skindex.,cNF-Skindex,clinical_assessment_tool,Other,"Adequate test-retest reliability with Spearman's correlation r=0.88 for total score, r=0.89 for Functioning, r=0.83 for Emotions, and r=0.85 for Symptoms (all p<0.001)",Results,"Adequate test-retest reliability was observed for both the total cNF-Skindex score (Spearman's correlation r = 0.88), the 'Functioning' subdomain (r = 0.89), 'Emotions' subdomain (r = 0.83), and 'Symptoms' subdomain (r = 0.85), with all p-values < 0.001.",0.95
PMID:38811427,10.1186/s41687-024-00732-w,Quality of life in individuals with neurofibromatosis type 1 associated cutaneous neurofibromas: validation of the Dutch cNF-Skindex.,cNF-Skindex,clinical_assessment_tool,Other,"Significant differences in scores between participants with ≤50 cNF vs >50 cNF (27.9 vs 45.4, p=0.017) and between those with vs without cNF-related intervention (30.5 vs 47.7, p=0.026)",Results,"For known-group validity, significant differences in cNF-Skindex scores were observed between participants with ≤ 50 cNF or more than 50 cNF, as well as for participants who had and who had not received a cNF-related intervention",0.95
PMID:30617350,10.1038/s41596-018-0105-7,"A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma.",murine NF2 −/− Schwann cell line,cell_line,Efficacy,Tumors are expected to grow and mice become moribund in 3-5 weeks following implantation,Results,Tumors are expected to grow and mice are expected to become moribund in 3–5 weeks,0.8
PMID:35741605,10.3390/brainsci12060720,Integrated Drug Mining Reveals Actionable Strategies Inhibiting Plexiform Neurofibromas.,ipNF05.5 (mixed clone),cell_line,Other,Used in drug screening with transcriptome data downloaded through NF Data Portal for network module analysis,Results,The transcriptomes of cell lines used in the drug screening and the untreated surgically-resected primary PN from Jessen et al. were downloaded through the NF Data Portal,0.8
PMID:35741605,10.3390/brainsci12060720,Integrated Drug Mining Reveals Actionable Strategies Inhibiting Plexiform Neurofibromas.,ipNF05.5 (single clone),cell_line,Other,Used in drug screening with transcriptome data downloaded through NF Data Portal for network module analysis,Results,The transcriptomes of cell lines used in the drug screening and the untreated surgically-resected primary PN from Jessen et al. were downloaded through the NF Data Portal,0.8
PMID:35741605,10.3390/brainsci12060720,Integrated Drug Mining Reveals Actionable Strategies Inhibiting Plexiform Neurofibromas.,ipNF95.11bC,cell_line,Other,Used in drug screening with transcriptome data downloaded through NF Data Portal for network module analysis,Results,The transcriptomes of cell lines used in the drug screening and the untreated surgically-resected primary PN from Jessen et al. were downloaded through the NF Data Portal,0.8
PMID:35741605,10.3390/brainsci12060720,Integrated Drug Mining Reveals Actionable Strategies Inhibiting Plexiform Neurofibromas.,ipNF95.6,cell_line,Other,Used in drug screening with transcriptome data downloaded through NF Data Portal for network module analysis,Results,The transcriptomes of cell lines used in the drug screening and the untreated surgically-resected primary PN from Jessen et al. were downloaded through the NF Data Portal,0.8
PMID:35741605,10.3390/brainsci12060720,Integrated Drug Mining Reveals Actionable Strategies Inhibiting Plexiform Neurofibromas.,ipnNF95.11c,cell_line,Other,Used in drug screening with transcriptome data downloaded through NF Data Portal for network module analysis,Results,The transcriptomes of cell lines used in the drug screening and the untreated surgically-resected primary PN from Jessen et al. were downloaded through the NF Data Portal,0.8
PMID:24595234,10.1371/journal.pone.0090853,In vivo functional analysis of the human NF2 tumor suppressor gene in Drosophila.,y w Mer4,animal_model,Mechanistic,Hemizygous null allele severely truncates the Merlin protein and causes lethality that can be rescued by NF2 transgenes,Results,"Ability to rescue was tested using ubiquitous expression via the Gal4/UAS system in animals hemizygous for the Mer4 null allele, which severely truncates the Merlin protein",0.9
PMID:24595234,10.1371/journal.pone.0090853,In vivo functional analysis of the human NF2 tumor suppressor gene in Drosophila.,4/FM7; T80-Gal4 y w Mer4,animal_model,Efficacy,NF2 Iso1 provided 59±7% rescue at 1 dose and 72% rescue at 2 doses; NF2 Iso2 provided 8±4% rescue at 1 dose and 0% rescue at 2 doses,Results,"expression of a transgene expressing NF2Iso1 using the ubiquitously expressed T80 Gal4 driver substantially rescued the lethality of the null Mer4 allele, while NF2Iso2 provided very poor rescue",0.95
PMID:30479396,10.1038/s41467-018-07452-y,NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation.,PLP CreERT2; Nf1 f/−; ROSA-LacZ mice,animal_model,Efficacy,74% of PLP CreERT2; Nf1 f/− mice developed pNF at one year vs 29% of PLP CreERT2; Nf1 f/f mice,Results,"At one year of age, the majority of PLP CreERT2; Nf1 f/− (77 out of 104, 74%) mice already developed pNF and showed the clinical signs of pNF, whereas only a minority of PLP CreERT2; Nf1 f/f (32 out of 112, 29%) mice did",0.95
PMID:30479396,10.1038/s41467-018-07452-y,NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation.,PLP CreERT2; Nf1 f/−; ROSA-LacZ mice,animal_model,Efficacy,0% of PLP CreERT2; Nf1 f/− mice developed MPNST vs 10% of PLP CreERT2; Nf1 f/f mice (exact Fischer test value = 0.001),Results,"no MPNST developed in PLP CreERT2; Nf1 f/− mice (0 out of 104, 0%), whereas all MPNST observed arose from PLP CreERT2; Nf1 f/f mice (10%, 11 out of 112) (exact Fischer test value = 0.001)",0.95
PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,Nf1flox/flox,animal_model,Efficacy,"Nf1 inactivation resulted in ≥2-fold increase in proliferation of astroglial cells from CB, BS and ON, but no increase in CTX astroglial cells",Results,"Using [3H]-thymidine incorporation, Nf1 inactivation resulted in ≥2-fold increase in proliferation of astroglial cells from CB, BS and ON. In contrast, no increase in proliferation was observed following Nf1 inactivation in CTX astroglial cells",0.95
PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,Nf1GFAP CKO,animal_model,Efficacy,"Nearly 2-fold increase in GFAP+ cells in BS and significant increase in CB, with 50% increase in NG2 staining in optic nerves, but no effect in CTX",Results,"Whereas there was no effect of Nf1 loss on the number of GFAP+ cells in the CTX, we observed nearly a 2-fold increase in the number of GFAP+ cells in the BS...we detected a 50% increase in NG2 staining in the Nf1GFAP CKO mouse optic nerves",0.95
PMID:29402968,10.1038/s41598-018-20894-0,Integrating Functional Analysis in the Next-Generation Sequencing Diagnostic Pipeline of RASopathies.,HEK-293T cells,cell_line,Mechanistic,Successfully demonstrated that RAF1:p.R391S and RIT1:p.D87H significantly increased pELK1 expression compared with WT transcripts,Results,Both RAF1:p.R391S and RIT1:p.D87H significantly increased pELK1 expression compared with the WT transcripts,0.92
PMID:29402968,10.1038/s41598-018-20894-0,Integrating Functional Analysis in the Next-Generation Sequencing Diagnostic Pipeline of RASopathies.,HEK-293T cells,cell_line,Mechanistic,A2ML1 mutations did not produce significant fold change in pELK1 levels in vitro,Results,"In contrast, the two A2ML1 mutations did not produce a significant fold change in pELK1 levels in vitro",0.9
PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,HEK 293T,cell_line,Mechanistic,Used for secondary screen with RFP-fused bait proteins cotransfected with Merlin-NanoLuc to test protein interactions,Results,We therefore designed a secondary screen in which bait proteins fused to red fluorescent protein (RFP) were cotransfected into HEK 293T cells with a probe consisting of Merlin fused to NanoLuc (NLuc),0.95
PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,HEK 293T,cell_line,Mechanistic,"Cotransfection experiments confirmed complex formation with Merlin for 7 of 10 proteins tested, with Angiomotin showing highest apparent affinity (~100-fold greater than negative control)",Results,"Cotransfection experiments in HEK 293T cells confirmed complex formation with Merlin for 7 of 10 proteins tested: Angiomotin α-actinin, afadin, ASPP2, Lats1, myosin IIB, Scrib, and ZO-1. Angiomotin interacted with the highest apparent affinity (~100-fold greater than the negative control)",0.95
PMID:40225167,10.1155/2023/9628049,Functional Assays Combined with Pre-mRNA-Splicing Analysis Improve Variant Classification and Diagnostics for Individuals with Neurofibromatosis Type 1 and Legius Syndrome.,HEK 293T,cell_line,Mechanistic,"Used for transfection experiments to assess NF RAS GAP activity, with expression dependent on amount of NF expression construct used",Results,...the NF signal and the estimated RAS GAP activity were dependent on the amount of NF expression construct used in the transfection experiments...,0.8
PMID:40225167,10.1155/2023/9628049,Functional Assays Combined with Pre-mRNA-Splicing Analysis Improve Variant Classification and Diagnostics for Individuals with Neurofibromatosis Type 1 and Legius Syndrome.,HEK 293T,cell_line,Mechanistic,"Under standard assay conditions, WT NF expression was sufficient to increase RAS GAP activity >5-fold compared to cells not expressing any exogenous NF",Results,...the expression of WT NF was sufficient to increase RAS GAP activity >5-fold compared to cells not expressing any exogenous NF...,0.9
PMID:23225063,10.1002/ana.23793,Dopamine deficiency underlies learning deficits in neurofibromatosis-1 mice.,Nf1 +/− GFAP CKO,animal_model,Biomarker,20% reduction in hippocampal dopamine levels compared to control mice,Results,direct measurements of hippocampal dopamine levels ( Fig. 1B ) and DARPP32 phosphorylation ( Fig. 1D ) reveal a 20% and 61% reduction in CKO mice relative to control mice,0.95
PMID:23225063,10.1002/ana.23793,Dopamine deficiency underlies learning deficits in neurofibromatosis-1 mice.,Nf1 +/− GFAP CKO,animal_model,Biomarker,61% reduction in DARPP32 phosphorylation compared to control mice,Results,direct measurements of hippocampal dopamine levels ( Fig. 1B ) and DARPP32 phosphorylation ( Fig. 1D ) reveal a 20% and 61% reduction in CKO mice relative to control mice,0.95
PMID:23225063,10.1002/ana.23793,Dopamine deficiency underlies learning deficits in neurofibromatosis-1 mice.,Nf1 +/− GFAP CKO,animal_model,Biomarker,Reduced tyrosine hydroxylase (TH) expression in the VTA compared to littermate controls,Results,we now show that tyrosine hydroxylase (TH) expression ( 5 Fig. 1A ) is also reduced in the VTA compared to littermate controls,0.9
PMID:23225063,10.1002/ana.23793,Dopamine deficiency underlies learning deficits in neurofibromatosis-1 mice.,Nf1 +/− GFAP CKO,animal_model,Behavioral,Diminished LTP with EPSP slope of 128.8±7.6% (n=8) compared to 165.2±6.8% (n=8) in controls,Results,"CKO slices display diminished LTP (closed circles, EPSP slope; 128.8+ 7.6%, n=8) in response to high frequency stimulation (HFS) (open circles, EPSP slope; 165.2 + 6.8%, n=8)",0.95
PMID:23225063,10.1002/ana.23793,Dopamine deficiency underlies learning deficits in neurofibromatosis-1 mice.,Nf1 +/− GFAP CKO,animal_model,Efficacy,"LTP defects rescued by 10 µM SKF38393 treatment, restoring EPSP slope to 158.5±7.7% (n=8, p<0.01 vs. untreated)",Results,"10 µM SKF38393 restored normal LTP in CKO slices ( Fig. 2C , circles, 158.5+7.7%, n=8, p<0.01 vs. untreated)",0.95
PMID:23225063,10.1002/ana.23793,Dopamine deficiency underlies learning deficits in neurofibromatosis-1 mice.,Nf1 +/− GFAP CKO,animal_model,Efficacy,"L-DOPA treatment ameliorated post-acquisition probe trial deficits, with treated mice showing control-like performance levels",Results,L-DOPA treatment ameliorated post-acquisition probe trial deficits (probe trial 2) in CKO mice...L-DOPA-treated CKO mice demonstrate control-like performance levels,0.9
PMID:23225063,10.1002/ana.23793,Dopamine deficiency underlies learning deficits in neurofibromatosis-1 mice.,Nf1 +/− GFAP CKO,animal_model,Biomarker,Reduced cAMP levels and increased Ras/ERK activity in hippocampal tissue relative to littermate controls,Results,CKO mice exhibit reduced cAMP ( Fig. 3A ) and increased Ras/ERK activity ( Fig. 3B ) relative to littermate controls,0.9
PMID:23225063,10.1002/ana.23793,Dopamine deficiency underlies learning deficits in neurofibromatosis-1 mice.,Nf1 +/− GFAP CKO,animal_model,Efficacy,L-DOPA treatment increased cAMP levels and DARPP32 phosphorylation in hippocampus but had no effect on Ras/ERK activity,Results,"systemic L-DOPA treatment (sufficient to rescue the behavioral and learning deficits) increased cAMP levels ( Fig. 3A ) and DARPP32 phosphorylation ( Fig. 3B ) in the hippocampus, but had no effect on Ras/ERK activity",0.9
PMID:23225063,10.1002/ana.23793,Dopamine deficiency underlies learning deficits in neurofibromatosis-1 mice.,Nf1 +/− GFAP CKO,animal_model,Mechanistic,Hippocampal neurons have shorter processes and reduced neuronal arborization compared to littermate counterparts,Results,neurons in the hippocampus of CKO mice have shorter processes and reduced neuronal arborization compared to their littermate counterparts,0.9
PMID:23225063,10.1002/ana.23793,Dopamine deficiency underlies learning deficits in neurofibromatosis-1 mice.,Nf1 +/− GFAP CKO,animal_model,Efficacy,"Attention deficits rescued by treatments that elevate dopamine levels, but not by Lovastatin (to inhibit Ras hyperactivation)",Discussion,"the attention deficits in Nf1 +/− GFAP CKO mice are rescued by treatments that elevate dopamine levels, but not by Lovastatin (to inhibit Ras hyperactivation)",0.9
PMID:21199799,10.1158/0008-5472.CAN-10-2732,Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice.,Nf1+/- mice,animal_model,Safety,"Survival was reduced compared to WT littermates (p=0.02, logrank test) with deaths occurring after one year of age",Results,"the survival of unirradiated Nf1+/− mice was reduced compared to WT littermates (p=0.02, logrank test) with deaths occurring after one year of age",0.95
PMID:21199799,10.1158/0008-5472.CAN-10-2732,Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice.,Nf1+/- mice,animal_model,Safety,"Cranial irradiation significantly decreased survival (p=0.05, logrank test) with median post-treatment survival of 503 days versus 596 days in WT mice",Results,"CI significantly decreased the survival of both WT (p=0.002, logrank test) and Nf1+/− (p=0.05, logrank test) mice...median post-treatment survival time was reduced in irradiated Nf1+/− mice compared to irradiated WT mice (503 versus 596 days; p =0.04)",0.95
PMID:21199799,10.1158/0008-5472.CAN-10-2732,Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice.,Nf1+/- mice,animal_model,Efficacy,"More likely than WT mice to develop hematologic malignancies (p=0.003, log-rank test) or solid cancers (p=0.05) after irradiation",Results,"irradiated Nf1+/− mutant mice were more likely than irradiated WT mice to develop hematologic malignancies (p=0.003, log-rank test) or solid cancers (p=0.05)",0.95
PMID:21199799,10.1158/0008-5472.CAN-10-2732,Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice.,Nf1+/- mice,animal_model,Efficacy,"Highest incidence of myeloid malignancies occurred at 15 Gy dose (0 Gy vs. 15 Gy: p=0.031, 15 Gy vs. 30 Gy: p=0.017)",Results,"highest incidence of myeloid malignancies in Nf1+/− mutant mice that received 15 Gy of CI (0 Gy vs. 15 Gy: p=0.031, 15 Gy vs. 30 Gy: p=0.017, Fisher exact tests)",0.95
PMID:21199799,10.1158/0008-5472.CAN-10-2732,Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice.,Nf1+/- mice,animal_model,Biomarker,"Anemia was largely restricted to mice that received 15 Gy of CI, with marked splenic erythroid hyperplasia and persistent bone marrow erythropoiesis",Results,anemia was largely restricted to Nf1+/− mice that received 15 Gy of CI...marked expansion of the red pulp in the spleen...characterized by a predominance of erythroid cells,0.9
PMID:21199799,10.1158/0008-5472.CAN-10-2732,Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice.,Nf1-/- mouse embryo fibroblasts,cell_line,Mechanistic,"Showed similar patterns of γH2AX foci formation and resolution over time as WT cells, suggesting Nf1 inactivation does not affect DNA repair",Results,"We observed similar patterns of γH2AX foci formation and resolution over time in WT and Nf1−/− mutant mouse embryo fibroblasts, which suggests that Nf1 inactivation does not have global effects on DNA repair",0.9
PMID:21199799,10.1158/0008-5472.CAN-10-2732,Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice.,Nf1+/- mouse embryo fibroblasts,cell_line,Mechanistic,"Showed similar patterns of γH2AX foci formation and resolution over time as WT cells, suggesting Nf1 inactivation does not affect DNA repair",Results,"We observed similar patterns of γH2AX foci formation and resolution over time in WT and Nf1+/− mutant mouse embryo fibroblasts, which suggests that Nf1 inactivation does not have global effects on DNA repair",0.9
PMID:21439418,10.1016/j.bone.2011.03.760,Primary osteopathy of vertebrae in a neurofibromatosis type 1 murine model.,Nf1(flox/-);Col2.3Cre(+) mice,animal_model,Biomarker,"L5 vertebrae height significantly reduced compared to WT, Nf1+/-, and Nf1flox/flox;Col2.3Cre+ mice (p<0.05)",Results,"The average height of L5 was significantly less in flox/−;Col2.3Cre+ Nf1 mice than in WT, flox/−;Col2.3Cre+ Nf1+/−, and Nf1 mice (flox/flox;Col2.3Cre+ Figs. 1A, B, *p<0.05)",0.95
PMID:21439418,10.1016/j.bone.2011.03.760,Primary osteopathy of vertebrae in a neurofibromatosis type 1 murine model.,Nf1(flox/-);Col2.3Cre(+) mice,animal_model,Biomarker,Significant reduction in BMD in L1-L5 vertebral region compared to other genotypes (p<0.05),Results,"a significant reduction in BMD was observed in the L1–L5 region of Nf1 mice (flox/−;Col2.3Cre+ Figs. 2C–D, *p<0.05)",0.95
PMID:21439418,10.1016/j.bone.2011.03.760,Primary osteopathy of vertebrae in a neurofibromatosis type 1 murine model.,Nf1(flox/-);Col2.3Cre(+) mice,animal_model,Biomarker,Reduced cortical bone density and significantly decreased cortical bone area in L5 vertebrae,Results,reduced cortical bone density was observed in L5 of the Nf1 and flox/flox;Col2.3Cre+ Nf1 mice...cortical bone area was significantly decreased in the L5 vertebrae,0.9
PMID:21439418,10.1016/j.bone.2011.03.760,Primary osteopathy of vertebrae in a neurofibromatosis type 1 murine model.,Nf1(flox/-);Col2.3Cre(+) mice,animal_model,Biomarker,Significant reduction in trabecular bone volumetric BMD,Results,a significant reduction in vBMD of trabecular bone was observed (Figs. 3C and D),0.9
PMID:21439418,10.1016/j.bone.2011.03.760,Primary osteopathy of vertebrae in a neurofibromatosis type 1 murine model.,Nf1(flox/-);Col2.3Cre(+) mice,animal_model,Biomarker,"Significant increase in spinal canal/vertebral body area ratio compared to WT, with further increase compared to Nf1+/- and Nf1flox/flox;Col2.3Cre+ mice",Results,"a significant increase in the C/V ratio was found in Nf1+/−, Nf1, and flox/flox;Col2.3Cre+ Nf1 mice...A further increase in the C/V ratio of L5 vertebrae from Nf1 mice",0.9
PMID:21439418,10.1016/j.bone.2011.03.760,Primary osteopathy of vertebrae in a neurofibromatosis type 1 murine model.,Nf1(flox/-);Col2.3Cre(+) mice,animal_model,Biomarker,"Significantly reduced peak load to failure and peak stress to failure in L5 vertebrae (p<0.05, p<0.01)",Results,"Peak load to failure in the L5 vertebrae of flox/−;Col2.3Cre+ Nf1+/−, Nf1, and flox/flox;Col2.3Cre+ Nf1 mice was significantly reduced (*p<0.05, **p<0.01)",0.95
PMID:21439418,10.1016/j.bone.2011.03.760,Primary osteopathy of vertebrae in a neurofibromatosis type 1 murine model.,Nf1(flox/-);Col2.3Cre(+) mice,animal_model,Biomarker,Significantly reduced osteoblast number per mm of bone surface in upper facet process compared to other genotypes,Results,significantly reduced osteoblast number per mm of bone surface was observed in the upper facet process of Nf1 mice than in the other three genotypes of mice,0.9
PMID:21439418,10.1016/j.bone.2011.03.760,Primary osteopathy of vertebrae in a neurofibromatosis type 1 murine model.,Nf1(flox/-);Col2.3Cre(+) mice,animal_model,Biomarker,Significantly reduced CFU-OBL forming capacity in bone marrow mononuclear cells compared to controls,Results,BMMNCs cultured from Nf1 mice demonstrated significantly reduced CFU-OBL forming capacity as compared to controls,0.9
PMID:21439418,10.1016/j.bone.2011.03.760,Primary osteopathy of vertebrae in a neurofibromatosis type 1 murine model.,Nf1(flox/-);Col2.3Cre(+) mice,animal_model,Biomarker,Reduced Alizarin staining and significant reduction in mineralized bone nodules in osteoblast cultures in gene dosage dependent fashion,Results,"reduced Alizarin staining was observed in Nf1+/−, Nf1, as well as in flox/flox;Col2.3Cre+ Nf1 cultures in a gene dosage dependent fashion...A significant reduction in the number of mineralized bone nodules",0.9
PMID:21439418,10.1016/j.bone.2011.03.760,Primary osteopathy of vertebrae in a neurofibromatosis type 1 murine model.,Nf1 +/− mice,animal_model,Biomarker,Significantly increased osteoclast number per mm of bone surface in upper facet process compared to WT,Results,Significantly increased osteoclast number per mm of bone surface was observed in the upper facet process of Nf1+/− and Nf1 mice compared with WT mice,0.9
PMID:24040940,10.1186/1479-5876-11-213,Molecular-guided therapy predictions reveal drug resistance phenotypes and treatment alternatives in malignant peripheral nerve sheath tumors.,NF02.2,cell_line,Biomarker,High ABCC1 expression confirmed by quantitative real-time PCR relative to benign neurofibroma-derived cells,Results,Quantitative real-time PCR confirms the high level of expression of ABCC1 in the NF02.2 cell line relative to benign neurofibroma-derived cells,0.95
PMID:24040940,10.1186/1479-5876-11-213,Molecular-guided therapy predictions reveal drug resistance phenotypes and treatment alternatives in malignant peripheral nerve sheath tumors.,NF02.2,cell_line,Efficacy,Doxorubicin EC50 of 0.861 μg/ml ± 0.17 alone versus 0.248 μg/ml ± 0.07 with verapamil (p = 0.0002),Results,"Significantly lower doxorubicin EC50 values are obtained when doxorubicin dose is combined with verapamil (0.861 μg/ml ± 0.17 versus 0.248 μg/ml ± 0.07, p = 0.0002",0.98
PMID:24040940,10.1186/1479-5876-11-213,Molecular-guided therapy predictions reveal drug resistance phenotypes and treatment alternatives in malignant peripheral nerve sheath tumors.,NF94.3,cell_line,Efficacy,Doxorubicin EC50 of 0.81 μg/ml ± 0.42 alone versus 0.34 μg/ml ± 0.20 with verapamil (p = 0.025),Results,"A small effect of verapamil channel blockade on doxorubicin EC50 is observed in NF94.3 cells (0.81 μg/ml ± 0.42 versus 0.34 μg/ml ± 0.20, p = 0.025",0.95
PMID:24040940,10.1186/1479-5876-11-213,Molecular-guided therapy predictions reveal drug resistance phenotypes and treatment alternatives in malignant peripheral nerve sheath tumors.,NF96.2,cell_line,Efficacy,"Doxorubicin EC50 of 0.44 μg/ml ± 0.31 alone versus 0.22 μg/ml ± 0.25 with verapamil (p = 0.16, not significant)",Results,"no significant effect is observed in low-ABCC1 expressing NF96.2 cells (0.44 μg/ml ± 0.31 versus 0.22 μg/ml ± 0.25, p = 0.16 paired Student's t-test",0.95
PMID:33673681,10.3390/cancers13050999,Hybrid Minigene Assay: An Efficient Tool to Characterize mRNA Splicing Profiles of ,HEK293 cells,cell_line,Efficacy,"Successfully expressed minigene constructs and allowed detection of aberrant splicing patterns, including multiple splicing products and residual wild-type transcript quantification",Results,"when expressed from the minigene construct, did not affect transcript maturation in HEK293 cells...expression of the minigene yielded a splicing pattern characterized by more products",0.9
PMID:34630515,10.3389/fgene.2021.721045,Assessment of Mosaicism and Detection of Cryptic Alleles in CRISPR/Cas9-Engineered Neurofibromatosis Type 1 and ,LLC-PK1 ATCC CL-101,cell_line,Efficacy,"Used for in vitro validation assay to design and select optimal genome editing reagents, testing two gRNA-donor pairs for HDR efficiency",Results,"First, we used an in vitro validation assay utilizing LLC-PK1 cells to design and select the optimal genome editing reagents. We tested two gRNA–donor pairs",0.8
PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,HEK 293T,cell_line,Mechanistic,"Used for luciferase assays to test hey1 promoter activation by NICD, showing dramatic reduction when Rbpj binding sites were mutated",Results,resulted in a dramatic reduction in promoter activation by NICD when assayed in transfected HEK293 cells,0.9
PMID:32457840,10.3389/fonc.2020.00687,"TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling.",MIAPaCa-2,cell_line,Biomarker,Showed elevated mRNA expression of NBCn1 and NBCe2 compared to HPDE cells,Results,MIAPaCa-2 cells predominantly showed upregulation of NBCn1 and NBCe2,0.85
PMID:32457840,10.3389/fonc.2020.00687,"TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling.",MIAPaCa-2,cell_line,Biomarker,NBCn1 protein level was significantly increased compared to HPDE cells,Results,"western blot analysis revealed that...the NBCn1 protein level in MIAPaCa-2 and Panc-1 cells, compared to that observed in HPDE cells",0.9
PMID:32457840,10.3389/fonc.2020.00687,"TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling.",Panc-1,cell_line,Biomarker,Showed upregulation of both NHE2 and NBCn1 mRNA compared to HPDE cells,Results,both NHE2 and NBCn1 were upregulated in Panc-1 cells,0.85
PMID:32457840,10.3389/fonc.2020.00687,"TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling.",Panc-1,cell_line,Biomarker,NBCn1 protein level was significantly increased compared to HPDE cells,Results,"western blot analysis revealed that...the NBCn1 protein level in MIAPaCa-2 and Panc-1 cells, compared to that observed in HPDE cells",0.9
PMID:32457840,10.3389/fonc.2020.00687,"TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling.",Panc-1,cell_line,Mechanistic,"TGFβ-1 treatment significantly reduced E-cadherin level and increased α-SMA and CTGF levels, consistent with EMT induction",Results,"In Panc-1 cells, TGFβ-1 treatment significantly reduced the level of E-cadherin, and increased that of α-SMA and CTGF, consistent with induction of EMT",0.95
PMID:32457840,10.3389/fonc.2020.00687,"TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling.",Panc-1,cell_line,Biomarker,TGFβ-1 treatment increased NHE1 protein expression by about 60% and NBCn1 by about 40%,Results,"The protein expression level of NHE1 increased by about 60%, and that of NBCn1 by about 40%, following TGFβ-1 treatment of Panc-1 cells",0.95
PMID:32457840,10.3389/fonc.2020.00687,"TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling.",Panc-1,cell_line,Biomarker,TGFβ-1 treatment significantly increased steady state pHi from 7.06 ± 0.105 to 7.26 ± 0.043,Results,"TGFβ-1 treatment significantly increased steady state pH i in Panc-1 cells, from an average value of 7.06 ± 0.105 in control cells to 7.26 ± 0.043 after TGFβ-1 treatment",0.95
PMID:32457840,10.3389/fonc.2020.00687,"TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling.",Panc-1,cell_line,Mechanistic,"TGFβ-1 treatment markedly increased the pHi recovery rate, indicating increased acid extrusion capacity",Results,TGFβ-1 treatment markedly increased the pH i recovery rate in Panc-1 cells,0.9
PMID:32457840,10.3389/fonc.2020.00687,"TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling.",Panc-1,cell_line,Mechanistic,TGFβ-1 treatment increased invasion through Matrigel more than 4-fold,Results,Stimulation with TGFβ-1 increased invasion of Panc-1 cells through Matrigel more than 4-fold,0.95
PMID:32457840,10.3389/fonc.2020.00687,"TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling.",BxPC-3,cell_line,Biomarker,Showed elevated expression of NHE1 and NHE2 compared to HPDE cells,Results,BxPC-3 and AsPC-1 cells showed elevated expression of NHE1 and−2,0.85
PMID:32457840,10.3389/fonc.2020.00687,"TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling.",BxPC-3,cell_line,Biomarker,NHE1 protein level was significantly increased compared to HPDE cells,Results,western blot analysis revealed that the NHE1 protein level was significantly increased in BxPC-3 cells,0.9
PMID:32457840,10.3389/fonc.2020.00687,"TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling.",BxPC-3,cell_line,Mechanistic,TGFβ-1 treatment elicited only a small yet significant decrease in E-cadherin of about 25% without detectable changes in α-SMA and CTGF,Results,"In BxPC-3 cells, TGFβ-1 treatment elicited a small yet significant decrease in E-cadherin of about 25%, which was not accompanied by detectable changes in α-SMA and CTGF expression",0.9
PMID:32457840,10.3389/fonc.2020.00687,"TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling.",BxPC-3,cell_line,Biomarker,"Steady state pHi was 7.01 ± 0.062 in controls and 7.09 ± 0.066 after TGFβ-1 treatment, not significantly different",Results,"the steady state pH i of BxPC-3 cells was 7.01 ± 0.062 in controls and 7.09 ± 0.066 after TGFβ-1 treatment, not significantly different",0.95
PMID:32457840,10.3389/fonc.2020.00687,"TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling.",AsPC-1,cell_line,Biomarker,Showed elevated expression of NHE1 and NHE2 compared to HPDE cells,Results,BxPC-3 and AsPC-1 cells showed elevated expression of NHE1 and−2,0.85
PMID:32457840,10.3389/fonc.2020.00687,"TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling.",HPDE H6c7,cell_line,Biomarker,Used as control reference for transporter expression comparisons with PDAC cell lines,Results,All PDAC cell lines studied exhibited increased mRNA levels of one or more of these transporters compared to HPDE cells,0.9
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,Ben-Men-1,cell_line,Biomarker,"Shows increased NRG1, HBEGF, and APLN expression compared to NF2(+) cells, with NRG1 showing 6.28 log2FC (p=1.45×10^-8)",Results,"qPCR confirmed increased expression of NRG1, HBEGF, and APLN in NF2-null(-) CRISPR-modified arachnoidal cells (AC-CRISPR) cells and MN line Ben-Men-1 compared with NF2-expressing(+) ACs",0.95
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,Ben-Men-1,cell_line,Biomarker,Secretes NRG1 ligand detectable in 48h concentrated medium,Results,"Immunoblotting revealed NRG1 secretion in 48 h-concentrated medium (48 h-CM) from NF2(−) AC cells and Ben-Men-1, whereas 48 h-CM from NF2(+) ACs or 0 h-CM from NF2(−) ACs showed no signal",0.9
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,ipn023λ,cell_line,Safety,"GRDC24 displayed far less cytotoxicity in non-NF1 cells, especially at lower MOI of 500 and 100",Results,"GRDC24 displayed far less cytotoxicity in non-NF1 cells, such as ipn02.3λ, especially at lower multiplicity of infection (MOI) of 500 and 100",0.9
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,ST88-14,cell_line,Mechanistic,333 AA GRD version showed highest expression and most potent inhibition of pERK1/2 in ST88-14 cells,Results,The 333 AA version (NF1 AA 1200-1532) showed the highest expression and most potent inhibition of pERK1/2.,0.9
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,ST88-14,cell_line,Mechanistic,GRDC24 induced apoptosis in ST88-14 cells after 24h treatment with annexin V staining,Results,GRDC24 induced apoptosis in NF1 cells. ipNF9511bc cells were transfected with AAV-GRDC24 and after 24 h cells were stained with annexin V.,0.85
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,FiPS,cell_line,Mechanistic,"FiPS-derived neural crest cells were less affected by GRDC24 expression compared to NF1-/- cells, especially at lower MOIs",Results,"Expression of GRDC24 via AAV inhibited pERK1/2 and significantly reduced viable cell numbers in NF1−/− NC cells, while FiPS-derived NC cells were less affected, especially at lower MOIs",0.85
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,"NF1−/−−/− edited FiPS Ctrl1-SV4F-7, D12",cell_line,Mechanistic,"GRDC24 rescued Schwann cell differentiation capacity when applied 3 days prior or 2 days after start of SC differentiation, enabling myelination around neurons",Results,GRDC24 packaged in AAV-DJ was applied to NF1−/− cells 3 days prior or 2 days after the start of SC differentiation and in both cases NF1−/− cells were able to acquire a SC morphology and stained positive for the SC marker S100B,0.9
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,RHT92,cell_line,Efficacy,"AAV-K55-GRDC24 markedly slowed down RHT92 tumor growth, with more substantial response when adding a second dose (n=4-5 mice)",Results,"In RHT92 xenograft model, AAV-K55-GRDC24 also markedly slowed down the tumor growth, and adding a second dose made a more substantial response",0.9
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,RHT92,cell_line,Biomarker,AAV-K55-GFP achieved 50-60% transduction in RHT92 xenograft tumors as measured by flow cytometry,Results,"we found AAV-K55-GFP achieved 30–40% transduction in ST88-14, 50–60% in RHT92 and over 20% in JH-2-002",0.95
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,LN229,cell_line,Biomarker,NF1-deficient glioma xenograft LN229 was transduced at approximately 30% by one dose of AAV-K55-GFP,Results,"NF1-deficient glioma xenograft, LN229, also was transduced at approximately 30% by one dose of AAV-K55-GFP",0.9
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,S462,cell_line,Efficacy,S462 MPNST was resistant to AAV-K55-GFP vector transduction,Results,while S462 MPNST and JH-2-031 PDX MPNST were resistant to this vector,0.85
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,JH-2-002,patient_derived_model,Biomarker,Patient-derived xenograft MPNST JH-2-002 achieved over 20% transduction with AAV-K55-GFP,Results,"we found AAV-K55-GFP achieved 30–40% transduction in ST88-14, 50–60% in RHT92 and over 20% in JH-2-002, a patient-derived xenograft (PDX) MPSNT",0.9
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,JH-2-031,patient_derived_model,Efficacy,JH-2-031 PDX MPNST was resistant to AAV-K55-GFP vector transduction,Results,while S462 MPNST and JH-2-031 PDX MPNST were resistant to this vector,0.85
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,3PNF_SiPSsv_MM_11,advanced_cellular_model,Biomarker,"AAV-K55-GFP demonstrated substantial transduction in NF1 iPSC-derived neurofibroma xenograft, primarily transducing S100B-positive population",Results,"this vector demonstrated substantial transduction in an NF1−/− iPSC-derived neurofibroma xenograft (3MM), as shown by anti-GFP IHC. We found that AAV-K55-GFP primarily transduced the S100B-positive population",0.9
PMID:34106871,10.1109/JBHI.2021.3087735,DINs: Deep Interactive Networks for Neurofibroma Segmentation in Neurofibromatosis Type 1 on Whole-Body MRI.,DINs (Deep Interactive Networks),computational_tool,Efficacy,Achieves accurate segmentation of multiple tumors with one click and iteratively improves segmentation with additional interactions,Results,DINs achieve accurate segmentation of multiple tumors with one click and iteratively improves segmentation with additional interactions.,0.8
PMID:34106871,10.1109/JBHI.2021.3087735,DINs: Deep Interactive Networks for Neurofibroma Segmentation in Neurofibromatosis Type 1 on Whole-Body MRI.,DINs (Deep Interactive Networks),computational_tool,Efficacy,Can recognize neurofibromas accurately compared to other interactive methods,Results,"In comparison, DINs can recognize neurofibromas accurately. The two groups of segmentation results support the advantages of the DINs.",0.8
PMID:34106871,10.1109/JBHI.2021.3087735,DINs: Deep Interactive Networks for Neurofibroma Segmentation in Neurofibromatosis Type 1 on Whole-Body MRI.,DINs (Deep Interactive Networks),computational_tool,Efficacy,Outperforms conventional interactive methods and performs significantly better than automated and interactive CNN-based methods,Discussion,Experiments on the training set and the test set show that the proposed method outperforms conventional interactive methods and performs significantly better than automated and interactive CNN-based methods.,0.9
PMID:34106871,10.1109/JBHI.2021.3087735,DINs: Deep Interactive Networks for Neurofibroma Segmentation in Neurofibromatosis Type 1 on Whole-Body MRI.,DINs (Deep Interactive Networks),computational_tool,Other,May fail in some cases such as neurofibromas near the orbits due to similar intensity,Discussion,DINs may failed in some cases such as neurofibromas near the orbits due to the similar intensity.,0.8
PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,dNF1‐KO,cell_line,Mechanistic,"Showed increased rate of growth in both presence and absence of serum, indicating accelerated culture growth decoupled from upstream growth factor signaling pathways",Results,dNF1‐KO cells showed an increased rate of growth as measured using CellTiter‐Glo assays to assess total ATP levels in the population. This effect was observed in both the presence and absence of serum,0.9
PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,dNF1‐KO,cell_line,Mechanistic,Showed significantly higher levels of autophagic flux under serum-free conditions compared to S2R+ controls,Results,We observed significantly higher levels of autophagic flux in dNF1‐KO cells under serum‐free conditions compared to S2R+ controls,0.9
PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,"ipNF95.11b 'C' (hTERT NF1 ipNF95.11b C, RRID: CVCL_UI67)",cell_line,Mechanistic,Showed significantly higher autophagic flux relative to NF1+/- controls and increased baseline expression of LC3B protein,Results,Autophagic flux was significantly higher in NF1−/− cells (ipNF95.11b 'C' and ipNF05.5) relative to NF1+/− controls...baseline expression of LC3B...was found to be increased in NF1−/− cells,0.9
PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,"ipNF05.5 (hTERT NF1 ipNF05.5, RRID: CVCL_UI71)",cell_line,Mechanistic,Showed significantly higher autophagic flux relative to NF1+/- controls,Results,Autophagic flux was significantly higher in NF1−/− cells (ipNF95.11b 'C' and ipNF05.5) relative to NF1+/− controls,0.9
PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,ST88‐14 (RRID: CVCL_8916),cell_line,Efficacy,"Xenograft tumor growth was significantly reduced by chloroquine (50 mg/kg, 3x weekly) and selumetinib (25 mg/kg, 3x weekly) compared to vehicle controls, with chloroquine showing superior effect over selumetinib",Results,"treatment with CQ (50 mg·kg−1 in saline, intraperitoneally, three times per week) or selumetinib (25 mg·kg−1 in saline, oral gavage, three times per week)...resulted in a significant reduction in tumor cell growth...Furthermore, there was a significant reduction in tumor cell growth in CQ‐treated mice in comparison to selumetinib‐treated mice",0.95
PMID:21111000,10.1016/j.jneumeth.2010.10.021,A novel imaging-compatible sciatic nerve schwannoma model.,HEI-193,cell_line,Efficacy,99% infectability with lentivirus vector as determined by mCherry expression under fluorescence microscopy,Results,Infectability of this cell line was 99% as determined by mCherry expression under fluorescence microscopy,0.95
PMID:21111000,10.1016/j.jneumeth.2010.10.021,A novel imaging-compatible sciatic nerve schwannoma model.,HEI-193,cell_line,Efficacy,Successful tumor establishment in 13 of 15 mice (87% success rate) with gradual increase in tumor volume over 10 weeks,Results,we observed a gradual increase in tumor volume over 10 weeks after tumor implantation in 13 of these 15 mice,0.95
PMID:21111000,10.1016/j.jneumeth.2010.10.021,A novel imaging-compatible sciatic nerve schwannoma model.,HEI-193,cell_line,Biomarker,"Tumor doubling times were 18, 16 and 24 days for 30,000, 100,000 and 300,000 cell groups, respectively",Results,"the doubling times were quite similar between the 3 groups (18, 16 and 24 days in 30,000, 100,000 and 300,000 groups, respectively)",0.95
PMID:38931352,10.3390/ph17060685,PET Imaging of Neurofibromatosis Type 1 with a Fluorine-18 Labeled Tryptophan Radiotracer.,"Trp53, Nf1, Suz12 triple mutant mice",animal_model,Biomarker,"Highest L-[18F]FETrp uptake in pancreas at 5 min (15.8 ± 1.6 ID%/g), increased at 30 min (24.4 ± 15.5 ID%/g), decreased at 60 min (20.5 ± 10.1 ID%/g)",Results,"A biodistribution study in triple mutant mice showed the highest uptake in the pancreas at 5 min post-injection (15.8 ± 1.6 ID%/g). The tracer uptake in the pancreas increased at 30 min (24.4 ± 15.5 ID%/g), followed by a decreased uptake at 60 min (20.5 ± 10.1 ID%/g).",0.95
PMID:38931352,10.3390/ph17060685,PET Imaging of Neurofibromatosis Type 1 with a Fluorine-18 Labeled Tryptophan Radiotracer.,"Trp53, Nf1, Suz12 triple mutant mice",animal_model,Safety,"Stable bone uptake during 90 min scans (1.49 ± 0.65 ID%/g at 5 min vs. 1.44 ± 0.45 ID%/g at 90 min), indicating stability towards defluorination",Results,"The bone uptake in the triple mutant group remained stable during the 90 min scans (1.49 ± 0.65 ID%/g at 5 min vs. 1.44 ± 0.45 ID%/g at 90 min), further indicating the stability of L-[18F]FETrp towards in vivo defluorination.",0.92
PMID:28126595,10.1016/j.ebiom.2017.01.020,Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target.,Ben-Men-1 cells,cell_line,Biomarker,PDLIM2 was found overexpressed in Ben Men-1 cells compared to normal HMC by Western blot analysis,Results,we validated PDLIM2 overexpression in Ben Men-1 cells and in six tumour-derived primary cells compared to normal HMC,0.9
PMID:28126595,10.1016/j.ebiom.2017.01.020,Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target.,Ben-Men-1 cells,cell_line,Biomarker,Phosphorylated PDLIM2 was statistically significantly enriched in Ben Men-1 cells (p < 0.012) compared to HMC,Results,"Phosphorylated PDLIM2 was statistically significantly enriched in Ben Men-1 cells (**,  p  < 0.012) compared to HMC",0.95
PMID:28126595,10.1016/j.ebiom.2017.01.020,Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target.,Ben-Men-1 cells,cell_line,Efficacy,PDLIM2 shRNA-mediated knockdown led to statistically significant reduced proliferation (p < 0.05) as measured by ki-67 proliferation assay,Results,we observed a reduction of protein expression after silencing leading to a significant decrease in cellular proliferation as measured by a ki-67 proliferation assay,0.9
PMID:28126595,10.1016/j.ebiom.2017.01.020,Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target.,Human meningeal cells (HMC),cell_line,Biomarker,"PDLIM2 was not expressed in HMC, serving as normal control for comparison with tumor cells",Discussion,PDLIM2 was not expressed in HMC or normal meningeal tissue and minimally expressed in the Schwann cell examined,0.9
PMID:34935315,10.1117/1.JBO.26.12.125001,Analysis of muscle tissue in vivo using fiber-optic autofluorescence and diffuse reflectance spectroscopy.,Nf1Prx1-/-,animal_model,Biomarker,Quadriceps muscle showed significantly different AF spectra means (p < 0.05 between ~450 and 720 nm) and DR spectra with more pronounced absorption feature between 500-600 nm compared to controls,Results,Normalized AF spectra from B6 and NF1 quadricep muscles showed significantly different means (p < 0.05 between ~450 and 720 nm). NF1 DR spectra showed a more pronounced absorption feature between 500 and 600 nm,0.95
PMID:34935315,10.1117/1.JBO.26.12.125001,Analysis of muscle tissue in vivo using fiber-optic autofluorescence and diffuse reflectance spectroscopy.,Nf1Prx1-/-,animal_model,Efficacy,Strong quadriceps separability from controls demonstrated by QDC classifier AUCs of 0.99 for AF and 0.97 for DR spectroscopy,Results,"Both AF and DR demonstrated strong quadriceps separability as indicated by distinct PC score clustering and QDC classifier AUC's of 0.99 and 0.97, respectively",0.95
PMID:34935315,10.1117/1.JBO.26.12.125001,Analysis of muscle tissue in vivo using fiber-optic autofluorescence and diffuse reflectance spectroscopy.,Nf1Prx1-/-,animal_model,Biomarker,Quadriceps muscle histology showed endomysial fibrosis and intramyocellular lipid accumulation by H&E and Oil Red O staining,Results,"NF1 muscle histology showed endomysial fibrosis and intramyocellular lipid by H&E and Oil Red O staining, respectively, consistent with prior findings",0.9
PMID:34935315,10.1117/1.JBO.26.12.125001,Analysis of muscle tissue in vivo using fiber-optic autofluorescence and diffuse reflectance spectroscopy.,Nf1Prx1-/-,animal_model,Biomarker,"Cardiac muscle showed no spectral differences from controls (p > 0.05) with poor QDC classification performance (ROC-AUCs of 0.67 AF, 0.63 DR)",Results,B6 and NF1 cardiac muscle showed similar spectral shapes and the same mean normalized intensity across almost all wavelengths for both AF and DR (p > 0.05). This similarity resulted in overlapping PC score clusters and poor QDC classification performance with ROC-AUCs of 0.67 and 0.63,0.95
PMID:8582272,10.1242/dev.121.11.3583,Neurofibromin-deficient fibroblasts fail to form perineurium in vitro.,Nf1 (+/-) mice,animal_model,Mechanistic,Nf1 (+/-) fibroblasts contained 60% as many fascicles as wild-type cultures at 30 days in vitro,Results,Cultures with Nf1 (+/−) fibroblasts contained 60% as many fascicles as wild-type cultures.,0.95
PMID:8582272,10.1242/dev.121.11.3583,Neurofibromin-deficient fibroblasts fail to form perineurium in vitro.,Nf1 (+/-) mice,animal_model,Mechanistic,Heterozygous cells showed reduced neurofibromin levels compared to wild-type cells by Western blot analysis,Results,"Western blot analysis confirmed that fibroblasts from Nf1 (−/−) embryos contained no detectable neurofibromin, while heterozygous cells showed a reduction as compared to wild-type cells",0.9
PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,Nf1flox/flox;PostnCre mice,animal_model,Efficacy,"After 12 weeks of daily cabozantinib treatment, the number of PN per mouse was reduced by approximately 60% with normalization of nerve microarchitecture",Results,"after 12 weeks of daily cabozantinib treatment, the number of PN per mouse was reduced by approximately 60% with normalization of nerve microarchitecture",0.95
PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,Nf1flox/flox;PostnCre mice,animal_model,Efficacy,Cabozantinib treatment reduced the mean volume of the proximal peripheral nerve roots by 38%,Results,Cabozantinib treatment also reduced the mean volume of the proximal peripheral nerve roots by 38%,0.95
PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,Nf1flox/flox;PostnCre mice,animal_model,Biomarker,Mast cell infiltration was not significantly changed despite cabozantinib treatment,Results,"despite the well-recognized modulation of c-kit by cabozantinib and the known role of c-kit in mast cell chemotaxis for PN, mast cell infiltration was not significantly changed",0.9
PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,OLN93 mouse oligodendrocyte cell line,cell_line,Efficacy,NF2 overexpression reduced cell proliferation by approximately 20% in XCELLigence measurements and significantly decreased process formation (66% of cells showed no projections vs 36% in controls),Results,"Reduction in cell indices over time amounted to about 20% in rat oligodendrocytes (OLN93)...While only 36% of the control-transfected OLN93 cells showed no process, 66% of Merlin overexpressing cells had no projections",0.95
PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,SC4-immortalized Nf2-/- primary Schwann cells,cell_line,Biomarker,"70 kDa Merlin band was absent, instead showing a smaller and weaker band corresponding to exon composition missing exons 2 and 3",Results,"However, the 70 kDa band of Merlin was absent in SC4 cells in which Merlin is more prominently degraded due to a deletion of exon 2 and 3",0.9
PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,RT4-D6PT2 schwannoma cell line,cell_line,Efficacy,NF2 overexpression reduced cell proliferation by approximately 15% and significantly decreased process formation (53% of cells showed no projections vs 26% in controls),Results,"to 15% in schwannoma cells (RT4)...Only 26% of control RT4 cells showed no projections, but 53% of Merlin overexpressing RT4 cells failed to build processes",0.95
PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,TC620 human oligodendroglioma cell line,cell_line,Efficacy,NF2 overexpression reduced cell proliferation by approximately 30% and significantly shortened process length (26.47 ± 0.81 μm vs 41.00 ± 1.18 μm in controls),Results,to 30% in human oligodendroglioma cells (TC620)...the length of these projections was significantly shorter in Merlin overexpressing (26.47 ± 0.81 μm; n > 400) as compared to the control-transfected TC620 cells (41.00 ± 1.18 μm; n > 1500; p < 0.001),0.95
PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,MPNST 88-14 cells,cell_line,Mechanistic,NF1-GRD expression significantly reduces Ras-GTP and downstream P-MEK and P-ERK at 32h,Results,At 32h GRD expression significantly reduces Ras-GTP and downstream P-MEK and P-ERK,0.9
PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,MPNST S462-TY cells,cell_line,Efficacy,MAF transduction for 48 hours significantly decreased metabolic activity as measured by MTS assay,Results,S462-TY cells transduced with MAF for 48 hours significantly decreased metabolic activity as measured by MTS assay,0.9
PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,MPNST S462-TY cells,cell_line,Efficacy,MAF transduction for 48 hours revealed increased apoptotic cell death by flow cytometric analysis,Results,Flow cytometric analysis of PI and Annexin stained S462-TY cells transduced with MAF for 48 hours revealed increased apoptotic cell death,0.9
PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,MPNST S462-TY cells,cell_line,Efficacy,MAF overexpression decreased anchorage independent growth in soft agar,Results,decreased anchorage independent growth in soft agar in S462-TY cells overexpressing MAF constitutively or inducibly,0.9
PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,MPNST S462-TY cells,cell_line,Efficacy,Combination of 10 or 30 nM RAD001 with MAF overexpression resulted in enhanced response compared to RAD001 alone,Results,the combination of treatment with 10 or 30 nM RAD001 in addition to MAF overexpression resulted in an enhanced response,0.9
PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,S462 cell line,cell_line,Biomarker,"MLN8237 IC-50 was significantly lower than 2884 cells (p=0.02), showing higher sensitivity despite equivalent AURKA expression",Results,"Despite equivalent growth rates and AURKA abundance in 2884 and S462 cells, however, the cellular responses to MLN8237 were significantly different (p=0.02) with S462 being the more sensitive",0.92
PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,S462 cell line,cell_line,Biomarker,2.2-9.2 fold more sensitive to pan-Aurora inhibitors VX680 (IC-50: 42±10 nM) and C1368 (IC-50: 1302±264 nM) compared to 2884 cells,Results,"S462 cells were also 2.2 – 9.2 fold more sensitive to the pan-Aurora inhibitors VX680 (IC-50- 2884, 387 ±47 nM; S462, 42 ±10 nM) and C1368 (IC-50- 2884, 2925 ±135 nM; S462, 1302 ±264 nM)",0.95
PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,S462 cell line,cell_line,Mechanistic,"5.6±1.2% of S462 cells (168±25 of 3,000 seeded) capable of forming spheroids under stem cell conditions, with secondary passage forming significantly more spheres",Results,"While no spheroids were identified in 2884 cultures, 5.6 ± 1.2% of S462 cells (168 ±25 of 3,000 seeded) are capable of forming spheroids. Secondary passage formed significantly more spheres",0.95
PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,2884 cell line,cell_line,Biomarker,"VX680 IC-50: 387±47 nM; C1368 IC-50: 2925±135 nM, showing lower sensitivity compared to S462 cells",Results,"S462 cells were also 2.2 – 9.2 fold more sensitive to the pan-Aurora inhibitors VX680 (IC-50- 2884, 387 ±47 nM; S462, 42 ±10 nM) and C1368 (IC-50- 2884, 2925 ±135 nM; S462, 1302 ±264 nM)",0.95
PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,2884 cell line,cell_line,Mechanistic,"No spheroids identified in 2884 cultures under stem cell conditions, unlike S462 cells",Results,"While no spheroids were identified in 2884 cultures, 5.6 ± 1.2% of S462 cells (168 ±25 of 3,000 seeded) are capable of forming spheroids",0.95
PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,2885 cell line,cell_line,Biomarker,"Required 400-725 fold higher MLN8237 concentrations to inhibit 50% of cellular growth (IC-50), consistent with negligible AURKA expression",Results,"The 2885 cell-line resisted MLN8237 treatment and required 400-725 fold higher concentrations to inhibit 50% of cellular growth (IC-50), which is consistent with the negligible expression of AURKA in this cell-line",0.95
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,T265,cell_line,Efficacy,Used in xenograft assays where ZEB1 shRNA knockdown impeded tumor growth compared to control,Results,lentivirus short hairpin RNA (shRNA)–mediated knockdown of ZEB1 impeded the tumor growth of an MPNST cell line when compared with control shRNA,0.8
PMID:21551250,10.1158/0008-5472.CAN-10-4577,Susceptible stages in Schwann cells for NF1-associated plexiform neurofibroma development.,NF1 flox/− mice,animal_model,Efficacy,100% of E12.5 tamoxifen-induced PLPCre-ERT2;NF1 flox/− mice developed plexiform neurofibromas at 5-6 months of age,Results,"The E12.5 PLPCre-ERT2;NF1 flox/− ;R26R progeny showed classic signs of illness beginning at 5 to 6-months of age and were necropsied along with control littermates. In all cases, the mice exhibited tumors along the cervical and thoracic DRG",0.95
PMID:21551250,10.1158/0008-5472.CAN-10-4577,Susceptible stages in Schwann cells for NF1-associated plexiform neurofibroma development.,NF1 flox/− mice,animal_model,Efficacy,100% of P0 tamoxifen-induced PLPCre-ERT2;NF1 flox/− mice developed plexiform neurofibromas at 5-6 months of age,Results,"the P0 tam;PLPCre-ERT2;NF1 flox/− mice began to show signs of lethargy, weight loss and paralysis at five to six-months of age requiring that they be sacrificed",0.95
PMID:21551250,10.1158/0008-5472.CAN-10-4577,Susceptible stages in Schwann cells for NF1-associated plexiform neurofibroma development.,NF1 flox/− mice,animal_model,Efficacy,Only 2 out of 19 (10.5%) adult tamoxifen-induced PLPCre-ERT2;NF1 flox/− mice developed plexiform neurofibromas in their second year of life,Results,"Two out of nineteen Atam;PLPCre-ERT2;NF1 flox/− ;R26R mice were sacrificed in their second year of life when they developed signs of sickness including lethargy, ruffled hair, weight loss, and limb paralysis",0.95
PMID:39890807,10.1038/s41598-024-84493-y,Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism.,ipn97.4 immortalized human Schwann cells,cell_line,Mechanistic,NF1 knockout cells showed 1.5-fold lower NADH-linked OXPHOS and electron transfer capacity compared to wild-type cells,Results,NADH-linked OXPHOS and electron transfer capacity was ~ 1.5fold lower in NF1 -/- cells compared to NF1 +/+ (Fig. 5 C-E),0.95
PMID:39890807,10.1038/s41598-024-84493-y,Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism.,ipn97.4 immortalized human Schwann cells,cell_line,Mechanistic,NF1 knockout cells displayed ~30% reduction in OXPHOS and electron transfer capacity with convergent substrate flow,Results,NF1 -/- cells displayed a ~ 30% reduction in OXPHOS and electron transfer capacity associated with convergent flow of NADH-linked substrates and succinate,0.95
PMID:39890807,10.1038/s41598-024-84493-y,Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism.,ipn97.4 immortalized human Schwann cells,cell_line,Biomarker,"148 proteins significantly altered in NF1 knockout vs wild-type cells (68 increased, 76 decreased)",Results,We identified 148 proteins that were significantly altered in spectral count abundance in the WT and null ipn97.4 cells; 68 proteins are increased and 76 proteins are decreased,0.95
PMID:37520682,10.1016/j.omtn.2023.06.018,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.,Schwann cells,cell_line,Biomarker,"NF1 transcript levels decreased by roughly 50% in NF1 Schwann cells from sciatic nerve compared with WT, and by 90% in Schwann cells with LOH",Results,"Transcript levels of NF1 were decreased by roughly 50% in NF1 Schwann cells from NF1 minipig sciatic nerve compared with WT, and by 90% in NF1 and NF1 Schwann cells",0.9
PMID:37520682,10.1016/j.omtn.2023.06.018,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.,Schwann cells,cell_line,Biomarker,"Schwann cells derived from cutaneous neurofibromas showed altered morphology, disorganized architecture, and increased proliferation compared with WT and NF1 sciatic nerve-derived Schwann cells",Results,"Schwann cells derived from cutaneous neurofibromas showed altered morphology, disorganized architecture, and increased proliferation compared with WT and NF1 sciatic nerve-derived Schwann cells",0.85
PMID:21949590,10.2478/v10134-010-0025-8,ALTERED CALCIUM CURRENTS AND AXONAL GROWTH IN Nf1 HAPLOINSUFFICIENT MICE.,Nf1+/- mice,animal_model,Biomarker,"Ca2+ current density was ~75% higher in neurons from Nf1+/- mice: 37.7 ± 4.2 (n=9) versus 21.5 ± 3.7 (n=10) pA pF−1 (Vt=0 mV, p<0.05)",Results,"At 5–7 DIV, the Ca2+ current density was ~75% higher in neurons from Nf1+/− wild-type mice: 37.7 ± 4.2 (n=9) versus versus 21.5 ± 3.7 (n=10) pA pF−1 (Vt=0 mV, p <0.05, Student's t-test).",0.95
PMID:21949590,10.2478/v10134-010-0025-8,ALTERED CALCIUM CURRENTS AND AXONAL GROWTH IN Nf1 HAPLOINSUFFICIENT MICE.,Nf1+/- mice,animal_model,Biomarker,Potassium-stimulated glutamate release was ~45% higher in neurons from Nf1+/- cells: 63.0 ± 3.3% versus 43.1 ± 1.8% total glutamate content/15 min (p<0.05),Results,potassium (50 mM KCl)-stimulated glutamate release was ~45% higher in neurons from Nf1+/− cells compared with wild-type cells; 63.0 ± 3.3% total glutamate content/15 min versus 43.1 ± 1.8% total glutamate content/15,0.95
PMID:21949590,10.2478/v10134-010-0025-8,ALTERED CALCIUM CURRENTS AND AXONAL GROWTH IN Nf1 HAPLOINSUFFICIENT MICE.,Nf1+/- mice,animal_model,Biomarker,Evoked glutamate release was higher in Nf1+/- cells: 51.1 ± 3.4% versus 31.9 ± 1.8% total glutamate content/15 min (p<0.05),Results,The evoked glutamate release (stimulated – initial basal release) was also higher in Nf1+/− cells compared with wild-type cells; 51.1 ± 3.4% total glutamate content/15 min versus 31.9 ± 1.8% total glutamate content/15,0.95
PMID:21949590,10.2478/v10134-010-0025-8,ALTERED CALCIUM CURRENTS AND AXONAL GROWTH IN Nf1 HAPLOINSUFFICIENT MICE.,Nf1+/- mice,animal_model,Biomarker,Total cellular glutamate content was lower in Nf1+/- mice: 26.6 ± 3.4 nmol/well versus 47.3 ± 3.8 nmol/well in wild-type (p<0.05),Results,"we observed a significant increase in the total cellular content of glutamate in cells from wild-type versus Nf1+/− mice: 47.3 ± 3.8 nmol/well (n = 117 wells) versus 26.6 ± 3.4 (n = 48 wells), p <0.05, t-test",0.95
PMID:21949590,10.2478/v10134-010-0025-8,ALTERED CALCIUM CURRENTS AND AXONAL GROWTH IN Nf1 HAPLOINSUFFICIENT MICE.,Nf1+/- mice,animal_model,Biomarker,N-type calcium currents showed hyperpolarizing shift in activation: V50% was -16.3± 1.9 mV in Nf1+/- versus -7.7 ± 1.1 mV in wild-type (p<0.05),Results,"V50% was −7.7 ± 1.1 mV (n=9) for wild-type neurons, which was significantly different from that of wild-type neurons (−16.3± 1.9 mV, n=7; p <0.05, Student's t-test)",0.95
PMID:21949590,10.2478/v10134-010-0025-8,ALTERED CALCIUM CURRENTS AND AXONAL GROWTH IN Nf1 HAPLOINSUFFICIENT MICE.,Nf1+/- mice,animal_model,Biomarker,Dendritic complexity increased with peak of ~20 crossings at 150-250 μm from soma in Nf1+/- neurons versus ~14 crossings in wild-type,Results,This increase reached a peak of ~20 crossings at about 150–250 μm from the soma in EGFP transfected Nf1+/− neurons compared with EGFP–expressing wild-type cells which reached a peak complexity of ~14 crossings,0.9
PMID:21949590,10.2478/v10134-010-0025-8,ALTERED CALCIUM CURRENTS AND AXONAL GROWTH IN Nf1 HAPLOINSUFFICIENT MICE.,Nf1+/- mice,animal_model,Biomarker,Axon length was increased in Nf1+/- neurons compared with wild-type neurons,Results,Axon length was increased in Nf1+/− neurons compared with wild-type neurons,0.85
PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,HSC1λ,cell_line,Efficacy,"PTCH1-knockout HSC1λ cells formed tumors in 75% of mice compared to 0% with control cells, and showed statistically significant increases in cellular proliferation, anchorage independent growth and migration",Results,"In 75% of mice HSC1λ-gPTCH1 formed tumors in the flank, compared to 0% of mice injected with control parental HSC1λ-gGFP cells...PTCH1-knockout resulted in statistically significant increase in cellular proliferation, anchorage independent growth and migration",0.95
PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,ipNF06.2A,cell_line,Efficacy,PTCH1-knockout in ipNF06.2A cells induced activation of the SHH pathway and significant increase in cellular proliferation and migration,Results,"Again, PTCH1-knockout in ipNF06.2A cells induced activation of the SHH pathway and a significant increase in cellular proliferation and migration",0.9
PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,S462TY,cell_line,Efficacy,"Sonidegib treatment resulted in twofold lower IC50 compared to STS-26T, and xenografts treated with sonidegib survived significantly longer (median survival 78 vs 45 days, p = 0.03)",Results,"In vitro treatment of S462TY with sonidegib resulted in a twofold lower half-maximal inhibitory concentration (IC50) compared to STS-26T...S462TY xenografts treated with sonidegib survived statistically significantly longer than xenografts treated with vehicle (median survival 78 vs 45 days, log-rank test, p = 0.03)",0.95
PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,STS-26T,cell_line,Efficacy,"STS-26T xenografts treated with sonidegib did not have improved survival, consistent with lack of SHH pathway activation in this cell line",Results,"In contrast, STS-26T xenografts treated with sonidegib did not have improved survival consistent with the lack of SHH pathway activation in this cell line.",0.9
PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,S462,cell_line,Biomarker,"Demonstrated significantly elevated levels of GLI1, GLI2, and SMO, and clustered with MPNST-G1 tumors in methylation profiling",Results,"We identified significantly elevated levels of GLI1, GLI2, and SMO in 3 of 4 MPNST cell lines (S462, S462TY, and T265)...cell lines S462, S462TY and T265 clustered with MPSNT-G1 tumors",0.9
PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,T265,cell_line,Biomarker,"Demonstrated significantly elevated levels of GLI1, GLI2, and SMO, and clustered with MPNST-G1 tumors in methylation profiling",Results,"We identified significantly elevated levels of GLI1, GLI2, and SMO in 3 of 4 MPNST cell lines (S462, S462TY, and T265)...cell lines S462, S462TY and T265 clustered with MPSNT-G1 tumors",0.9
PMID:25772366,10.1016/j.celrep.2015.02.041,Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties.,Nf1 +/− GFAP CKO,animal_model,Biomarker,Neurosphere formation frequency from optic nerve cultures ranged from 0.06% to 0.28% (0.15 +/− 0.11%; n=3),Results,"The frequency of this stem cell population in the murine optic gliomas ranged from 0.06% to 0.28% (0.15 +/− 0.11%; n=3), determined using a primary sphere formation assay",0.95
PMID:25772366,10.1016/j.celrep.2015.02.041,Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties.,Nf1 flox/flox,animal_model,Efficacy,"Cells took nearly 3 weeks to form smaller clusters, which could not be maintained by serial passaging due to loss of proliferation and self-renewal ability",Results,"cells from Nf1 flox/flox (WT) and Nf1+/− mice took nearly 3 weeks to form smaller clusters, which could not be maintained by serial passaging due to loss of proliferation and self-renewal ability",0.85
PMID:25772366,10.1016/j.celrep.2015.02.041,Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties.,Nf1 +/−,animal_model,Efficacy,"Cells took nearly 3 weeks to form smaller clusters, which could not be maintained by serial passaging due to loss of proliferation and self-renewal ability",Results,"cells from Nf1 flox/flox (WT) and Nf1+/− mice took nearly 3 weeks to form smaller clusters, which could not be maintained by serial passaging due to loss of proliferation and self-renewal ability",0.85
PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",S462,cell_line,Biomarker,Expressed EIF3E-RSPO2 fusion transcript with 1295-fold increase in RSPO2 expression,Results,We identified a fusion transcript expressed by the S462 MPNST cell line that was not present in any of the other MPNST or immortalized human Schwann cell lines. Expression of this fusion correlated with a 1295-fold increase in RSPO2 expression,0.95
PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",S462-TY,cell_line,Efficacy,IC50 values of 0.047-2.22μM for XAV-939 and 0.055-186.87μM for IWR-1,Results,the MPNST cell lines were quite sensitive with relatively low IC50s of 0.047uM to 2.22uM for XAV-939 and 0.055uM to 186.87uM for IWR-1,0.9
PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",STS-26T,cell_line,Efficacy,IC50 values of 0.047-2.22μM for XAV-939 and 0.055-186.87μM for IWR-1,Results,the MPNST cell lines were quite sensitive with relatively low IC50s of 0.047uM to 2.22uM for XAV-939 and 0.055uM to 186.87uM for IWR-1,0.9
PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",S462,cell_line,Efficacy,Combination treatment with IC25 doses of RAD-001 and Wnt inhibitors approached 100% TUNEL-positive cells,Results,"when the MPNST cell lines were treated with their IC25 dose of RAD-001 in combination with either IWR-1 or XAV-939 also at their IC25 dose, the percentage of TUNEL positive cells often went above 50%, and in the S462 cell line, even approached 100%",0.9
PMID:22901811,10.1016/j.cell.2012.06.034,ERK inhibition rescues defects in fate specification of Nf1-deficient neural progenitors and brain abnormalities.,hGFAP-cre,genetic_reagent,Mechanistic,"Onset of expression occurs in ~95% of E12/13 radial glia in the forebrain, inactivating Nf1 in both embryonic and adult neural stem cells",Results,"The onset of hGFAP-cre expression occurs in ~95% of E12/13 radial glia in the forebrain, thus inactivating Nf1 in both embryonic and adult neural stem cells as well as their differentiated progeny",0.95
PMID:22901811,10.1016/j.cell.2012.06.034,ERK inhibition rescues defects in fate specification of Nf1-deficient neural progenitors and brain abnormalities.,Nf1 hGFAP CKO,animal_model,Efficacy,Caused 10-15% increase in cerebral cortical surface area and significant increase in corpus callosum thickness at all three SVZ-associated positions,Results,Nf1 conditional bi-allelic inactivation caused a 10-15% increase in the size of cerebral cortical surface area...Nf1 inactivation caused a significant increase in the thickness of the CC,0.95
PMID:22901811,10.1016/j.cell.2012.06.034,ERK inhibition rescues defects in fate specification of Nf1-deficient neural progenitors and brain abnormalities.,Nf1 hGFAP CKO,animal_model,Biomarker,Exhibited 2- to 3-fold size increase in SVZ compared to controls and 48.3% of Ascl1+ TAP/IPCs expressed Olig2 versus 9% in controls,Results,Nf1 hGFAP CKO SVZ exhibited a 2- to 3-fold size increase compared to controls...nearly half of Ascl1+ TAP/IPCs expressed Olig2 in the Nf1 hGFAP CKO SVZ (48.3%,0.95
PMID:22901811,10.1016/j.cell.2012.06.034,ERK inhibition rescues defects in fate specification of Nf1-deficient neural progenitors and brain abnormalities.,Nf1 hGFAP CKO,animal_model,Safety,"Mice became hunched, scruffy and exhibited growth retardation within a week, weighing only half as much as control littermates by P18",Results,"Nf1 hGFAP CKO mice became hunched, scruffy and exhibited growth retardation within a week...weighed only half as much as control littermates by P18",0.95
PMID:22901811,10.1016/j.cell.2012.06.034,ERK inhibition rescues defects in fate specification of Nf1-deficient neural progenitors and brain abnormalities.,Nf1 NcreER CKO,animal_model,Biomarker,"Percentage of β-gal+ cells expressing Olig2 was greatly increased after acute Nf1 inactivation, with dramatic increase in CC clustering",Results,the percentage of β-gal+ cells expressing Olig2 was greatly increased...β-gal+ cells that all expressed Olig2 were dramatically increased and often formed clusters in the CC,0.9
PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,HeLa cells,cell_line,Mechanistic,70-80% of HK2 localizes in MAMs and most cellular MAMs harbor HK2 proteins,Results,quantification indicate both that 70–80% of HK2 localizes in MAMs and that most cellular MAMs harbor HK2 proteins,0.95
PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,HeLa cells,cell_line,Mechanistic,cl-HK2pep induces HK2 displacement from MAMs in <2 minutes,Results,"cl‐HK2pep is indeed able to enter cells, to interact with mitochondria and to induce HK2 detachment from MAMs in < 2 min",0.95
PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,HeLa cells,cell_line,Mechanistic,"cl-HK2pep triggers mitochondrial depolarization in most tumor cells after 2-4 minutes, followed by cell death in <1 hour",Results,"Peptide administration triggers mitochondrial depolarization in most tumor cells after 2–4 min, followed by phosphatidylserine exposure on the cell surface and plasma membrane rupture in < 1 h",0.95
PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,S462 cells,cell_line,Mechanistic,HK2 localizes in MAMs as demonstrated by fluorescence co-staining with SPLICS probe,Results,These experiments have been extended to diverse HK2‐expressing tumor cell models,0.85
PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,C2C12 cells,cell_line,Mechanistic,"Express HK2 but it is barely located in MAMs, making cells poorly responsive to cl-HK2pep-induced death",Results,"Mouse RAW 264.7 macrophages and mouse C2C12 myoblasts express HK2, even though it is barely located in MAMs. Treatment with cl‐HK2pep is poorly effective in inducing death of these cell models",0.9
PMID:38481529,10.3389/fcell.2024.1359561,Generation of heterozygous and homozygous NF1 lines from human-induced pluripotent stem cells using CRISPR/Cas9 to investigate bone defects associated with neurofibromatosis type 1.,NF1-1 hiPSC line,cell_line,Biomarker,Showed 50% reduction in neurofibromin expression compared to control lines,Results,"According to Western blot analysis, expression of full-length neurofibromin was reduced by half in NF1-1 and NF1-2 hiPSC-MSCs compared to WT-1 and WT-2 hiPSC-MSCs",0.95
PMID:38481529,10.3389/fcell.2024.1359561,Generation of heterozygous and homozygous NF1 lines from human-induced pluripotent stem cells using CRISPR/Cas9 to investigate bone defects associated with neurofibromatosis type 1.,NF1-1 hiPSC line,cell_line,Efficacy,Exhibited decreased alkaline phosphatase activity after 14 days of osteogenic differentiation compared to control lines,Results,"After 14 days of differentiation, NF1-1 and NF1-2 cells harbored decreased alkaline phosphatase activity compared to WT-1 and WT-2 cells",0.9
PMID:38481529,10.3389/fcell.2024.1359561,Generation of heterozygous and homozygous NF1 lines from human-induced pluripotent stem cells using CRISPR/Cas9 to investigate bone defects associated with neurofibromatosis type 1.,NF1-1 hiPSC line,cell_line,Efficacy,Showed significant decrease in calcium deposition compared to control NF1 (+/+) cells,Results,"Furthermore, alizarin red staining solution showed a significant decrease in calcium deposition in cells derived from NF1 patients in comparison to control NF1 (+/+)",0.9
PMID:38481529,10.3389/fcell.2024.1359561,Generation of heterozygous and homozygous NF1 lines from human-induced pluripotent stem cells using CRISPR/Cas9 to investigate bone defects associated with neurofibromatosis type 1.,NF1-2 hiPSC line,cell_line,Biomarker,Showed 50% reduction in neurofibromin expression compared to control lines,Results,"According to Western blot analysis, expression of full-length neurofibromin was reduced by half in NF1-1 and NF1-2 hiPSC-MSCs compared to WT-1 and WT-2 hiPSC-MSCs",0.95
PMID:38481529,10.3389/fcell.2024.1359561,Generation of heterozygous and homozygous NF1 lines from human-induced pluripotent stem cells using CRISPR/Cas9 to investigate bone defects associated with neurofibromatosis type 1.,NF1-2 hiPSC line,cell_line,Efficacy,Exhibited decreased alkaline phosphatase activity after 14 days of osteogenic differentiation compared to control lines,Results,"After 14 days of differentiation, NF1-1 and NF1-2 cells harbored decreased alkaline phosphatase activity compared to WT-1 and WT-2 cells",0.9
PMID:38481529,10.3389/fcell.2024.1359561,Generation of heterozygous and homozygous NF1 lines from human-induced pluripotent stem cells using CRISPR/Cas9 to investigate bone defects associated with neurofibromatosis type 1.,NF1-2 hiPSC line,cell_line,Efficacy,Showed significant decrease in calcium deposition compared to control NF1 (+/+) cells,Results,"Furthermore, alizarin red staining solution showed a significant decrease in calcium deposition in cells derived from NF1 patients in comparison to control NF1 (+/+)",0.9
PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,Nf1+/- mice,animal_model,Behavioral,Exhibited increased hyperactivity in open field task measured by total distance traveled,Results,"As expected, Nf1+/- mice that were WT for Fbxw11 (NF1) showed increased hyperactivity in the OF task measured by total distance traveled",0.85
PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,Nf1+/- mice,animal_model,Behavioral,Chose higher percentage of small rewards rather than waiting for large reward in delay discounting task,Results,chose a higher percentage of small rewards rather than waiting to receive the large reward,0.85
PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,Nf1+/- mice,animal_model,Behavioral,Demonstrated decreased preference for novel versus familiar partner mouse on day 2 of social preference task,Results,demonstrated a decreased preference for a novel versus a familiar partner mouse on day 2 of the SP task,0.85
PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,Nf1+/- mice,animal_model,Behavioral,"Had increased number of falls, over-the-edge time, and edge time in cliff avoidance reaction task",Results,"had an increase in the number of falls, over-the-edge time, and edge time while performing the CAR task",0.85
PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,HEK293T cells,cell_line,Mechanistic,Used for mass spectrometry analysis revealing endogenous phosphorylation of serine 1159 and serine 1164 in GRD1 phosphodegron,Results,we conducted mass spectrometry analysis using gel-purified GRD1 from HEK293T cells. This analysis revealed endogenous phosphorylation of serine 1159 (S1159) and serine 1164 (S1164),0.95
PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,HeLa cells,cell_line,Mechanistic,FBXW11 and FBXO3 depletion by RNAi stabilized neurofibromin and suppressed constitutive phosphorylation of ERK1 and ERK2,Results,FBXW11 and FBXO3 depletion by RNAi in HeLa cells also stabilized neurofibromin and suppressed constitutive phosphorylation of the Ras effectors ERK1 and ERK2,0.95
PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,HeLa cells,cell_line,Mechanistic,Neurofibromin levels were unchanged in cells transfected with FBXW11 or FBXO3 siRNA 2 hours following cycloheximide chase,Results,neurofibromin levels were unchanged in HeLa cells transfected with FBXW11 or FBXO3 siRNA 2 hours following the CHX chase,0.95
PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,LUVA cells,cell_line,Mechanistic,"Used to validate siRNA sequences from library screen, showing neurofibromin accumulation with FBXW11 and FBXO3 targeting",Results,"we validated these siRNA sequences from the library in a human mast cell line (LUVA), which is amenable to transfection and screening",0.85
PMID:23175151,10.1038/bjc.2012.518,MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tumour suppressor gene involved in tumour progression.,sNF96.2,cell_line,Biomarker,"Low miR-29c expression, consistent with low miR-29c expression in MPNST",Results,"We chose sNF96.2 as a previous TaqMan assay showed that the sNF96.2 cell line had low miR-29c expression, a finding consistent with low miR-29c expression in MPNST.",0.9
PMID:23175151,10.1038/bjc.2012.518,MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tumour suppressor gene involved in tumour progression.,sNF96.2,cell_line,Efficacy,Cell motility was significantly reduced in transwell plates and scratch/wound healing assays when transfected with miR-29c mimic,Results,"Transient transfection of the MPNST cell line, sNF96.2, using a miR-29c mimic, and scrambled oligonucleotides (control) revealed that cell motility was significantly reduced in transwell plates, and the scratch/wound healing assays",0.9
PMID:23175151,10.1038/bjc.2012.518,MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tumour suppressor gene involved in tumour progression.,sNF96.2,cell_line,Efficacy,No effect on cell growth/proliferation following transfection with miR-29c mimics using multiple assays,Results,"No effect on cell growth/proliferation of the sNF96.2 cells was noted following transfection with the miR-29c mimics using a number of assays, including a live-cell imaging system IncuCyte, the MTS assay and growing the cells in 3-D culture using soft agar",0.9
PMID:23175151,10.1038/bjc.2012.518,MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tumour suppressor gene involved in tumour progression.,sNF96.2,cell_line,Mechanistic,Significantly reduced proteolytic activity compared with control cultures when transfected with miR-29c mimics,Results,"We found loss of bands corresponding to MMP2, which supports the hypothesis that the cells expressing miR-29c mimics had significantly reduced proteolytic activity compared with control cultures",0.9
PMID:38216587,10.1038/s41467-023-40408-5,Epigenetic reprogramming shapes the cellular landscape of schwannoma.,HEI-193,cell_line,Mechanistic,"CRISPRi suppression of NF2 in HEI-193 cells promoted cell proliferation compared to control sgRNAs, suggesting NF2 retains tumor suppressor functionality",Results,CRISPRi suppression of NF2 in HEI-193 cells stably expressing dCas9-KRAB promoted cell proliferation compared to HEI-193 cells expressing non-targeted control sgRNAs (sgNTC),0.85
PMID:38216587,10.1038/s41467-023-40408-5,Epigenetic reprogramming shapes the cellular landscape of schwannoma.,HEI-193,cell_line,Efficacy,Radiotherapy blocked the growth of HEI-193 schwannoma cells with both fractionated (1.8 Gy x 5 fractions) and hypofractionated (12.5 Gy x 1 fraction) treatments,Results,"Radiotherapy blocked the growth of schwannoma cells (Supplementary Fig. 14a, b), and qPCR assessment of genes distinguishing molecular groups of human schwannomas",0.9
PMID:38216587,10.1038/s41467-023-40408-5,Epigenetic reprogramming shapes the cellular landscape of schwannoma.,HEI-193,cell_line,Mechanistic,"Radiotherapy blocked HEI-193 Hedgehog target gene expression, consistent with results from human Schwann cells",Results,"Consistent with results from human Schwann cells (Supplementary Fig. 13h–j), radiotherapy blocked HEI-193 Hedgehog target gene expression",0.85
PMID:38216587,10.1038/s41467-023-40408-5,Epigenetic reprogramming shapes the cellular landscape of schwannoma.,HEI-193,cell_line,Mechanistic,CRISPRi suppression of APOD or SOX6 attenuated schwannoma cell proliferation compared to cells expressing control sgRNAs,Results,"APOD or SOX6 were suppressed in HEI-193 cells using CRISPRi, which each attenuated schwannoma cell proliferation compared to cells expressing sgNTC",0.85
PMID:38216587,10.1038/s41467-023-40408-5,Epigenetic reprogramming shapes the cellular landscape of schwannoma.,HEI-193,cell_line,Mechanistic,CRISPRi suppression of PTPRG enhanced schwannoma cell apoptosis when combined with radiotherapy,Results,CRISPRi suppression of PTPRG enhanced schwannoma cell apoptosis with radiotherapy,0.85
PMID:38216587,10.1038/s41467-023-40408-5,Epigenetic reprogramming shapes the cellular landscape of schwannoma.,"Human Schwann Cells (HSC, ScienCell Research Laboratories #1700)",cell_line,Mechanistic,"Primary cilia were identified on cultured human Schwann cells, which accumulated Smoothened in cilia and activated the Hedgehog transcriptional program in response to recombinant Sonic Hedgehog",Results,"Primary cilia were also identified on cultured human Schwann cells, which accumulated Smoothened in cilia and activated the Hedgehog transcriptional program in response to recombinant Sonic Hedgehog",0.9
PMID:38216587,10.1038/s41467-023-40408-5,Epigenetic reprogramming shapes the cellular landscape of schwannoma.,"Human Schwann Cells (HSC, ScienCell Research Laboratories #1700)",cell_line,Efficacy,Schwann cell proliferation was blocked by the Smoothened antagonist vismodegib or radiotherapy,Results,Schwann cell proliferation was blocked by the Smoothened antagonist vismodegib or radiotherapy,0.9
PMID:38216587,10.1038/s41467-023-40408-5,Epigenetic reprogramming shapes the cellular landscape of schwannoma.,"Human Schwann Cells (HSC, ScienCell Research Laboratories #1700)",cell_line,Mechanistic,"Radiotherapy reduced ciliary length, attenuated Smoothened accumulation in primary cilia, and blocked Hedgehog target gene expression",Results,"radiotherapy also reduced ciliary length, attenuated Smoothened accumulation in primary cilia, and blocked Hedgehog target gene expression",0.9
PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,NF37,patient_derived_model,Biomarker,Pellets presented a polar area with a group of smaller cells with eosinophilic cytoplasm during chondrogenic differentiation,Results,"CT10, CT11 and NF37 pellets presented a polar area with a group of smaller cells with eosinophilic cytoplasm.",0.8
PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,NF87,patient_derived_model,Biomarker,Showed increased GAGs stained area compared to controls after chondrogenic differentiation in 2D cultures,Results,"the percentage of GAGs stained area was higher in the NF1 group compared with the control group (p = 0.004, Mann-Whitney test)",0.9
PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,CT10,patient_derived_model,Biomarker,Pellets presented a polar area with a group of smaller cells with eosinophilic cytoplasm during chondrogenic differentiation,Results,"CT10, CT11 and NF37 pellets presented a polar area with a group of smaller cells with eosinophilic cytoplasm.",0.8
PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,CT11,patient_derived_model,Biomarker,Pellets presented a polar area with a group of smaller cells with eosinophilic cytoplasm during chondrogenic differentiation,Results,"CT10, CT11 and NF37 pellets presented a polar area with a group of smaller cells with eosinophilic cytoplasm.",0.8
PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,SNF02.2,cell_line,Efficacy,TAZ/YAP silencing resulted in robust reduction in downstream target gene expression and attenuation of proliferation,Results,We detected a robust reduction in downstream target gene expression and attenuation of proliferation in these MPNST cells,0.9
PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,SNF96.2,cell_line,Efficacy,TAZ/YAP silencing resulted in robust reduction in downstream target gene expression and attenuation of proliferation,Results,We detected a robust reduction in downstream target gene expression and attenuation of proliferation in these MPNST cells,0.9
PMID:28193237,10.1186/s12955-017-0607-y,Evaluation of quality of life in adults with neurofibromatosis 1 (NF1) using the Impact of NF1 on Quality Of Life (INF1-QOL) questionnaire.,Impact of NF1 on Quality Of Life (INF1-QOL) questionnaire,clinical_assessment_tool,Other,Final version comprised 14 items with good internal reliability (Cronbach's alpha 0.87),Results,The final version of the INF1-QOL questionnaire showed good internal reliability (Cronbach's alpha 0.87).,0.95
PMID:28193237,10.1186/s12955-017-0607-y,Evaluation of quality of life in adults with neurofibromatosis 1 (NF1) using the Impact of NF1 on Quality Of Life (INF1-QOL) questionnaire.,Impact of NF1 on Quality Of Life (INF1-QOL) questionnaire,clinical_assessment_tool,Behavioral,"Mean total INF1-QOL score was 8.64 (SD 6.3), median 7.0 with a range of 0–30",Results,"The mean total INF1-QOL score was 8.64 (SD 6.3), median 7.0 with a range of 0–30",0.95
PMID:28193237,10.1186/s12955-017-0607-y,Evaluation of quality of life in adults with neurofibromatosis 1 (NF1) using the Impact of NF1 on Quality Of Life (INF1-QOL) questionnaire.,Impact of NF1 on Quality Of Life (INF1-QOL) questionnaire,clinical_assessment_tool,Other,"Strong correlation with EuroQol (r = 0.82, p < 0.0001)",Results,"The correlation of total INF1-QOL score with total EuroQol was r = 0.82, p < 0.0001.",0.95
PMID:28193237,10.1186/s12955-017-0607-y,Evaluation of quality of life in adults with neurofibromatosis 1 (NF1) using the Impact of NF1 on Quality Of Life (INF1-QOL) questionnaire.,Impact of NF1 on Quality Of Life (INF1-QOL) questionnaire,clinical_assessment_tool,Other,"Moderate correlation with clinical severity score (r = 0.34, p < 0.05)",Results,The mean clinical severity score was 1.95 (SD 0.65) correlated r = 0.34 with total INF1-QOL score p < 0.05,0.95
PMID:29847659,10.1167/iovs.17-22588,Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization.,Nf1+/- mice,animal_model,Mechanistic,Enhanced EC outgrowth from aortic rings in response to VEGF compared to WT mice,Results,EC outgrowth was significantly higher in Nf1+/− aortic rings stimulated with VEGF when compared with WT aortic rings stimulated with VEGF,0.9
PMID:29847659,10.1167/iovs.17-22588,Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization.,Nf1+/- mice,animal_model,Mechanistic,Increased CD31-positive vessel-like networks in Matrigel plugs containing VEGF compared to WT mice,Results,Matrigel plugs harvested from Nf1+/− mice were invested with more CD31-positive vessel-like networks when compared with Matrigel plugs harvested from WT mice,0.9
PMID:29847659,10.1167/iovs.17-22588,Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization.,Nf1+/- mice,animal_model,Mechanistic,Increased central vessel dropout area and enhanced neovascularization in oxygen-induced retinopathy model at P17,Results,exposure to hyperoxia from P7 to P12 increased central vessel dropout area and enhanced neovascularization in Nf1+/− mice at P17 when compared with WT mice,0.9
PMID:29847659,10.1167/iovs.17-22588,Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization.,Nf1+/- mice,animal_model,Mechanistic,Increased number of branching capillaries adjacent to avascular retina compared to WT mice,Results,The number of branching capillaries adjacent to the avascular retina was increased in Nf1+/− mice when compared with WT mice,0.9
PMID:36890585,10.1186/s40478-023-01525-w,Neurofibromatosis type 1-dependent alterations in mouse microglia function are not cell-intrinsic.,Nf1 ± mice,animal_model,Biomarker,~50% reduction in neurofibromin expression in Nf1± relative to WT microglia (male: p = 0.0006; female: p = 0.0003),Results,"Consistent with a heterozygous Nf1 mutation, there was a ~ 50% reduction in neurofibromin expression in Nf1± relative to WT microglia (male: p = 0.0006; female: p = 0.0003)",0.95
PMID:36890585,10.1186/s40478-023-01525-w,Neurofibromatosis type 1-dependent alterations in mouse microglia function are not cell-intrinsic.,Nf1 ± mice,animal_model,Behavioral,Male Nf1± microglia showed reduced surveillance index (86.4 ± 5.1 µm²/min) compared to male WT microglia (153.5 ± 8.7 µm²/min; p < 0.0001),Results,"the surveillance index, which is a measure of the process retractions and extensions per unit time, was reduced in male Nf1± microglia (86.4 ± 5.1 µm²/min) compared to male WT microglia (153.5 ± 8.7 µm²/min; p < 0.0001)",0.95
PMID:36890585,10.1186/s40478-023-01525-w,Neurofibromatosis type 1-dependent alterations in mouse microglia function are not cell-intrinsic.,Nf1 ± mice,animal_model,Behavioral,Male Nf1± microglia had reduced ramification index (4.8 ± 0.1) compared to male WT microglia (6.2 ± 0.2; p < 0.0001),Results,male Nf1± microglia had a ramification index (4.8 ± 0.1; n = 106 cells/4 mice) that was smaller than that observed for male WT microglia (6.2 ± 0.2; n = 53 cells/2 mice; p < 0.0001),0.95
PMID:36890585,10.1186/s40478-023-01525-w,Neurofibromatosis type 1-dependent alterations in mouse microglia function are not cell-intrinsic.,Nf1 ± mice,animal_model,Behavioral,"Female WT and Nf1± microglia showed no differences in surveillance parameters (initial rates, cumulative areas, surveillance indexes)",Results,"in female mouse brains, there were no differences in the surveillance of WT and Nf1± microglia processes...neither in the initial rates of surveillance...nor in the cumulative areas surveyed after 40 min",0.9
PMID:36890585,10.1186/s40478-023-01525-w,Neurofibromatosis type 1-dependent alterations in mouse microglia function are not cell-intrinsic.,hGFAP-Cre,genetic_reagent,Behavioral,Male Nf1flox/wt;hGFAP-Cre microglia showed reduced branch points (32 ± 1) compared to WT (42 ± 1; p < 0.0001) and decreased process lengths (500 ± 14 μm vs 652 ± 16 μm; p < 0.0001),Results,the number of branch points per microglial cell was reduced in male Nf1flox/wt;hGFAP-Cre (32 ± 1) compared to WT microglia (42 ± 1; p < 0.0001)...there was a sexually dimorphic decrease in the cumulative process lengths,0.95
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,TM-31,cell_line,Biomarker,IC50 for Trametinib is 97nM,Results,The IC50s for Trametinib varied between 14 and 17nM for the mouse glioma cell lines and is 97nM for the human serum grown TM-31 line,0.95
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,TM-31,cell_line,Biomarker,"Has full loss/inactivation of NF1, ATRX, TP53 and CDKN2A",Results,"Our human NF1-HGG line was derived from a malignant astrocytoma of a 42-year-old female Neurofibromatosis Type I patient and has full loss/inactivation of NF1, ATRX, TP53 and CDKN2A",0.95
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,TM-31,cell_line,Biomarker,Expresses OPC identity markers even when grown in serum conditions,Results,"Importantly, even though this line is grown in serum conditions, which induces differentiation, markers consistent with OPC identity are still expressed",0.85
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,TM-31,cell_line,Efficacy,Shows high baseline sensitivity to compounds with LD50 values at or below 25th percentile of IC50 values from cancer cell line databases,Discussion,This is also true for most of the combinations evaluated in our human TM31 cell line (see Tables 1 and 2). Our results highlight the degree to which the NF1-HGG are sensitive to these drugs,0.9
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,TM-31,cell_line,Efficacy,None of the drug combinations worked synergistically (12 additive and 1 antagonistic combination),Discussion,None of the combinations worked synergistically in the human TM-31 line (12 additive and 1 antagonistic combination),0.95
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,17,cell_line,Biomarker,IC50 for Trametinib varies between 14 and 17nM,Results,The IC50s for Trametinib varied between 14 and 17nM for the mouse glioma cell lines,0.9
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,17,cell_line,Biomarker,IC50 for GDC-0941 varies between 688 and 2412nM,Results,IC50s varied between 688 and 2412nM for GDC-0941,0.9
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,17,cell_line,Biomarker,Shows complete loss of wildtype allele for Nf1 and Tp53,Results,The glioma cell lines show complete loss of the wildtype allele for Nf1 and Tp53,0.95
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,5653,cell_line,Biomarker,IC50 for Trametinib varies between 14 and 17nM,Results,The IC50s for Trametinib varied between 14 and 17nM for the mouse glioma cell lines,0.9
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,5653,cell_line,Biomarker,Shows complete loss of wildtype allele for Nf1 and Tp53,Results,The glioma cell lines show complete loss of the wildtype allele for Nf1 and Tp53,0.95
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,5746,cell_line,Biomarker,IC50 for Trametinib varies between 14 and 17nM,Results,The IC50s for Trametinib varied between 14 and 17nM for the mouse glioma cell lines,0.9
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,5746,cell_line,Biomarker,Shows complete loss of wildtype allele for Nf1 and Tp53,Results,The glioma cell lines show complete loss of the wildtype allele for Nf1 and Tp53,0.95
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,5746,cell_line,Efficacy,LD50 values consistently at or below 25th percentile of IC50 values from cancer cell line databases,Discussion,"Crucially, the observed LD50 values, i.e. the concentration that causes 50% cell death, were consistently at or below the 25th percentile of the IC50 values...in our mouse 5746 line",0.95
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,spheroid culture system,advanced_cellular_model,Mechanistic,Considered more accurate models for glioma and more representative of in vivo models compared to 2D culture,Discussion,"Non-serum grown glioma cell lines are considered more accurate models for glioma, moreover, compared to 2D, a 3D organoid like growth activates different signaling pathways and is considered more representative of in vivo models",0.85
PMID:30274821,10.1016/j.ebiom.2018.09.042,Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors.,Human Schwann cells (HSCs),cell_line,Safety,"Cell viability decreased with MG-132 treatment starting at 5 μM, with dramatic reduction at continued doses",Results,The treatment with MG-132 conferred decreases in the viabilities of normal human Schwann cells (HSCs) with an initial dose of 5 μM at all time-points; cell viabilities were however dramatically reduced with continued doses,0.85
PMID:30274821,10.1016/j.ebiom.2018.09.042,Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors.,Human Schwann cells (HSCs),cell_line,Efficacy,EdU-positive cells increased significantly with merlin shRNA (29.2 ± 6.90% vs. 15.8 ± 3.0%; P = .021),Results,the percentage of EdU-positive cells was significantly increased in HSCs with merlin shRNA compared to the control (29.2 ± 6.90% vs. 15.8 ± 3.0%; P = .021),0.95
PMID:30274821,10.1016/j.ebiom.2018.09.042,Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors.,RT4-D6P2T schwannoma cells,cell_line,Efficacy,"Cell viability decreased in dose- and time-dependent manner with Nutlin-3, maximum p53 level at 10 μM for 48 h",Results,"cell viability decreased in a dose- and time-dependent manner in response to Nutlin-3, which resulted in the accumulation of p53 in these cells with a maximum level at 10 μM for 48 h",0.9
PMID:30274821,10.1016/j.ebiom.2018.09.042,Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors.,RT4-D6P2T schwannoma cells,cell_line,Efficacy,Combined Nutlin-3 and MG-132 treatment resulted in Nutlin-3-dose-dependent increases in apoptosis rates,Results,the combined treatment with Nutlin-3 (0–10 μM) and MG-132 (2.5 μM) resulted in a Nutlin-3-dose-dependent increases in the apoptosis rates of the cells,0.9
PMID:30274821,10.1016/j.ebiom.2018.09.042,Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors.,HEI-193,cell_line,Efficacy,"Combined Nutlin-3 and MG-132 fully blocked tumor growth in xenografts, with initial inhibition observed on day 6",Results,combined treatment with Nutlin-3 and MG-132 fully blocked tumour growth...The initial inhibition of tumour growth of both the RT4 and HEI-193 schwannomas in Nutlin-3 & MG-132 groups was observed on day 6,0.95
PMID:37446790,10.3390/molecules28135128,Icariin Promotes Osteogenic Differentiation in a Cell Model with NF1 Gene Knockout by Activating the cAMP/PKA/CREB Pathway.,C2C12,cell_line,Mechanistic,"NF1 gene knockout in C2C12 cells resulted in significantly reduced osteogenic differentiation with decreased mRNA expression of ALP, Runx2, Osx and Col1a1 at all time points",Results,"the mRNA expression levels of ALP, Runx2, Osx and Col1a1 in the 2−7 group were significantly lower than those in the control group at different time points of osteogenic differentiation",0.95
PMID:37446790,10.3390/molecules28135128,Icariin Promotes Osteogenic Differentiation in a Cell Model with NF1 Gene Knockout by Activating the cAMP/PKA/CREB Pathway.,C2C12,cell_line,Biomarker,NF1 knockout C2C12 cells showed significantly decreased intracellular cAMP levels compared to control cells,Results,"after knocking out the NF1 gene, we observed the intracellular cAMP levels in 2−7 and 2−12 decreased, which was statistically significant compared with the control group",0.95
PMID:37446790,10.3390/molecules28135128,Icariin Promotes Osteogenic Differentiation in a Cell Model with NF1 Gene Knockout by Activating the cAMP/PKA/CREB Pathway.,C2C12,cell_line,Efficacy,"Icariin treatment at 10^-5 M concentration promoted osteogenic differentiation in NF1 knockout C2C12 cells, with increased cell viability and enhanced ALP activity especially at days 5 and 7",Results,the viability of the cells gradually increased with the time of icariin addition...The ALP activity of the 2−7 and 2−12 groups treated with icariin was higher than those of the control group,0.95
PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,NF1-null 293T cells,cell_line,Mechanistic,Successfully transduced with doxycycline-inducible HA-mScarlet-NF1 expression system showing dose-dependent expression,Results,We successfully introduced a fluorescent epitope-tagged (HA-mScarlet) WT and L847P NF1 which was expressed in a Dox dose-dependent manner,0.9
PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,NF1-null 293T cells,cell_line,Mechanistic,L847P mutant expressed considerably less than wild-type under same conditions in doxycycline-inducible system,Results,"We observed that the L847P mutant expressed considerably less than the WT under the same conditions, confirming that the previous response was not transient-transfection-specific",0.9
PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,ipNF95.11b C,cell_line,Mechanistic,Showed same phenotype as 293T cells regarding mutant protein stability after NF1 knockout and transduction,Results,we transduced a previously characterized immortalized peripheral neurofibroma-derived Schwann cell line (ipNF95.11b C) in which we had knocked out NF1. We saw the same phenotype as in the 293T,0.8
PMID:38990917,10.1371/journal.pone.0305548,Optical coherence tomography of the macular ganglion cell layer in children with neurofibromatosis type 1 is a useful tool in the assessment for optic pathway gliomas.,Cirrus HD-OCT,clinical_assessment_tool,Biomarker,"GC-IPL measurements obtained in 132 eyes (88% complete scans) from 71 patients, with 95% success rate in eyes without symptomatic OPG and 69% in eyes with OPG",Results,GC-IPL data were obtained in 132 eyes (Complete scans 88%) from 71 patients...GC-IPL was obtained in 95% eyes without symptomatic OPG and in 69% eyes with OPG,0.95
PMID:38990917,10.1371/journal.pone.0305548,Optical coherence tomography of the macular ganglion cell layer in children with neurofibromatosis type 1 is a useful tool in the assessment for optic pathway gliomas.,Cirrus HD-OCT,clinical_assessment_tool,Biomarker,"Mean GC-IPL thickness: 85±0.4 μm in NF1 without OPG, 70±0.7 μm in NF1-OPG, and 62±1.4 μm in sporadic OPG (p<0.001)",Results,"GC-IPL, mean ± SE (95CI) μm...85 ± 0.4 (84–85) N = 103...70 ± 0.7 (68–70) N = 22...62 ± 1.4 (60–65) N = 7 <0.001",0.95
PMID:38990917,10.1371/journal.pone.0305548,Optical coherence tomography of the macular ganglion cell layer in children with neurofibromatosis type 1 is a useful tool in the assessment for optic pathway gliomas.,Cirrus HD-OCT,clinical_assessment_tool,Biomarker,"GC-IPL showed significant correlation with pRNFL (r=0.662, p<0.001), VA (r=-0.661, p<0.001), and VFI (r=0.644, p<0.001)",Results,"The GC-IPL was significantly correlated to pRNFL (correlation coefficient (r) = 0.662, confidence interval (CI) = .507 to .773 p<0.001), VA (r = -0.661, CI = -7.45 to -.551, p<0.001) and VFI (r = 0.644, CI = .452 to .774, p<0.001)",0.95
PMID:38990917,10.1371/journal.pone.0305548,Optical coherence tomography of the macular ganglion cell layer in children with neurofibromatosis type 1 is a useful tool in the assessment for optic pathway gliomas.,Cirrus HD-OCT,clinical_assessment_tool,Biomarker,"Mean age for first reliable GC-IPL measurement was 5.6±1.5 years, significantly lower than pRNFL at 6.8±1.3 years (p<0.001)",Results,Mean age for first reliable VA measurement was significantly lower than for VFI (5.4±1.6 yrs vs 7.3±1.0 yrs; p<0.001) and for first reliable GC-IPL measurement compared to pRNFL (5.6±1.5 vs 6.8±1.3; p<0.001),0.95
PMID:38990917,10.1371/journal.pone.0305548,Optical coherence tomography of the macular ganglion cell layer in children with neurofibromatosis type 1 is a useful tool in the assessment for optic pathway gliomas.,Cirrus HD-OCT,clinical_assessment_tool,Biomarker,"GC-IPL showed slight but significant decline over time in NF1-OPG group (slope -0.1207μm/trimester, p=0.004)",Results,"A slight but significant decline in GC-IPL was observed in the NF1-OPG group (slope -0.1207μm/trimester, p = 0.004) and insignificant changes were seen in the remaining groups (p>0.05)",0.95
PMID:38990917,10.1371/journal.pone.0305548,Optical coherence tomography of the macular ganglion cell layer in children with neurofibromatosis type 1 is a useful tool in the assessment for optic pathway gliomas.,Cirrus HD-OCT,clinical_assessment_tool,Efficacy,GC-IPL distinguished well between eyes with MRI-verified OPG and eyes without symptomatic OPG in children with NF1 and correlated well with visual function,Discussion,The macular GC-IPL as measured with OCT distinguished well between eyes with MRI-verifed OPG and eyes without symptomatic OPG in children with NF1 and correlated well with visual function,0.9
PMID:38990917,10.1371/journal.pone.0305548,Optical coherence tomography of the macular ganglion cell layer in children with neurofibromatosis type 1 is a useful tool in the assessment for optic pathway gliomas.,Cirrus HD-OCT,clinical_assessment_tool,Other,"Unlike VA, GC-IPL is not affected by age in young children, rendering GC-IPL measurements more reliable in follow-up of OPG",Discussion,"Unlike VA, GC-IPL is not affected by age in young children, rendering GC-IPL measurements more reliable in the follow-up of OPG",0.9
PMID:38990917,10.1371/journal.pone.0305548,Optical coherence tomography of the macular ganglion cell layer in children with neurofibromatosis type 1 is a useful tool in the assessment for optic pathway gliomas.,Cirrus HD-OCT,clinical_assessment_tool,Biomarker,"pRNFL measurements obtained in 73 eyes (49%) from 43 patients, with 54% success rate in eyes without symptomatic OPG and 33% in eyes with OPG",Results,pRNFL in 73 (49%) eyes from 43 patients...pRNFL in 54% eyes without symptomatic OPG and in 33% with OPG,0.95
PMID:38990917,10.1371/journal.pone.0305548,Optical coherence tomography of the macular ganglion cell layer in children with neurofibromatosis type 1 is a useful tool in the assessment for optic pathway gliomas.,Cirrus HD-OCT,clinical_assessment_tool,Biomarker,"Mean pRNFL thickness: 100±0.9 μm in NF1 without OPG, 70±2.1 μm in NF1-OPG, and 77±2.6 μm in sporadic OPG (p<0.001)",Results,"pRNFL, mean ± SE (95CI) μm...100 ± 0.9 (98–101) N = 59...70 ± 2.1 (66–74) N = 11...77 ± 2.6 (72–83) N = 3 <0.001",0.95
PMID:38990917,10.1371/journal.pone.0305548,Optical coherence tomography of the macular ganglion cell layer in children with neurofibromatosis type 1 is a useful tool in the assessment for optic pathway gliomas.,Cirrus HD-OCT,clinical_assessment_tool,Biomarker,"pRNFL showed significant thinning over time in NF1-OPG group (slope -0.7211μm/trimester, p<0.001)",Results,"All three groups showed a thinning in pRNFL over time, however reaching statistical significance in NF1-OPG group (slope -0.7211μm/trimester, p<0.001)",0.95
PMID:38990917,10.1371/journal.pone.0305548,Optical coherence tomography of the macular ganglion cell layer in children with neurofibromatosis type 1 is a useful tool in the assessment for optic pathway gliomas.,Humphrey Field Analyzer perimetry,clinical_assessment_tool,Biomarker,"VFI measurements obtained in 55 eyes (37%) from 36 patients, with 39% success rate in eyes without symptomatic OPG and 31% in eyes with OPG",Results,VFI measurements in 55 eyes (37%) from 36 patients...VFI in 39% of eyes without symptomatic OPG and in 31% eyes with OPG,0.95
PMID:38990917,10.1371/journal.pone.0305548,Optical coherence tomography of the macular ganglion cell layer in children with neurofibromatosis type 1 is a useful tool in the assessment for optic pathway gliomas.,Humphrey Field Analyzer perimetry,clinical_assessment_tool,Biomarker,"Mean VFI: 95±0.6% in NF1 without OPG, 88±3.0% in NF1-OPG, and 47±1.8% in sporadic OPG (p<0.001)",Results,"VFI, mean ± SE (95CI) %...95 ± 0.6 (94–97) N = 42...88 ± 3.0 (83–94) N = 9...47 ± 1.8 (43–50) N = 4 <0.001",0.95
PMID:38990917,10.1371/journal.pone.0305548,Optical coherence tomography of the macular ganglion cell layer in children with neurofibromatosis type 1 is a useful tool in the assessment for optic pathway gliomas.,Humphrey Field Analyzer perimetry,clinical_assessment_tool,Other,"Mean age for first reliable VFI measurement was 7.3±1.0 years, significantly higher than VA at 5.4±1.6 years (p<0.001)",Results,Mean age for first reliable VA measurement was significantly lower than for VFI (5.4±1.6 yrs vs 7.3±1.0 yrs; p<0.001),0.95
PMID:38990917,10.1371/journal.pone.0305548,Optical coherence tomography of the macular ganglion cell layer in children with neurofibromatosis type 1 is a useful tool in the assessment for optic pathway gliomas.,Humphrey Field Analyzer perimetry,clinical_assessment_tool,Biomarker,"VFI showed improvement over time in all groups but reached statistical significance only in NF1 without OPG group (slope 0.3789%/trimester, p<0.001)",Results,"Visual field index was improving in all groups but significant results were obtained only in the NF1 noOPG group (slope 0.3789%/trimester, p<0.001)",0.95
PMID:34065204,10.3390/ijms22105367,RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner.,Mouse embryonic fibroblasts (MEFs),cell_line,Efficacy,Rabl6 knockout MEF cultures displayed reduced proliferation compared to wildtype culture and reduced percentage in S phase,Results,Two different Rabl6 knockout MEF cultures were generated from separate embryos and both displayed reduced proliferation compared to the wildtype culture,0.9
PMID:34065204,10.3390/ijms22105367,RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner.,Mouse embryonic fibroblasts (MEFs),cell_line,Biomarker,"MEFs lacking Rabl6 displayed higher p16 expression at earlier passage and decreased RB1 phosphorylation (S807/811), with premature senescence relative to wildtype MEFs",Results,MEFs lacking Rabl6 displayed higher p16 expression at an earlier passage...heightened p16 expression...strongly correlated with decreased phosphorylation of RB1 (S807/811),0.9
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,JH-2-002,cell_line,Efficacy,PTPN11 genetic depletion significantly reduced MPNST cell growth as evidenced by long-term colony formation assay and short-term real-time cell confluence monitoring,Results,"PTPN11/SHP2 genetic depletion significantly reduced MPNST cell growth, as evidenced by long-term colony formation assay (Fig. 1A and fig. S1A) and short-term real-time cell confluence monitoring",0.9
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,JH-2-002,cell_line,Biomarker,37 of 51 genes (73%) in the MEK-dependent set demonstrated significant down-regulation after PTPN11 depletion (P adj < 0.05),Results,Thirty-seven of the 51 genes (73%) in the MEK-dependent set demonstrated significant down-regulation after PTPN11 depletion (P adj < 0.05),0.95
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,JH-2-002,cell_line,Efficacy,TNO155 treatment led to fewer differentially expressed genes (740) compared to trametinib (3301) or shPTPN11 (3156),Results,"740 genes were significantly altered (P adj < 0.05 and absolute fold change > 1.5) following TNO155, while 3301 and 3156 genes were significantly altered after trametinib and shPTPN11",0.95
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,JH-2-002,cell_line,Efficacy,Median inhibitory concentration increase of 5-fold with WT E7 expression compared to parental cells for TNO155 resistance,Results,"We observed that WT E7–expressing cells were more resistant to TNO155, relative to parental and E7 d21-24 mutant cells, with the median inhibitory concentration increase of 5-fold in JH-2-002",0.95
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,JH-2-079c,cell_line,Mechanistic,TNO155 induced caspase-3/7 activation as demonstrated by IncuCyte real-time monitoring system,Results,"Further investigation in ST8814 and JH-2-079c cell lines treated with dimethyl sulfoxide (DMSO) or 0.3 μM TNO155, using IncuCyte real-time monitoring system, demonstrated caspase-3/7 activation induced by TNO155",0.9
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,JH-2-079c,cell_line,Biomarker,Universally decreased expression of survivin/BIRC5 and claspin/CLSPN with TNO155 and ribociclib combination treatment,Results,we found universally decreased expression of two inhibitors of apoptosis proteins (IAPs) survivin/BIRC5 and claspin/CLSPN in ST8814 and JH-2-079c treated with the combination,0.9
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,JH-2-103,cell_line,Efficacy,Showed increasing trend of percent cells in G1 phase and decreasing trend in S phase when treated with TNO155 and ribociclib combination,Results,"we saw an increasing trend of percent cells in G1 phase and a decreasing trend of percent cells in S phase when comparing cells treated with DMSO, TNO155, ribociclib, and the combination",0.8
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,JH-2-002 PDX,patient_derived_model,Efficacy,Classified as very sensitive (VS) PDX showing almost equal sensitivity to combination and TNO155 alone over 4 weeks,Results,We thus defined the top three PDXs that were almost equally sensitive to the combination and TNO155 alone as very sensitive (VS; Fig. 7A),0.85
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,JH-2-031 PDX,patient_derived_model,Efficacy,Classified as very sensitive (VS) PDX with activating PIK3CA Q546K mutation retaining sensitivity to TNO155,Results,The VS PDX JH-2-031 with activating PIK3CA Q546K mutation and WU-225 with TSC2 in frame deletion retained sensitivity to TNO155,0.9
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,JH-2-031 PDX,patient_derived_model,Efficacy,Showed combination benefit with TNO155 and ribociclib after drug holiday retreatment,Results,We observed combination benefit regardless of intermittent (Fig. 7H) or continuous dosing of therapy over a 10-week treatment,0.85
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,JH-2-079c PDX,patient_derived_model,Efficacy,Classified as partially sensitive (PS) PDX displaying differential sensitivity to combination versus TNO155 alone,Results,the bottom three PDXs that displayed differential sensitivity to the combination and TNO155 as partially sensitive (PS; Fig. 7B),0.85
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,WU-225 PDX,patient_derived_model,Efficacy,Classified as very sensitive (VS) PDX with TSC2 in frame deletion retaining sensitivity to TNO155,Results,The VS PDX JH-2-031 with activating PIK3CA Q546K mutation and WU-225 with TSC2 in frame deletion retained sensitivity to TNO155,0.9
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,WU-225 PDX,patient_derived_model,Biomarker,Cleaved caspase-3 increased in tumors treated with TNO155 and ribociclib combination compared to either drug alone,Results,"Moreover, cleaved caspase-3 increased in WU-225 (fig. S7C), and the IAP survivin markedly decreased in WU-386",0.85
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,WU-386 PDX,patient_derived_model,Efficacy,Classified as partially sensitive (PS) PDX displaying differential sensitivity to combination versus TNO155 alone,Results,the bottom three PDXs that displayed differential sensitivity to the combination and TNO155 as partially sensitive (PS; Fig. 7B),0.85
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,WU-386 PDX,patient_derived_model,Biomarker,IAP survivin markedly decreased in tumors treated with TNO155 and ribociclib combination,Results,"Moreover, cleaved caspase-3 increased in WU-225 (fig. S7C), and the IAP survivin markedly decreased in WU-386",0.85
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,WU-545 PDX,patient_derived_model,Efficacy,Showed most potent antitumor effects with TNO155 and ribociclib combination relative to TNO155 alone or TNO155 and trametinib,Results,"We observed the most potent antitumor effects seen with TNO155 and ribociclib, relative to TNO155 or TNO155 and trametinib in WU-545",0.9
PMID:23685747,10.1038/ng.2641,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.,iHSCs,advanced_cellular_model,Efficacy,FOXR2 overexpression in iHSC clone HSC1λ minimally increased in vitro proliferation and significantly increased soft-agar colony formation compared to luciferase control (two-tailed t-test p<0.0001),Results,"FOXR2 overexpression in the iHSC clone HSC1λ increased total FOXR2 protein and cytoplasmic staining, minimally increased in vitro proliferation, and significantly increased soft-agar colony formation compared to luciferase control (two-tailed t-test p<0.0001)",0.95
PMID:23685747,10.1038/ng.2641,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.,iHSCs,advanced_cellular_model,Efficacy,"No tumor formation in control HSC1λ cells, but 3/5 mice harboring FOXR2 overexpressing cells developed a tumor in xenograft experiments",Results,"Xenograft experiments demonstrated no tumor formation in the control HSC1λ cells, but 3/5 mice harboring FOXR2 overexpressing cells developed a tumor",0.95
PMID:23685747,10.1038/ng.2641,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.,STS26T,cell_line,Efficacy,FOXR2 knockout and mutation detected cell lines had reduced proliferation and significant reductions in colony formation ability compared to HPRT knockout control cells (t-test p<0.0001),Results,FOXR2 knockout and mutation detected cell lines had reduced proliferation and significant reductions in colony formation ability compared to HPRT knockout control cells (t-test p<0.0001),0.95
PMID:23685747,10.1038/ng.2641,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.,STS26T,cell_line,Efficacy,FOXR2 loss inhibited the ability of STS26T cells to form tumors in xenograft experiments compared to HRPT knockout controls,Results,"Additionally, FOXR2 loss inhibited the ability of STS26T cells to form tumors in xenograft experiments compared to HRPT knockout controls",0.9
PMID:23685747,10.1038/ng.2641,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.,S462-TY,cell_line,Efficacy,FOXR2 knockout and mutation detected cell lines had reduced proliferation and significant reductions in colony formation ability compared to HPRT knockout control cells (t-test p<0.0001),Results,FOXR2 knockout and mutation detected cell lines had reduced proliferation and significant reductions in colony formation ability compared to HPRT knockout control cells (t-test p<0.0001),0.95
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,sNF96.2,cell_line,Biomarker,"Expressed HER1 antigen, confirmed by flow cytometry analysis",Results,"After confirming the expression of HER1 on sNF96.2 (Fig. 2 A), we assessed the tumor-lysing capabilities of 806, E2 and NEC.",0.9
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,sNF96.2,cell_line,Biomarker,Released nearly 2000 pg/ml of TGFβ1 in culture medium,Results,The concentration of TGFβ1 in the sNF96.2 culture medium reached nearly 2000 pg/ml (Fig. 3 C).,0.95
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,sNF96.2,cell_line,Biomarker,Approximately 95% of cells were PDL1-positive,Results,"Additionally, approximately 95% of sNF96.2, T20210108 and T20210618, around 85% of T20210304, T20210401 and T20211105 cells, and nearly 60% of T20210106 cells were PDL1-positive",0.9
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,HFFs,cell_line,Biomarker,Showed 98.6% HER1 positivity with low expression intensity,Results,While HFFs showed 98.6% HER1 positivity with low expression intensity.,0.9
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,NCI-H266,cell_line,Biomarker,Was nearly 100% HER1 positive with high expression intensity,Results,NCI-H266 was nearly 100% HER1 positive with high expression intensity.,0.9
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,K562,cell_line,Biomarker,Had no HER1 expression,Results,K562 had no HER1 expression.,0.95
PMID:34011935,10.1038/s41419-021-03802-9,Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine.,Neurofibromatosis 1 fibroblasts,patient_derived_model,Biomarker,"NFFs showed significantly downregulated NF1 protein expression compared to HEFs, while NF1 mRNA expression was comparable between groups",Results,"Although the mRNA expression of NF1 was comparable between HEFs and NFFs (Fig. 2a), the protein expression of NF1 was significantly downregulated in NFFs compared with that in HEFs",0.95
PMID:34011935,10.1038/s41419-021-03802-9,Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine.,Neurofibromatosis 1 fibroblasts,patient_derived_model,Biomarker,"NFFs showed significantly decreased MMP1 protein expression compared to HEFs, with no detectable MMP1 release in supernatants",Results,"the expression of MMP1 protein was significantly decreased in NFFs compared with that in HEFs...significant amounts of MMP1 protein were detected in the supernatants of HEFs, while NFFs did not release detectable amounts",0.95
PMID:34011935,10.1038/s41419-021-03802-9,Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine.,Neurofibromatosis 1 fibroblasts,patient_derived_model,Biomarker,COL1A1 protein expression was comparable between NFFs and HEFs,Results,The protein expression of COL1A1 was comparable between HEFs and NFFs,0.9
PMID:34011935,10.1038/s41419-021-03802-9,Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine.,Neurofibromatosis 1 fibroblasts,patient_derived_model,Efficacy,"HCQ treatment at 50 μM significantly increased MMP1 mRNA and protein levels in NFFs, with restored MMP1 release in culture supernatants",Results,CQ and HCQ significantly increased the mRNA (Fig. 3b) and protein (Fig. 3c and Supplementary Fig. S4) levels of MMP1...The MMP1 proteins upregulated by CQ and HCQ were actually released in the culture supernatants,0.95
PMID:41444363,10.1038/s41598-025-32031-9,Focused ultrasound-mediated drug delivery of bevacizumab in treating NF2-related schwannomatosis in an animal model.,Postn-Cre; Nf2flox/flox,animal_model,Safety,"High mortality and frailty of transgenic line, with significant animal losses during treatment (5 out of 9 animals died during human bevacizumab + FUS treatment)",Both,Establishing the colony was challenging due to the frailty of this specific transgenic line...out of 9 animals 5 died during treatment,0.95
PMID:41444363,10.1038/s41598-025-32031-9,Focused ultrasound-mediated drug delivery of bevacizumab in treating NF2-related schwannomatosis in an animal model.,Postn-Cre; Nf2flox/flox,animal_model,Efficacy,"Consistently developed DRG schwannomas detectable by MRI at 2 months, but no vestibular schwannomas up to 13 months of age",Both,Schwannomas of the DRGs were readily detectable on initial MRI at 2 months...we could not detect vestibular schwannomas on the vestibulocochlear nerve up to 13 months,0.95
PMID:41444363,10.1038/s41598-025-32031-9,Focused ultrasound-mediated drug delivery of bevacizumab in treating NF2-related schwannomatosis in an animal model.,Postn-Cre; Nf2flox/flox,animal_model,Biomarker,"Tumor growth progression measured by MRI voxel counts: age 4-5 months (87.2 ± 30.1), age 7-8 months (109.4 ± 35.5), age 9-11 months (112.4 ± 40.6)",Results,"pooled lumbar DRG voxel counts across the cohort...age 4–5 months: n = 120, 87.2 ± 30.1; age 7–8 months: n = 68, 109.4 ± 35.5; age 9–11 months: n = 60, 112.4 ± 40.6",0.95
PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,iHSCs,cell_line,Mechanistic,NF1-deficient iHSCs showed increased basal RAS-GTP levels compared to NF1-proficient sister clones,Results,"NF1-deficient clones also show increased basal RAS–GTP levels, as expected, when compared with the isogenic-matched NF1-proficient sister clones",0.9
PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,iHSCs,cell_line,Efficacy,"NF1-deficient iHSCs exhibited robust colony formation in low-serum soft agar conditions, while NF1-proficient cells formed limited numbers of colonies",Results,"All NF1-deficient lines tested exhibited robust colony formation in these conditions, similar to the phenotype of an HSC1λ cell line in which the tumor-suppressor PTEN has been knocked out",0.9
PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,iHSCs,cell_line,Efficacy,"NF1-deficient iHSCs formed tumors with 50% penetrance in athymic nude mice, while NF1-proficient lines never formed tumors",Results,"Tumor formation was never observed for the NF1-proficient cell lines. In contrast, all NF1-deficient lines showed the ability to form tumors upon xenograft, with 50% penetrance",0.9
PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,S462-TY,cell_line,Efficacy,"Digoxin showed >1 log shift in IC50 concentration against S462-TY compared to NF1-proficient iHSCs, with near doubling of potency",Results,"When digoxin was used against NF1-deficient iHSCs, a shift of more than 1 log was seen in the IC50 concentration when comparing the MPNST cell line S462-TY with NF1-proficient iHSCs, with a near doubling of potency",0.9
PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,S462-TY,cell_line,Efficacy,Rigosertib showed IC50 concentration in nmol/L range for S462-TY cells but was ineffective against NF1-proficient iHSCs,Results,Rigosertib showed an IC50 concentration in the nmol/L range for S462-TY cells but was ineffective against NF1-proficient iHSCs,0.9
PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,S462-TY,cell_line,Mechanistic,"S462-TY cells showed limited sensitivity to MEK inhibition, with 125 μmol/L selumetinib resulting in ~65% cells in S-phase at 24 hours",Results,"S462-TY MPNST cells show limited sensitivity to MEK inhibition. At 24 hours, 125 µmol/L selumetinib alone results in ∼65% of the cells showing an accumulation in the S-phase",0.9
PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,S462-TY,cell_line,Mechanistic,Treatment with selumetinib alone for 24 hours resulted in significant feedback activation of RAS pathway as detected by RAS-GTP levels,Results,Treatment of S462-TY cells with selumetinib alone for 24 hours resulted in significant (P < 0.0001) feedback activation of the RAS pathway as detected by RAS–GTP levels,0.9
PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,"Dhh::Cre, Nf1fl/fl, Pten",animal_model,Efficacy,"Vehicle-treated animals had median survival of 18 days, while single-agent treatments extended survival: rigosertib (22 days), LB100 (24 days), digoxin (27 days), DMAPT (27.5 days), selumetinib (24 days)",Results,"Vehicle-treated animals had a median survival of 18 days, whereas the cohorts treated with rigosertib (22 days), LB100 (24 days), digoxin (27 days), DMAPT (27.5 days), and selumetinib (24 days) showed increased survival",0.9
PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,"Dhh::Cre, Nf1fl/fl, Pten",animal_model,Efficacy,"Combination therapies showed dramatic increases in median survival: rigosertib + selumetinib (22 to 47 days) and digoxin + selumetinib (27 to 47.5 days), P < 0.001",Results,"The rigosertib + selumetinib and digoxin + selumetinib combinations each showed dramatic increases in median survival when compared with their single-agent results (22 to 47 days and 27 to 47.5 days, respectively, P < 0.001)",0.9
PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,"Dhh::Cre, Nf1fl/fl, Pten",animal_model,Safety,All single agents and combinations were well tolerated with no signs of toxicity including therapy-related lethargy or gastrointestinal issues,Results,"These compounds were well tolerated, with none of the single agents or combinations tested in this model eliciting signs of toxicity in the mice, including therapy-related lethargy or gastrointestinal issues",0.9
PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,Patient-derived xenograft (PDX) MPNST model,patient_derived_model,Efficacy,"Selumetinib + digoxin combination showed increase in survival and reduction in tumor growth, though not as robust as in GEMM or cell line xenograft",Results,"We also tested the selumetinib + digoxin combination in an MPNST PDX grown in NRG mice. In the PDX, an increase in survival and reduction in tumor growth was also observed, although it was not as robust as the response seen in the GEMM or MPNST cell line xenograft",0.8
PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,Patient-derived xenograft (PDX) MPNST model,patient_derived_model,Efficacy,"Selumetinib + rigosertib combination showed superior tumor growth control compared to monotherapy with corresponding increase in overall survival, and significantly better response than selumetinib + digoxin combination",Results,"when the selumetinib + rigosertib combination was tested in the MPNST PDX mentioned, control of tumor growth was superior to either monotherapy, and there was a corresponding increase in overall survival. The response of this combination in the PDX model was significantly better than the selumetinib + digoxin combination",0.9
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,MPNST-SP-01,cell_line,Efficacy,480 active compounds identified from MIPE library screening with CRC scores of -1.1,Results,"480 active compounds at MPNST-SP-01 cell line, 507 at S462 and 410 at sNF96.2) ( 24 , 32 ). The CRC score is a measure of both potency (AC 50 ) and maximum response (MAXR)",0.95
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,S462,cell_line,Efficacy,507 active compounds identified from MIPE library screening with CRC scores of -1.2,Results,"480 active compounds at MPNST-SP-01 cell line, 507 at S462 and 410 at sNF96.2) ( 24 , 32 ). The CRC score is a measure of both potency (AC 50 ) and maximum response (MAXR)",0.95
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,sNF96.2,cell_line,Efficacy,410 active compounds identified from MIPE library screening with CRC scores of -2.1,Results,"480 active compounds at MPNST-SP-01 cell line, 507 at S462 and 410 at sNF96.2) ( 24 , 32 ). The CRC score is a measure of both potency (AC 50 ) and maximum response (MAXR)",0.95
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,MPNST-SP-01,cell_line,Efficacy,Showed stronger synergies at 48h treatment compared to S462 and sNF96.2 cell lines,Results,"synergies are stronger for the MPNST-SP-01 cell line at 48h, while they are weaker and similar between the S462 and sNF96.2 cell lines",0.9
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,MPNST-SP-01,cell_line,Efficacy,"18 combinations met DBSumNeg values lower than -7, with 7 including Panobinostat",Results,"from the eighteen combinations that met this criterion for the MPNST-SP-01 cell line, seven included Panobinostat (histone deacetylase inhibitor) combined with compounds targeting many different targets",0.95
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,S462,cell_line,Efficacy,"11 combinations met DBSumNeg values lower than -7, with 4 including Doxorubicin",Results,"from the eleven combinations that met the criterion for S462, four included Doxorubicin with NVP-BGT226, Englerin A, Neratinib, and Torin 2",0.95
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,sNF96.2,cell_line,Efficacy,"16 combinations met DBSumNeg values lower than -7, with 4 combining Sirolimus",Results,"from sixteen combinations for sNF96.2, four combined Sirolimus (mTOR inhibitor) with AT-9283, Cabozantinib, Crizotinib, and CUDC-101",0.95
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,S462,cell_line,Biomarker,"Showed greater apoptotic response to treatments compared to MPNST-SP-01, proving higher sensitivity",Results,"the combined treatment and the single compounds caused a greater apoptotic response in the S462 cell line, proving that this cell line is more sensitive to the treatments",0.9
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,Human Foreskin Fibroblast (HFF),cell_line,Safety,"Synergism observed in Panobinostat combinations but at higher concentrations than MPNST cell lines, indicating tumor cell selectivity",Results,"Synergism was observed in all the combinations containing Panobinostat, but at higher concentrations than in the MPNST cell lines, indicating that tumor cells are more sensitive to the treatment",0.9
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,Human Foreskin Fibroblast (HFF),cell_line,Safety,"MK-1775 with Doxorubicin did not show synergism, indicating selectivity for tumor cells",Results,MK-1775 with Doxorubicin did not show synergism in the HFF cell line,0.95
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,MPNST-SP-01 PDOX,patient_derived_model,Efficacy,MK-1775 with Doxorubicin reduced final tumor volume 7 times lower than vehicle after 18 days treatment,Results,The treatment caused the final tumor volume in mice to be seven times lower than the vehicle in the sporadic model after eighteen days of treatment,0.95
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,MPNST-NF1-09 PDOX,patient_derived_model,Efficacy,MK-1775 with Doxorubicin reduced final tumor volume almost 4 times lower than vehicle,Results,almost four times lower in the NF1-PDOX model,0.95
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,MPNST-SP-01 PDOX,patient_derived_model,Efficacy,Tumor weight was almost 2 times lower than control with MK-1775 and Doxorubicin treatment,Results,"In the sporadic model, tumor weight was almost two times lower than control",0.95
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,MPNST-NF1-09 PDOX,patient_derived_model,Efficacy,Tumor weight was 3 times lower than control with MK-1775 and Doxorubicin treatment,Results,three times lower in the case of the NF1-related PDOX-MPNST,0.95
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,MPNST-NF1-09 PDOX,patient_derived_model,Safety,Treatment minimally reduced mice body weight by approximately 10%,Results,treatment minimally reduced mice's body weight: approximately 10% in the NF1-related PDOX,0.95
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,MPNST-SP-01 PDOX,patient_derived_model,Safety,No detectable weight loss observed with MK-1775 and Doxorubicin treatment,Results,no detectable weight loss in the sporadic model,0.95
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,MPNST-SP-01 PDOX,patient_derived_model,Efficacy,Panobinostat combinations did not reduce tumor volume or weight after 25 days treatment,Results,the three combinations selected with Panobinostat neither reduced the tumor volume nor the final tumor weight in the sporadic PDOX model (MPNST-SP-01) after 25 days of treatment,0.95
PMID:28029918,10.1056/NEJMoa1605943,Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas.,DhhCre;Nf1fl/fl,animal_model,Efficacy,Selumetinib was associated with decreases from baseline in neurofibroma volume in 12 of 18 mice (67%),Results,Selumetinib was associated with decreases from baseline in neurofibroma volume in 12 of 18 mice (67%) in the animal model of neurofibromatosis type 1– related neurofibroma,0.95
PMID:28029918,10.1056/NEJMoa1605943,Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas.,DhhCre;Nf1fl/fl,animal_model,Efficacy,Vehicle-treated control animals showed neurofibroma volume increase from baseline in 14 of 15 animals,Results,"in contrast, neurofibroma volume increase from baseline was observed in 14 of the 15 vehicle-treated control animals",0.95
PMID:28029918,10.1056/NEJMoa1605943,Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas.,DhhCre;Nf1fl/fl,animal_model,Mechanistic,Mouse tumor samples showed a transient decrease in phosphorylated extracellular signal-regulated kinase (ERK),Results,Mouse tumor samples showed a transient decrease in phosphorylated extracellular signal-regulated kinase (ERK),0.9
PMID:28029918,10.1056/NEJMoa1605943,Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas.,DhhCre;Nf1fl/fl,animal_model,Efficacy,MEK inhibitors showed the greatest activity among targeted agents tested in the neurofibroma animal model,Discussion,MEK inhibitors also showed the greatest activity among the targeted agents that have been tested in the neurofibroma animal model,0.85
PMID:28029918,10.1056/NEJMoa1605943,Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas.,DhhCre;Nf1fl/fl,animal_model,Mechanistic,Intermittent dosing was efficacious despite modest and transient target inhibition of MEK in tumor tissue,Discussion,"It is of interest that in the mouse model, intermittent dosing was efficacious, even though target inhibition of MEK in tumor tissue was modest and transient",0.85
PMID:28166733,10.1186/s12864-017-3519-7,A machine learning classifier trained on cancer transcriptomes detects NF1 inactivation signal in glioblastoma.,U87-MG,cell_line,Biomarker,"Used as NF1-low control with similar or less NF1 signal than 8 GBM samples (H5M, LNA, YXL, VVN, R7K, TRM, UNY, W31)",Results,"Eight other samples had similar or less NF1 signal than the U87-MG NF1-low control (H5M, LNA, YXL, VVN, R7K, TRM, UNY, W31)",0.9
PMID:28166733,10.1186/s12864-017-3519-7,A machine learning classifier trained on cancer transcriptomes detects NF1 inactivation signal in glioblastoma.,U87-MG,cell_line,Biomarker,"With proteasome inhibitors served as positive control with equal or greater NF1 than two samples (PBH, RIW)",Results,"Two samples (PBH, RIW) had equal or greater NF1 than the positive control, U87-MG + proteasome inhibitors (preventing NF1 degradation)",0.9
PMID:25026211,10.1016/j.ccr.2014.05.001,Merlin/NF2 loss-driven tumorigenesis linked to CRL4(DCAF1)-mediated inhibition of the hippo pathway kinases Lats1 and 2 in the nucleus.,Meso-33,cell_line,Efficacy,Complete proliferation arrest in response to re-expression of Merlin,Results,Meso-33 mesothelioma cells undergo a complete proliferation arrest in response to re-expression of Merlin,0.95
PMID:25026211,10.1016/j.ccr.2014.05.001,Merlin/NF2 loss-driven tumorigenesis linked to CRL4(DCAF1)-mediated inhibition of the hippo pathway kinases Lats1 and 2 in the nucleus.,Meso-33,cell_line,Mechanistic,Re-expression of Merlin induced robust phosphorylation of YAP at Ser 127,Results,"re-expression of Merlin induced robust phosphorylation of YAP at its major negative regulatory site, Ser 127",0.95
PMID:25026211,10.1016/j.ccr.2014.05.001,Merlin/NF2 loss-driven tumorigenesis linked to CRL4(DCAF1)-mediated inhibition of the hippo pathway kinases Lats1 and 2 in the nucleus.,Meso-33,cell_line,Mechanistic,Depletion of DCAF1 induced phosphorylation of YAP and suppressed expression of YAP target genes CTGF,Results,depletion of DCAF1 induced phosphorylation of YAP and suppressed expression of the YAP target genes CTGF,0.95
PMID:25026211,10.1016/j.ccr.2014.05.001,Merlin/NF2 loss-driven tumorigenesis linked to CRL4(DCAF1)-mediated inhibition of the hippo pathway kinases Lats1 and 2 in the nucleus.,FC-1801,cell_line,Efficacy,Undergo proliferation arrest and are no longer tumorigenic in response to re-expression of Merlin,Results,"In response to re-expression of Merlin, these cells undergo proliferation arrest and are no longer tumorigenic",0.95
PMID:25026211,10.1016/j.ccr.2014.05.001,Merlin/NF2 loss-driven tumorigenesis linked to CRL4(DCAF1)-mediated inhibition of the hippo pathway kinases Lats1 and 2 in the nucleus.,FC-1801,cell_line,Mechanistic,Silencing of DCAF1 provoked almost complete YAP/TAZ extrusion to the cytoplasm in most cells,Results,silencing of DCAF1 provoked almost complete YAP/TAZ extrusion to the cytoplasm in most cells,0.95
PMID:25026211,10.1016/j.ccr.2014.05.001,Merlin/NF2 loss-driven tumorigenesis linked to CRL4(DCAF1)-mediated inhibition of the hippo pathway kinases Lats1 and 2 in the nucleus.,293T,cell_line,Mechanistic,Flag-HA-DCAF1 associates efficiently with endogenous Lats1 and 2 but not with MST1 or 2,Results,Flag-HA-DCAF1 associates efficiently with endogenous Lats1 and 2 but not with MST1 or 2 in HEK 293T cells,0.95
PMID:21072183,10.1371/journal.pone.0013791,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,NIH-3T3,cell_line,Efficacy,ΔBB cells showed almost twice the invasiveness of control NIH-3T3 cells in Matrigel invasion assay,Results,the invasiveness of ΔBB cells was almost twice that of control NIH-3T3 cells,0.9
PMID:21072183,10.1371/journal.pone.0013791,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,NIH-3T3,cell_line,Efficacy,PID expression reduced invasiveness by about 10% in control NIH-3T3 cells,Results,"In control NIH-3T3 cells, PID expression had a slight effect on morphology, and reduced invasiveness by about 10%",0.9
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,H1838,cell_line,Efficacy,NF1-null NSCLC cell line showed comparable sensitivity to RMC-4550 as other NF1-deficient cancer cell lines,Results,"These results were comparable to other NF1-deficient cancer cell lines (WM3918 and M308, NF1-null melanoma; H1838, NF1-null NSCLC, Figure 3E)",0.8
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,WM3918,cell_line,Efficacy,NF1-null melanoma cell line showed comparable sensitivity to RMC-4550 as other NF1-deficient cancer cell lines,Results,"These results were comparable to other NF1-deficient cancer cell lines (WM3918 and M308, NF1-null melanoma; H1838, NF1-null NSCLC, Figure 3E)",0.8
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,M308,cell_line,Efficacy,NF1-null melanoma cell line harboring BRAF V600E mutation showed resistance to SHP2 inhibition,Results,"Of note, the sporadic MPNST cell line STS26T and the melanoma cell line M308 harbor the BRAF V600E mutation, which confers resistance to SHP2 inhibition",0.9
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,STS26T,cell_line,Efficacy,Sporadic MPNST cell line harboring BRAF V600E mutation showed resistance to SHP2 inhibition,Results,"Of note, the sporadic MPNST cell line STS26T and the melanoma cell line M308 harbor the BRAF V600E mutation, which confers resistance to SHP2 inhibition",0.9
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,ST8814,cell_line,Efficacy,Demonstrated >50% inhibition of proliferation at 10 μM SHP099 and intermediate sensitivity to RMC-4550 with GI50 within 3 μM,Results,"only two cell lines (ST8814 and JH-2–009) demonstrated > 50% inhibition of proliferation at the maximum dose of SHP099 tested of 10 μM...Three cell lines (ST8814, NF11.1 and JH-2–009) demonstrated intermediate sensitivity to RMC-4550",0.9
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,ST8814,cell_line,Biomarker,"Showed increases in phospho-AKT, phospho-S6-kinase and phospho-ribosomal protein S6 in response to MEK inhibition",Results,"In ST8814, we observed increases in phospho-AKT (pAKT), phospho-S6-kinase (pS6K) and phospho-ribosomal protein S6 (pS6) in response to MEK inhibition",0.9
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,NF11.1,cell_line,Efficacy,Demonstrated intermediate sensitivity to RMC-4550 with GI50 within 3 μM,Results,"Three cell lines (ST8814, NF11.1 and JH-2–009) demonstrated intermediate sensitivity to RMC-4550, with the concentration for 50% of maximal inhibition of cell proliferation (GI50) within 3 μM",0.9
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,JH-2–009,cell_line,Efficacy,Demonstrated >50% inhibition of proliferation at 10 μM SHP099 and intermediate sensitivity to RMC-4550 with GI50 within 3 μM,Results,"only two cell lines (ST8814 and JH-2–009) demonstrated > 50% inhibition of proliferation at the maximum dose of SHP099 tested of 10 μM...Three cell lines (ST8814, NF11.1 and JH-2–009) demonstrated intermediate sensitivity to RMC-4550",0.9
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,JH-2–031,cell_line,Efficacy,"Did not demonstrate additive effect of combined MEK and SHP2 inhibition, harbors oncogenic PIK3CA Q546K mutation",Results,"Indeed, the one cell line (JH-2–031) that did not demonstrate an additive effect of combined MEK and SHP2 inhibition harbors an oncogenic mutation (PIK3CA Q546K)",0.9
PMID:34010628,10.1016/j.stem.2021.04.029,Stem-like cells drive NF1-associated MPNST functional heterogeneity and tumor progression.,Nf1f/f;Trp53f/f;Nes-TK,animal_model,Efficacy,"GCV treatment significantly inhibited tumor development compared to saline-treated controls, with significant reduction of GFP+ tumor population",Results,"GCV treatment significantly inhibited tumor development compared to saline-treated controls, and the GFP+ tumor population was significantly reduced",0.85
PMID:34010628,10.1016/j.stem.2021.04.029,Stem-like cells drive NF1-associated MPNST functional heterogeneity and tumor progression.,Nf1f/f;Trp53f/f;Nes-TK,animal_model,Safety,Nes-TK;cisNP cohort exhibited significantly extended survival compared to control cisNP cohort (p=0.0061),Results,the Nes-TK;cisNP cohort exhibited significantly extended survival compared to the control cisNP cohort (p=0.0061,0.95
PMID:34010628,10.1016/j.stem.2021.04.029,Stem-like cells drive NF1-associated MPNST functional heterogeneity and tumor progression.,Nf1f/f;Trp53f/f;Nes-TK,animal_model,Biomarker,"GFP+ tumor cells incorporated BrdU at significantly slower rate, reaching near saturating levels only on day 20 of pulse period",Results,GFP+ tumor cells incorporated BrdU at a significantly slower rate and only reached near saturating levels of GFP and BrdU coexpression on day 20 of the pulse period,0.9
PMID:34010628,10.1016/j.stem.2021.04.029,Stem-like cells drive NF1-associated MPNST functional heterogeneity and tumor progression.,Nf1f/f;Trp53f/f;CGD,animal_model,Efficacy,DT treatment impeded tumor initiation resulting in significant survival benefit compared to saline cohort (p=0.034),Results,DT treatment impeded tumor initiation resulting in a significant survival benefit compared to the saline cohort (p=0.034,0.95
PMID:34010628,10.1016/j.stem.2021.04.029,Stem-like cells drive NF1-associated MPNST functional heterogeneity and tumor progression.,Nf1f/f;Trp53f/f;CGD,animal_model,Efficacy,Four DT doses (50 µg/kg) given on alternate days essentially eliminated CGD-expressing GFP+ cells,Results,Four DT doses (50 µg/kg) given on alternate days essentially eliminated CGD-expressing GFP+ cells without significantly altering the proportion of KI67+ cells,0.9
PMID:34010628,10.1016/j.stem.2021.04.029,Stem-like cells drive NF1-associated MPNST functional heterogeneity and tumor progression.,Nf1f/f;Trp53f/f;CGD,animal_model,Efficacy,Doxo+DT group exhibited the greatest tumor volume inhibition compared to other treatment groups,Results,"All drug-treated mice exhibited varying degrees of tumor inhibition as compared to the saline group. However, the Doxo+DT group exhibited the greatest tumor volume inhibition",0.85
PMID:34010628,10.1016/j.stem.2021.04.029,Stem-like cells drive NF1-associated MPNST functional heterogeneity and tumor progression.,cisNP,animal_model,Biomarker,Spontaneous Nes-TK;cisNP MPNST contained approximately 3% GFP+ cells with low cycling frequency,Results,"Spontaneous Nes-TK;cisNP MPNST were found to contain approximately 3% GFP+ cells and as for the Nes-TK;SKP model, KI67+ or BrdU incorporating tumor cells were seldom GFP positive",0.9
PMID:18242513,10.1016/j.ccr.2008.01.003,The loss of Nf1 transiently promotes self-renewal but not tumorigenesis by neural crest stem cells.,Nf1-/- mice,animal_model,Safety,Germline Nf1-/- embryos die from cardiac defect by embryonic day E14.5,Results,Germline Nf1−/− embryos die from a cardiac defect by embryonic day (E)14.5,0.95
PMID:18242513,10.1016/j.ccr.2008.01.003,The loss of Nf1 transiently promotes self-renewal but not tumorigenesis by neural crest stem cells.,Nf1-/- mice,animal_model,Biomarker,"3-6 fold higher frequency of cells forming multipotent neurospheres in sympathetic chain, DRG, and sciatic nerve compared to controls (p<0.05)",Results,"The sympathetic chain, DRG, and sciatic nerve from Nf1−/− embryos contained a significantly higher percentage of cells (3−6 fold higher; p<0.05) that formed multipotent neurospheres",0.95
PMID:18242513,10.1016/j.ccr.2008.01.003,The loss of Nf1 transiently promotes self-renewal but not tumorigenesis by neural crest stem cells.,Nf1-/- mice,animal_model,Mechanistic,"Increased phosphorylated Erk (pErk) in Nf1-/- colonies, consistent with increased Ras signaling",Results,"Western blot demonstrated increased phosphorylated Erk (pErk) in the Nf1−/− colonies, consistent with increased Ras signaling in these cells",0.9
PMID:18242513,10.1016/j.ccr.2008.01.003,The loss of Nf1 transiently promotes self-renewal but not tumorigenesis by neural crest stem cells.,Nf1-/- mice,animal_model,Biomarker,"Significantly larger multipotent neurospheres formed by NCSCs from DRG, sciatic nerve, and sympathetic chain",Results,"Multipotent neurospheres formed by NCSCs from DRG, sciatic nerve, and sympathetic chain were significantly larger in the absence of Nf1",0.9
PMID:18242513,10.1016/j.ccr.2008.01.003,The loss of Nf1 transiently promotes self-renewal but not tumorigenesis by neural crest stem cells.,Nf1-/- mice,animal_model,Biomarker,"4 to 10 times as many multipotent daughter neurospheres compared to control neurospheres from DRG, nerve, or sympathetic chain",Results,"When cultured from the DRG, nerve, or sympathetic chain, Nf1−/− neurospheres gave rise to 4 to 10 times as many multipotent daughter neurospheres as compared to control neurospheres",0.95
PMID:21216928,10.1158/1535-7163.MCT-10-0654,Interpreting mammalian target of rapamycin and cell growth inhibition in a genetically engineered mouse model of Nf1-deficient astrocytes.,K4622 grade II glioma cell line,cell_line,Mechanistic,5-fold increase in AKT activation with 0.75nM rapamycin compared to vehicle control,Results,we found that 0.75nM rapamycin resulted in a 5-fold increase in AKT activation compared to vehicle control,0.95
PMID:21216928,10.1158/1535-7163.MCT-10-0654,Interpreting mammalian target of rapamycin and cell growth inhibition in a genetically engineered mouse model of Nf1-deficient astrocytes.,K4622 grade II glioma cell line,cell_line,Efficacy,Maximum inhibitory effect on cell growth with 10nM rapamycin treatment,Results,we observed a maximum inhibitory effect on cell growth and histone-H3 phosphorylation following 10nM rapamycin treatment,0.9
PMID:21216928,10.1158/1535-7163.MCT-10-0654,Interpreting mammalian target of rapamycin and cell growth inhibition in a genetically engineered mouse model of Nf1-deficient astrocytes.,K4622 grade II glioma cell line,cell_line,Efficacy,Combined 0.750nM rapamycin and 30 μM LY294002 treatment resulted in 81% reduction in cell proliferation,Results,combined 0.750nM rapamycin and 30 μM LY294002 treatment resulted in an 81% reduction in cell proliferation,0.95
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,HSR-GBM1,cell_line,Biomarker,"Identified as NF1 intact with lack of MGMT expression, conveying sensitivity to TMZ",Results,"We identified two lines as NF1 intact (HSR-GBM1, JHU-0879)...lack of MGMT expression (HSR-GBM1, JHH-520, JHU-1016B) conveyed sensitivity to TMZ",0.9
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,JHH-520,cell_line,Efficacy,Exhibited decreased growth in response to combined MEKi and radiation therapy in heterotopic xenografts,Results,NF1-deficient heterotopic xenografts (JHH-520 and JHH-136) exhibited decreased growth in response to combined treatment as compared to monotherapy,0.9
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,JHU-0879,cell_line,Biomarker,Identified as NF1 intact with intact MGMT expression associated with TMZ resistance,Results,"We identified two lines as NF1 intact (HSR-GBM1, JHU-0879)...intact MGMT expression was associated with resistance (JHU-0879 and JHH-136)",0.9
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,JHU-1016B,cell_line,Biomarker,"Identified as NF1 deficient with lack of MGMT expression, conveying sensitivity to TMZ",Results,"three as NF1 deficient (JHH-136, JHH-520, JHH-1016B)...lack of MGMT expression (HSR-GBM1, JHH-520, JHU-1016B) conveyed sensitivity to TMZ",0.9
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,JHH-136,cell_line,Efficacy,Exhibited decreased growth in response to combined MEKi and radiation therapy in heterotopic xenografts,Results,NF1-deficient heterotopic xenografts (JHH-520 and JHH-136) exhibited decreased growth in response to combined treatment as compared to monotherapy,0.9
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,B76,cell_line,Biomarker,Identified as having BRAF V600E with intact NF1,Results,"three having BRAF V600E with intact NF1 (B76, DBTRG, NMCG1)",0.9
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,NGT-41,cell_line,Biomarker,Identified as having BRAF V600E and deficient NF1,Results,one having BRAF V600E and deficient NF1 (NGT41),0.9
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,NMCG-1,cell_line,Biomarker,Identified as having BRAF V600E with intact NF1,Results,"three having BRAF V600E with intact NF1 (B76, DBTRG, NMCG1)",0.9
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,DBTRG,cell_line,Biomarker,Identified as having BRAF V600E with intact NF1,Results,"three having BRAF V600E with intact NF1 (B76, DBTRG, NMCG1)",0.9
PMID:33934112,10.1038/s41419-021-03716-6,HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,U251,cell_line,Biomarker,TRAP1 protein levels increased rapidly following exposure to hypoxic conditions,Results,"We also observed a fast induction of TRAP1 following exposure to hypoxic conditions in several human tumor cell types, encompassing MIA PaCa-2 pancreatic cancer cells (Fig. 3d), U87 and U251 glioblastoma cells",0.8
PMID:33934112,10.1038/s41419-021-03716-6,HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,MiaPaCa-2,cell_line,Biomarker,TRAP1 protein levels increased following 2-6 hours of hypoxia (0.5% O2) or treatment with CoCl2 (0.5 mM for 6 h),Results,Western blot analysis and quantification of TRAP1 expression in MIA PaCa-2 human pancreatic adenocarcinoma cells following 2–6 h of hypoxia (0.5% O2) or treatment with CoCl2 (0.5 mM for 6 h),0.9
PMID:33934112,10.1038/s41419-021-03716-6,HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,MiaPaCa-2,cell_line,Biomarker,TRAP1 mRNA expression levels increased when exposed to hypoxia,Results,"we exposed to hypoxia both Zebrafish embryos and human pancreatic adenocarcinoma MIA PaCa-2 cells, finding an increase of TRAP1 mRNA levels (Fig. 4d, e)",0.8
PMID:33934112,10.1038/s41419-021-03716-6,HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,BxPc3,cell_line,Biomarker,TRAP1 protein levels increased rapidly following exposure to hypoxic conditions,Results,"We also observed a fast induction of TRAP1 following exposure to hypoxic conditions in several human tumor cell types, encompassing MIA PaCa-2 pancreatic cancer cells (Fig. 3d), U87 and U251 glioblastoma cells, BxPC3 pancreatic carcinoma cells",0.8
PMID:33934112,10.1038/s41419-021-03716-6,HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,ipNF95.6,cell_line,Biomarker,TRAP1 protein levels increased rapidly following exposure to hypoxic conditions,Results,"We also observed a fast induction of TRAP1 following exposure to hypoxic conditions in several human tumor cell types, encompassing MIA PaCa-2 pancreatic cancer cells (Fig. 3d), U87 and U251 glioblastoma cells, BxPC3 pancreatic carcinoma cells, and ipNF95.6 plexiform neurofibroma cells",0.8
PMID:25340526,10.1371/journal.pone.0107760,Nilotinib is more potent than imatinib for treating plexiform neurofibroma in vitro and in vivo.,PNF-derived Schwann cells,cell_line,Efficacy,"Nilotinib IC50 values were 4.0 µM (proliferation) and 4.7 µM (viability), much lower than imatinib's 12.4 µM and 14.6 µM respectively",Results,"However, the IC 50 values of nilotinib were 4.0 and 4.7 µM, much lower than the 12.4 and 14.6 µM of imatinib.",0.95
PMID:29787563,10.1371/journal.pone.0190001,Graph complexity analysis identifies an ETV5 tumor-specific network in human and murine low-grade glioma.,Nf1flox/flox,animal_model,Biomarker,"Used as normal control group (N) equivalent to wild-type mice, showed no Etv5 expression by qPCR",Results,Etv5 expression was detected in in one representative murine Nf1 optic glioma model (OPG-1) but was not detected (n.d.) in the normal murine optic nerve (N) by qPCR,0.9
PMID:28256556,10.1038/srep43315,An inflammatory gene signature distinguishes neurofibroma Schwann cells and macrophages from cells in the normal peripheral nervous system.,Nf1fl/fl;DhhCre,animal_model,Biomarker,Content of F4/80+;CD11b+ macrophages was 2.6 fold higher (P < 0.01) in 7-month-old Nf1fl/fl;DhhCre (0.77 ± 0.09%) than in 1-month-old Nf1fl/fl;DhhCre mice (0.27 ± 0.03%),Results,Content of F4/80+;CD11b+ macrophages was 2.6 fold (P < 0.01) higher in 7-month-old Nf1fl/fl;DhhCre (0.77 ± 0.09%) than in 1-month-old Nf1fl/fl;DhhCre mice (0.27 ± 0.03%),0.95
PMID:28256556,10.1038/srep43315,An inflammatory gene signature distinguishes neurofibroma Schwann cells and macrophages from cells in the normal peripheral nervous system.,Nf1fl/fl;DhhCre,animal_model,Mechanistic,"51.5% of p75+ cells are p75+/EGFP+, and 42.9% are p75+/EGFP−, confirming Cre-mediated recombination pattern",Results,"We found that 51.5% of p75+ cells are p75+/EGFP+, and 42.9% are p75+/EGFP−, confirming prior descriptions of this model",0.92
PMID:31053133,10.1186/s13023-019-1067-8,Burden of adult neurofibromatosis 1: development and validation of a burden assessment tool.,BoN (Burden of NF1) questionnaire,clinical_assessment_tool,Behavioral,"Cronbach's alpha coefficient was 0.91 for the entire questionnaire, reflecting excellent internal coherence",Results,"Cronbach's alpha coefficient was 0.91 for the entire questionnaire, reflecting its excellent internal coherence, while intradimensional coherences exhibiting good reliability.",0.95
PMID:31053133,10.1186/s13023-019-1067-8,Burden of adult neurofibromatosis 1: development and validation of a burden assessment tool.,BoN (Burden of NF1) questionnaire,clinical_assessment_tool,Behavioral,Test-retest reliability demonstrated good reproducibility with intraclass correlation >0.85 for each domain,Results,"The test-retest reliability was obtained on 23 evaluable subjects (Day 1 and Day 10), demonstrating good reproducibility. The intraclass correlation of each dimension was > 0.85 for each domain.",0.95
PMID:31053133,10.1186/s13023-019-1067-8,Burden of adult neurofibromatosis 1: development and validation of a burden assessment tool.,BoN (Burden of NF1) questionnaire,clinical_assessment_tool,Behavioral,"Mean BoN score was 28.42 (±16.87), with men scoring 22.48 (±16.47) versus women 31.67 (±16.38) (p<0.001)",Results,"In our patient cohort, the mean BoN score obtained was 28.42 (±16.87), the mean score for men being 22.48 (±16.47) versus 31.67 (±16.38) for women ( p  < 0.001).",0.95
PMID:31053133,10.1186/s13023-019-1067-8,Burden of adult neurofibromatosis 1: development and validation of a burden assessment tool.,BoN (Burden of NF1) questionnaire,clinical_assessment_tool,Behavioral,"BoN scores varied significantly by disease severity: low severity 17.6 (±11.9), moderate 29.3 (±14.4), high 45.5 (±18.2)",Results,"The BoN score of the low severity group was 17.6 (±11.9), while that of the moderate severity group was 29.3 (±14.4), and that of the high severity group 45.5 (±18.2), the BoN score differences statistically significant.",0.95
PMID:31053133,10.1186/s13023-019-1067-8,Burden of adult neurofibromatosis 1: development and validation of a burden assessment tool.,Dermatology Life Quality Index (DLQI),clinical_assessment_tool,Behavioral,"DLQI highly correlated with BoN questionnaire (r=0.69930, p<0.0001)",Results,"The BoN questionnaire highly correlated with the Dermatology Life Quality Index (DLQI), Perceived Stress Scale (PSS), and SF12 mental scores",0.95
PMID:31053133,10.1186/s13023-019-1067-8,Burden of adult neurofibromatosis 1: development and validation of a burden assessment tool.,SF12,clinical_assessment_tool,Behavioral,"SF12 mental composite score correlated with BoN (r=-0.57650, p<0.0001), while physical score showed weaker correlation (r=-0.26242, p=0.0347)",Results,"The correlation coefficients between BoN and validated questionnaires were relatively high, confirming BoN's external validity; the correlation with the SF12 physical score proved the weakest.",0.95
PMID:20049725,10.1002/emmm.200900027,Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene.,ST88-14,cell_line,Mechanistic,MPNST cell line used in DNA microarray gene expression profiling to identify gene programmes normally expressed at neural crest stage,Results,"DNA microarrays to profile the gene expression in normal Schwann cells, Schwann cells cultured from primary benign neurofibromas (dermal and plexiform subtypes), MPNST cell lines and solid tumours",0.8
PMID:20049725,10.1002/emmm.200900027,Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene.,STS26T,cell_line,Mechanistic,MPNST cell line used in DNA microarray gene expression profiling to identify gene programmes normally expressed at neural crest stage,Results,"DNA microarrays to profile the gene expression in normal Schwann cells, Schwann cells cultured from primary benign neurofibromas (dermal and plexiform subtypes), MPNST cell lines and solid tumours",0.8
PMID:20049725,10.1002/emmm.200900027,Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene.,S520,cell_line,Mechanistic,MPNST cell line used in DNA microarray gene expression profiling to identify gene programmes normally expressed at neural crest stage,Results,"DNA microarrays to profile the gene expression in normal Schwann cells, Schwann cells cultured from primary benign neurofibromas (dermal and plexiform subtypes), MPNST cell lines and solid tumours",0.8
PMID:20049725,10.1002/emmm.200900027,Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene.,S462,cell_line,Mechanistic,MPNST cell line used in DNA microarray gene expression profiling to identify gene programmes normally expressed at neural crest stage,Results,"DNA microarrays to profile the gene expression in normal Schwann cells, Schwann cells cultured from primary benign neurofibromas (dermal and plexiform subtypes), MPNST cell lines and solid tumours",0.8
PMID:20049725,10.1002/emmm.200900027,Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene.,88-3,cell_line,Mechanistic,MPNST cell line used in DNA microarray gene expression profiling to identify gene programmes normally expressed at neural crest stage,Results,"DNA microarrays to profile the gene expression in normal Schwann cells, Schwann cells cultured from primary benign neurofibromas (dermal and plexiform subtypes), MPNST cell lines and solid tumours",0.8
PMID:20049725,10.1002/emmm.200900027,Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene.,90-8,cell_line,Mechanistic,MPNST cell line used in DNA microarray gene expression profiling to identify gene programmes normally expressed at neural crest stage,Results,"DNA microarrays to profile the gene expression in normal Schwann cells, Schwann cells cultured from primary benign neurofibromas (dermal and plexiform subtypes), MPNST cell lines and solid tumours",0.8
PMID:20049725,10.1002/emmm.200900027,Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene.,YST1,cell_line,Mechanistic,MPNST cell line used in DNA microarray gene expression profiling to identify gene programmes normally expressed at neural crest stage,Results,"DNA microarrays to profile the gene expression in normal Schwann cells, Schwann cells cultured from primary benign neurofibromas (dermal and plexiform subtypes), MPNST cell lines and solid tumours",0.8
PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,icNF97.2a,cell_line,Other,Already published in a study for testing exon skipping approach due to specific mutation repertoire,Discussion,"One cell line (icNF97.2a) has already been published in a study by our group, chosen for its specific mutation repertoire to test an exon skipping approach",0.85
PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,icNF97.2b,cell_line,Other,Published to evaluate transcriptomic effects of selumetinib,Discussion,This cell line as well as 2 others (icNF97.2b and icNF98.4d) have also been published by our group to evaluate the transcriptomic effects of selumetinib,0.85
PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,icNF98.4d,cell_line,Other,Published to evaluate transcriptomic effects of selumetinib,Discussion,This cell line as well as 2 others (icNF97.2b and icNF98.4d) have also been published by our group to evaluate the transcriptomic effects of selumetinib,0.85
PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,icNF98.4c,cell_line,Biomarker,Showed lowest pERK:ERK ratio despite predicted high pERK from germline and somatic mutations,Results,"icNF98.4c has the lowest pERK:ERK ratio, which is difficult to interpret given that the germline pathogenic variant results in out-of-frame skipping of exon 43, and the somatic mutation is deletion of the gene",0.8
PMID:35393510,10.1038/s41418-022-00991-4,Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD,cisMPNST cells,cell_line,Efficacy,NDI1 expression increases OCR and reduces tumorigenicity,Results,"NDI1 expression increases OCR (Fig.  5A, B ) and reduces tumorigenicity (Fig.  5C ) in MPNST cells too",0.9
PMID:17924978,10.1111/j.1750-3639.2007.00105.x,Natural history of meningioma development in mice reveals: a synergy of Nf2 and p16(Ink4a) mutations.,Nf2 flox2/flox2 mice,animal_model,Efficacy,13% meningioma development rate (9 of 72 histologically examined mice) when injected with adCre,Results,adCre;Nf2 flox2/flox2 (9 of 72 histologically examined mice; 13%) mice,0.95
PMID:17924978,10.1111/j.1750-3639.2007.00105.x,Natural history of meningioma development in mice reveals: a synergy of Nf2 and p16(Ink4a) mutations.,Nf2 flox2/flox2 mice,animal_model,Biomarker,46% meningothelial proliferation rate (33/72 mice) when injected with adCre,Results,adCre;Nf2 flox2/flox2 (33/72; 46%) mice,0.95
PMID:17924978,10.1111/j.1750-3639.2007.00105.x,Natural history of meningioma development in mice reveals: a synergy of Nf2 and p16(Ink4a) mutations.,Nf2 flox2/flox2 ;p16 Ink4a*/* mice,animal_model,Efficacy,"37% meningioma development rate (10 of 27 histologically examined mice), significantly higher than Nf2 flox2/flox2 alone (P < 0.01)",Results,"adCre;Nf2 flox2/flox2 ;Ink4a*/* (10 of 27 histologically examined mice; 37%) compared with adCre;Nf2 flox2/flox2 (9 of 72 histologically examined mice; 13%) mice (χ2, P < 0.01)",0.95
PMID:17924978,10.1111/j.1750-3639.2007.00105.x,Natural history of meningioma development in mice reveals: a synergy of Nf2 and p16(Ink4a) mutations.,Nf2 flox2/flox2 ;p16 Ink4a*/* mice,animal_model,Biomarker,"77% meningothelial proliferation rate (21/27 mice), significantly higher than Nf2 flox2/flox2 alone (P < 0.01)",Results,"adCre;Nf2 flox2/flox2 ;Ink4a*/* (21/27; 77%) than in adCre;Nf2 flox2/flox2 (33/72; 46%) mice (χ2, P < 0.01)",0.95
PMID:17924978,10.1111/j.1750-3639.2007.00105.x,Natural history of meningioma development in mice reveals: a synergy of Nf2 and p16(Ink4a) mutations.,Nf2 flox2/flox2 ;p16 Ink4a*/* mice,animal_model,Safety,Survival was not reduced compared with Nf2 flox2/flox2 mice,Results,The survival of adCre;Nf2 flox2/flox2 ;Ink4a*/* mice was not reduced compared with that of adCre;Nf2 flox2/flox2,0.9
PMID:38499890,10.1186/s41687-024-00714-y,"The PlexiQoL, a patient-reported outcome measure on quality of life in neurofibromatosis type 1-associated plexiform neurofibroma: translation, cultural adaptation and validation into the Dutch language for the Netherlands.",PlexiQoL,clinical_assessment_tool,Behavioral,Mean completion time of 4 minutes (range 2-8 minutes) in Dutch NF1 patients with plexiform neurofibromas,Results,The mean time to complete the PlexiQoL questionnaire was 4 min (range 2–8 min).,0.95
PMID:38499890,10.1186/s41687-024-00714-y,"The PlexiQoL, a patient-reported outcome measure on quality of life in neurofibromatosis type 1-associated plexiform neurofibroma: translation, cultural adaptation and validation into the Dutch language for the Netherlands.",PlexiQoL,clinical_assessment_tool,Other,High internal consistency with Cronbach's α of 0.825 at first administration and 0.844 at second administration,Results,The PlexiQoL showed high internal consistency at both administrations (Table 2).,0.95
PMID:38499890,10.1186/s41687-024-00714-y,"The PlexiQoL, a patient-reported outcome measure on quality of life in neurofibromatosis type 1-associated plexiform neurofibroma: translation, cultural adaptation and validation into the Dutch language for the Netherlands.",PlexiQoL,clinical_assessment_tool,Other,Excellent test-retest reliability with correlation coefficient of 0.928 between first and second administration (p<0.001),Results,"We found a correlation coefficient of 0.928 between the first and second administration, indicating excellent test-retest reliability (p-value < 0.001).",0.95
PMID:38499890,10.1186/s41687-024-00714-y,"The PlexiQoL, a patient-reported outcome measure on quality of life in neurofibromatosis type 1-associated plexiform neurofibroma: translation, cultural adaptation and validation into the Dutch language for the Netherlands.",PlexiQoL,clinical_assessment_tool,Other,No floor effects observed and no significant ceiling effects,Results,"For the PlexiQoL there were no floor effects, and the observed ceiling effects were not significant.",0.9
PMID:38499890,10.1186/s41687-024-00714-y,"The PlexiQoL, a patient-reported outcome measure on quality of life in neurofibromatosis type 1-associated plexiform neurofibroma: translation, cultural adaptation and validation into the Dutch language for the Netherlands.",PlexiQoL,clinical_assessment_tool,Other,"Strong correlation with NHP Emotional Reactions (0.793) and Social Isolation (0.831) subsections, moderate correlation with Energy Scale (0.584) and Physical Mobility (0.567)",Results,The PlexiQoL score showed strong correlation with the NHP 'Emotional Reactions' and 'Social Isolation' subsections...There was a moderate correlation between the 'Energy Scale' and the 'Physical Mobility' subsections.,0.95
PMID:38499890,10.1186/s41687-024-00714-y,"The PlexiQoL, a patient-reported outcome measure on quality of life in neurofibromatosis type 1-associated plexiform neurofibroma: translation, cultural adaptation and validation into the Dutch language for the Netherlands.",PlexiQoL,clinical_assessment_tool,Other,"Significant differences in scores between participants with different self-reported general health (effect size 0.48, p=0.002) and plexiform neurofibroma severity (effect size 0.42, p=0.009)",Results,"Significant differences in PlexiQoL scores were observed between participants regarding their self-reported general health and plexiform neurofibroma severity (with effect sizes of 0.48 and 0.42, respectively)",0.95
PMID:20551058,10.1158/0008-5472.CAN-09-3769,Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,Nf1^flox/mut;GFAP-Cre,animal_model,Efficacy,"8 of 13 OPG mice developed induced cortical gliomas following PDE4A1 injection (statistically significant, P=0.02)",Results,"Eight of the 13 OPG mice with increased BLI following PDE4A1 injection were considered to have induced cortical gliomas (Table 1). This was a statistically significant rate of induced tumor formation, as determined by Fisher's Exact Test (P=0.02).",0.95
PMID:20551058,10.1158/0008-5472.CAN-09-3769,Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,Nf1^flox/mut;GFAP-Cre,animal_model,Efficacy,Four weeks of Rolipram treatment resulted in tumor regression with restoration of optic nerve volumes to near normal values,Results,"Using this preclinical paradigm, four weeks of Rolipram resulted in tumor regression as measured by a restoration of optic nerve volumes to near normal values (Figure 5B, C).",0.9
PMID:20551058,10.1158/0008-5472.CAN-09-3769,Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,Nf1^flox/flox;GFAP-Cre,animal_model,Efficacy,Only 1 of 7 Tumor Progenitor mice had evidence of induced glioma following PDE4A1 injection,Results,"In contrast, only 1 of 7 Tumor Progenitor mice and 1 of 6 wild-type mice had evidence of induced glioma.",0.9
PMID:20551058,10.1158/0008-5472.CAN-09-3769,Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,Daoy,cell_line,Mechanistic,"Only catalytically-active PDE4A1 decreased intracellular cAMP levels, while both active and inactive forms were equally expressed",Results,"While both forms of PDE4A1 were equally expressed (Supplemental Figure 2A) and localized to the Golgi apparatus (Supplemental Figure 2B), only catalytically-active PDE4A1 decreased intracellular cAMP levels",0.9
PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,DhhCre mice,animal_model,Biomarker,"Cenpf expression was significantly increased in GEM-PNST compared to PST (p=0.0035), but was not significant compared to NF (p=0.1126)",Results,"In the DhhCre model, Cenpf expression was significantly increased in GEM-PNST compared to PST (p=0.0035), but was not significant compared to NF (p=0.1126)",0.95
PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,Nf1flox/flox;PostnCre+ mice,animal_model,Biomarker,Cenpf expression demonstrated upregulation in MPNST compared to both PNF (p=0.0647) and ANNUBP (p=0.0783) but not achieving significance,Results,"Cenpf expression demonstrated upregulation in MPNST compared to both PNF (p=0.0647) and ANNUBP (p=0.0783) in the PostnCre model, though not achieving significance",0.9
PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,Nf1flox/flox;Arf flox/flox;PostnCre+ mice,animal_model,Biomarker,Robust expression of Birc5 observed in GEM-PNST/MPNST arising in this model,Results,We observed robust expression of Birc5 in GEM-PNST/MPNST arising in both models,0.85
PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,ST-8814 cell line,cell_line,Efficacy,"Significant reduction in cell viability with BIRC5 inhibitors YM155 and LQZ-7I, with minimal effect on wild-type and NF1 mutant Schwann cells",Results,"observed a significant reduction in cell viability with both drugs in human MPNST and murine MPNST precursor ecell lines, with minimal effect on the viability of human wild-type and NF1 mutant Schwann cells",0.9
PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,JH-2-002 cell line,cell_line,Efficacy,"Significant reduction in cell viability with BIRC5 inhibitors YM155 and LQZ-7I, and siRNA-mediated depletion of CENPF or BIRC5 impaired viability",Results,siRNA-mediated depletion of CENPF or BIRC5 impaired viability of human MPNST cell lines,0.9
PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,hTERT ipn02.3 2λ cell line,cell_line,Efficacy,Minimal effect on cell viability with BIRC5 inhibitors YM155 and LQZ-7I compared to MPNST cell lines,Results,with minimal effect on the viability of human wild-type and NF1 mutant Schwann cells,0.85
PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,hTERT NF1 ipNF95.6 cell line,cell_line,Efficacy,Minimal effect on cell viability with BIRC5 inhibitors YM155 and LQZ-7I compared to MPNST cell lines,Results,with minimal effect on the viability of human wild-type and NF1 mutant Schwann cells,0.85
PMID:31527226,10.1158/1535-7163.MCT-19-0123,"Ketotifen Modulates Mast Cell Chemotaxis to Kit-Ligand, but Does Not Impact Mast Cell Numbers, Degranulation, or Tumor Behavior in Neurofibromas of ",Nf1flox/flox;PostnCre+ mice,animal_model,Efficacy,Begin to acquire Schwann cell hyperplasia at approximately 4-6 weeks of age prior to pNF formation,Results,Nf1 flox/flox ;PostnCre+ mice begin to acquire Schwann cell hyperplasia at approximately 4–6 weeks of age prior to the formation of multiple pNFs.,0.95
PMID:31527226,10.1158/1535-7163.MCT-19-0123,"Ketotifen Modulates Mast Cell Chemotaxis to Kit-Ligand, but Does Not Impact Mast Cell Numbers, Degranulation, or Tumor Behavior in Neurofibromas of ",Nf1flox/flox;PostnCre+ mice,animal_model,Efficacy,Uniformly acquire multiple pNFs by four months of age,Results,Nf1 flox/flox ;PostnCre+ mice uniformly acquire multiple pNFs by four months of age.,0.95
PMID:31527226,10.1158/1535-7163.MCT-19-0123,"Ketotifen Modulates Mast Cell Chemotaxis to Kit-Ligand, but Does Not Impact Mast Cell Numbers, Degranulation, or Tumor Behavior in Neurofibromas of ",Nf1flox/flox;PostnCre+ mice,animal_model,Efficacy,Tumor number ranged from 0-22 in water/vehicle-treated mice and 0-20 in ketotifen-treated mice at seven months,Results,Tumor number ranged from 0–22 in water/vehicle-treated Nf1 flox/flox ;PostnCre+ mice and 0–20 in the ketotifen-treated Nf1 flox/flox ;PostnCre + mice at seven months.,0.95
PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,M3,cell_line,Efficacy,DAC treatment showed selective antitumor activity against PRC2-WT tumors in orthotopic xenografts,Results,Growth curves over time of orthotopically transplanted human PRC2-WT (M3) and PRC2-loss (M14) cell line–derived xenografts,0.85
PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,M3,cell_line,Biomarker,Enhanced sensitivity to DNMT1 knockdown in PRC2-loss setting via shRNA-linked GFP FACS-based growth competition assay,Results,Validation of increased sensitivity to DNMT1 knockdown in PRC2-loss setting via shRNA-linked GFP FACS-based growth competition assay in PRC2-isogenic MPNST cells,0.9
PMID:38136356,10.3390/cancers15245811,Drug Responses in Plexiform Neurofibroma Type I (PNF1) Cell Lines Using High-Throughput Data and Combined Effectiveness and Potency.,ipNF05.5-MX,cell_line,Efficacy,"Particularly sensitive to PD-0325901 (mirdametinib) and trametinib, and to a lesser extent, selumetinib",Results,"we show that these cells are particularly sensitive to PD-0325901 (mirdametinib) and trametinib, and to a lesser extent, selumetinib",0.85
PMID:38136356,10.3390/cancers15245811,Drug Responses in Plexiform Neurofibroma Type I (PNF1) Cell Lines Using High-Throughput Data and Combined Effectiveness and Potency.,ipNF05.5-MX,cell_line,Efficacy,Showed resistance to a panel of TOP2A inhibitors compared to control cell line,Results,"ipNF05.5-MX cells showed resistance to a panel of TOP2A inhibitors, compared to the response of the control ipnNF95.11C cell line",0.85
PMID:38136356,10.3390/cancers15245811,Drug Responses in Plexiform Neurofibroma Type I (PNF1) Cell Lines Using High-Throughput Data and Combined Effectiveness and Potency.,ipNF05.5-MX,cell_line,Efficacy,Drug resistance found for 6/7 anthracyclines,Results,"Furthermore, drug resistance was found for 6/7 anthracyclines in ipNF05.5-MX cells",0.9
PMID:38136356,10.3390/cancers15245811,Drug Responses in Plexiform Neurofibroma Type I (PNF1) Cell Lines Using High-Throughput Data and Combined Effectiveness and Potency.,ipNF05.5-MX,cell_line,Other,Individual low-concentration responses higher than 100% of DMSO control were indicative of drug-stimulated growth when treated with MEK inhibitors and doxorubicin,Results,"Individual low-concentration responses higher than 100% of the DMSO control were indicative of drug-stimulated growth, as found for ipNF05.5-MX treated with MEK inhibitors and doxorubicin",0.8
PMID:38136356,10.3390/cancers15245811,Drug Responses in Plexiform Neurofibroma Type I (PNF1) Cell Lines Using High-Throughput Data and Combined Effectiveness and Potency.,ipnNF95.11C,cell_line,Other,Used as reference control cell line (NF1 +/−) for drug sensitivity comparisons,Results,We assessed the drug sensitivity of ipNF05.5-MX cells (ΔS NF1 −/−) using ipnNF95.11C (NF1 +/−) as the reference cell line,0.9
PMID:32839340,10.1073/pnas.2008391117,Brain-wide structural and functional disruption in mice with oligodendrocyte-specific ,Nf1 fl/+,genetic_reagent,Behavioral,"Plp-Nf1 fl/+ mice showed impaired initial motor coordination (U = 42, P = 0.006) but normal learning rate (U = 73, P = 0.17) on rotarod test",Results,"Plp-Nf1 fl/+ mice showed reduced initial motor coordination (U = 42, P = 0.006) but a normal learning rate (U = 73, P = 0.17)",0.95
PMID:32839340,10.1073/pnas.2008391117,Brain-wide structural and functional disruption in mice with oligodendrocyte-specific ,Nf1 fl/+,genetic_reagent,Biomarker,"Plp-Nf1 fl/+ mice showed widespread reduction in fractional anisotropy (FA) across the brain, with recovery to control levels in 6 out of 7 regions after L-NAME treatment",Results,"We observed a reliable recovery of FA to control levels in six out of seven regions including the brachium of superior colliculus (Z = 2.31, P = 0.01), fasciculus reticulata (Z = 2.03, P = 0.02)",0.95
PMID:32839340,10.1073/pnas.2008391117,Brain-wide structural and functional disruption in mice with oligodendrocyte-specific ,Nf1 fl/+,genetic_reagent,Biomarker,"Plp-Nf1 fl/+ mice showed reduced interhemispheric connectivity (U = 15, P = 0.037) that was rescued by L-NAME administration (Z = 2.134, P = 0.033)",Results,"Plp-Nf1 fl/+ mice showed reduced interhemispheric connectivity (Mann–Whitney U test: U = 15, P = 0.037). This reduced connectivity was rescued by L-NAME administration (Wilcoxon signed-rank test: Z = 2.134, P = 0.033)",0.95
PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,cNF organoids,advanced_cellular_model,Efficacy,"Successfully established from 100+ cNFs with 66% success rate from 12 patients, yielding 0.3-7.5 million cells per cNF and demonstrating exponential growth over time",Results,We processed over 100 cNFs in total; those with sizes greater than 0.5 cm were processed individually and yielded between 0.3 and 7.5 million cells/cNF,0.9
PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,cNF organoids,advanced_cellular_model,Biomarker,"Maintained high transcriptional correlation with parental tumors (Spearman's rank correlations >0.8 for all culture conditions, with StemPro showing median 0.91)",Results,"Our results showed that cNF organoids correlate strongly with the parental tumors, with calculated Spearman's rank correlations >0.8 for all culture conditions",0.9
PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,cNF organoids,advanced_cellular_model,Efficacy,"Demonstrated drug screening capability with 43 targeted kinase inhibitors, identifying 4 compounds (copanlisib, onalespib, linsitinib, digoxin) that induced ≤50% residual viability across all samples",Results,"These include copanlisib, a PI3K inhibitor; onalespib, an Hsp90 inhibitor; linsitinib, an IGF-1R inhibitor; and digoxin, an Na+/K+ ATPase inhibitor, which induced an average residual viability of ≤50% across all samples",0.9
PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,Cutaneous neurofibroma samples,patient_derived_model,Biomarker,"Showed variable cell proportions with dominant S100+ Schwann cells (19-48%), CD34+ fibroblasts (18-35%), and c-Kit+ mast cells (3-9%)",Results,"There were variable proportions of cells in the parental cNFs, with a dominant population of S100+ Schwann cells (19%–48% across samples) followed by CD34+ fibroblasts (18%–35%) and a smaller population of c-Kit+ cells (3%–9%)",0.9
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,NF95.11b,cell_line,Efficacy,CRISPRi suppression of SUZ12 or EED attenuated selumetinib responses compared to non-targeted control sgRNAs but did not render cells insensitive to selumetinib,Results,"CRISPRi suppression of the PRC2 components SUZ12 or EED inhibited Schwann cell differentiation marker expression and attenuated selumetinib responses compared to non-targeted control sgRNAs (sgNTC), but did not render NF95.11b cells insensitive to selumetinib",0.85
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,NF95.11b,cell_line,Mechanistic,"Cells showed initial repression of ERK phosphorylation and early induction of apoptosis after selumetinib treatment, followed by recovery of pERK in cells that persisted despite continued treatment",Results,"Immunoblotting of neurofibroma cell lysates after selumetinib treatment showed initial repression of ERK phosphorylation (pERK) and early induction of apoptosis (cleaved Caspase-3, cleaved Caspase-7), followed by recovery of pERK",0.9
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,NF95.11b,cell_line,Efficacy,"Cells with combined loss of NF1 and NF2 were resistant to selumetinib compared to NF1-mutant, NF2-intact cells",Results,"Moreover, NF95.11b cells with combined loss of NF1 and NF2 were resistant to selumetinib compared to NF1-mutant, NF2-intact NF95.11b cells",0.9
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,NF95.11b,cell_line,Mechanistic,"CRISPRi suppression of NF2 induced PAK1 phosphorylation without significantly affecting pMEK, pERK, or pAKT",Results,"CRISPRi suppression of NF2 in NF1-mutant NF95.11b neurofibroma cells induced PAK1 phosphorylation (pPAK1) without significantly affecting pMEK, pERK, or pAKT compared to sgNTC",0.9
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,NF95.11b,cell_line,Mechanistic,"NF1-mutant, NF2-mutant cells maintained pERK in response to selumetinib monotherapy compared to NF1-mutant, NF2-intact cells",Results,"NF1-mutant, NF2-mutant NF95.11b cells maintained pERK in response to selumetinib monotherapy compared to NF1-mutant, NF2-intact NF95.11b cells",0.9
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,NF95.11b,cell_line,Mechanistic,Combination treatment with selumetinib and NVS-PAK1-1 showed greater initial repression of pERK and sustained repression of pPAK1,Results,"Moreover, combination treatment with selumetinib and NVS-PAK1-1 showed greater initial repression of pERK and sustained repression of pPAK1 after compared to control NF95.11b cells",0.85
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,ST88-14,cell_line,Efficacy,PRC2-mutant ST88-14 MPNST cells demonstrated resistance to selumetinib compared to PRC2-intact cells,Results,PRC2-mutant ST88-14 MPNST cells demonstrated resistance to selumetinib compared to PRC2-intact cells,0.85
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,ST88-14,cell_line,Biomarker,"High pPAK1 was observed in NF1-mutant, SUZ12-mutant ST88-14 MPNST cells independent of CRISPRi suppression of NF2",Results,"High pPAK1 was observed in NF1-mutant, SUZ12-mutant ST88-14 MPNST cells independent of CRISPRi suppression of NF2",0.85
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,JW23.3,animal_model,Efficacy,Combination molecular therapy with selumetinib and NVS-PAK1-1 additively inhibited allograft growth compared to vehicle or monotherapy,Results,combination molecular therapy additively inhibited JW23.3 and JW18.2 allograft growth compared to vehicle or selumetinib or NVS-PAK1-1 monotherapy,0.9
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,JW18.2,animal_model,Efficacy,Combination molecular therapy with selumetinib and NVS-PAK1-1 additively inhibited allograft growth compared to vehicle or monotherapy,Results,combination molecular therapy additively inhibited JW23.3 and JW18.2 allograft growth compared to vehicle or selumetinib or NVS-PAK1-1 monotherapy,0.9
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,JW23.3,animal_model,Biomarker,Proliferating tumor cells and Nf2 expression were reduced in MPNST allografts after selumetinib compared to vehicle control treatment,Results,"Moreover, proliferating tumor cells (Fig. 2e) and Nf2 (Fig. 2f) were reduced in JW23.3 MPNST allografts after selumetinib compared to vehicle control treatment",0.9
PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,Periostin-CRE;NF2 fl/fl,animal_model,Efficacy,73% and 52% decrease in tumor cell proliferation in VG with VT1 and VT2 treatment respectively,Results,"Both VT1 and VT2 showed significant decreases in tumour cell proliferation (73% and 52%, respectively) within the VG",0.95
PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,Periostin-CRE;NF2 fl/fl,animal_model,Efficacy,Significant reductions in tumor volume in VG and DRG with VT1 or VT2 treatment in 9-month-old animals,Results,We observed significant reductions in tumour volume in VT1- or VT2-treated animals,0.9
PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,Periostin-CRE;NF2 fl/fl,animal_model,Safety,No apparent side effects or weight loss in animals treated with VT1 and VT2,Results,"There were no apparent side effects or weight loss in animals, as in their previous use",0.85
PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,BenMen-1,cell_line,Efficacy,Proliferation reduced by ALDH1A1-specific inhibitor in dose-dependent manner,Results,use of an ALDH1A1-specific inhibitor slowed the proliferation of BenMen-1 meningioma cells,0.85
PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,BenMen-1,cell_line,Efficacy,Strong synergistic effects of cisplatin and ALDH1A1 inhibitor combination on proliferation reduction,Results,"Either reagent alone reduced BenMen-1 cell proliferation, but the combination was strongly synergistic in reducing cell proliferation",0.9
PMID:25043298,10.1038/onc.2014.185,Oncogenic role of Merlin/NF2 in glioblastoma.,U251,cell_line,Efficacy,"U251-S subpopulation was highly tumorigenic compared to U251-R cells (p<0.01), which were not able to generate tumors. Tumors were significantly larger in U251-S than U251p (p<0.05)",Results,"Consistent with our in vitro studies, the U251-S subpopulation was highly tumorigenic compared to U251-R cells (p<0.01), which were not able to generate tumors. Of note, tumors were significantly larger in U251-S than U251p",0.95
PMID:25043298,10.1038/onc.2014.185,Oncogenic role of Merlin/NF2 in glioblastoma.,U251,cell_line,Mechanistic,"U251-S cells showed 70% Ki67-positive cells at high confluence (p<0.01) compared to U251-R (33%) and astrocytes (41%), indicating defective cell-contact inhibition",Results,"the percentage of Ki67-positive cells was higher in U251-S cells at high confluence (70%, p<0.01) compared to U251-R and astrocytes (33% and 41%, respectively",0.92
PMID:36420221,10.1016/j.omtn.2022.10.026,Antisense oligonucleotides targeting exon 11 are able to partially rescue the NF2-related schwannomatosis phenotype ,HeLa cells,cell_line,Mechanistic,Used to verify that induced skipping of exons 4 or 8 caused decrease in Merlin levels rather than lack of immunoreactivity by transfecting exon-less NF2 cDNAs with N-terminal FLAG tag,Results,"To verify that the induced skipping of exons 4 or 8 caused a decrease in Merlin levels rather than a lack of immunoreactivity, the exon-less NF2 cDNAs were cloned to an N-terminal FLAG tag expression vector and transfected to HeLa cells",0.8
PMID:36420221,10.1016/j.omtn.2022.10.026,Antisense oligonucleotides targeting exon 11 are able to partially rescue the NF2-related schwannomatosis phenotype ,NF2 primary fibroblasts,patient_derived_model,Mechanistic,"Showed actin cytoskeleton abnormalities and loss of contact inhibition consistent with Merlin loss, with recovery of cell-cell contact inhibition and capacity for monolayer growth after Merlin-e11 induction",Results,pediatric-derived NF2 (+/−) fibroblasts recovered part of the cell-cell contact inhibition and recovered the capacity of growth as a monolayer after the induction of Merlin-e11,0.8
PMID:32438526,10.1002/lary.28671,Effects of Neurod1 Expression on Mouse and Human Schwannoma Cells.,Postn-cre;Nf2f/f,animal_model,Biomarker,Showed significant increase in EdU-positive proliferating cells in vestibular ganglia compared to control animals,Results,Quantifying the EdU positive profiles showed significant increase in proliferation of Nf2 cKOs compared to control animals,0.9
PMID:32438526,10.1002/lary.28671,Effects of Neurod1 Expression on Mouse and Human Schwannoma Cells.,Postn-cre;Nf2f/f,animal_model,Behavioral,"Showed statistically significant reduction in VsEP amplitudes and significantly longer response latencies (p1: p=0.015, n1: p=0.002, p2: p=0.001) when combined with ND1",Results,"there is a statistically significant reduction in VsEP amplitudes in Nf2 cKO mice. mean latencies of p1, n1 and p2 were significantly longer only for Nf2 cKO+ND1 compared to controls",0.95
PMID:32438526,10.1002/lary.28671,Effects of Neurod1 Expression on Mouse and Human Schwannoma Cells.,Primary human vestibular schwannoma (VS) cell cultures,patient_derived_model,Efficacy,Showed statistically significant and dose-dependent reduction in proliferation (EdU uptake) when transduced with Neurod1-expressing vectors,Results,"statistically significant and dose dependent reduction in EdU uptake in VS cells that express Neurod1 relative to those treated with EV. Thus, gene transfer with Neurod1 expressing viral vectors reduces human VS proliferation in vitro",0.95
PMID:18367665,10.1124/jpet.107.135830,Induction of apoptosis in neurofibromatosis type 1 malignant peripheral nerve sheath tumor cell lines by a combination of novel farnesyl transferase inhibitors and lovastatin.,NF90-8,cell_line,Mechanistic,"Reduction of Ras prenylation observed following combination treatment of 1 μM FTI compounds with 1 μM lovastatin, with near complete inhibition achieved",Results,"However, a reduction of Ras prenylation was observed in the NF90-8 cells following combination treatment of 1 μM 1 or 2 with 1 μM lovastatin",0.9
PMID:18367665,10.1124/jpet.107.135830,Induction of apoptosis in neurofibromatosis type 1 malignant peripheral nerve sheath tumor cell lines by a combination of novel farnesyl transferase inhibitors and lovastatin.,NF90-8,cell_line,Efficacy,Combination treatments of 500 nM FTI plus 500 nM lovastatin were cytostatic after 24 hours and reduced total cell number below initial plating after 72 hours,Results,"However, combination treatments of 500 nM 1 plus 500 nM lovastatin were cytostatic after 24 hours of treatment, and reduced total cell number below initial plating after 72 hours",0.95
PMID:18367665,10.1124/jpet.107.135830,Induction of apoptosis in neurofibromatosis type 1 malignant peripheral nerve sheath tumor cell lines by a combination of novel farnesyl transferase inhibitors and lovastatin.,NF90-8,cell_line,Mechanistic,Combination treatment resulted in increased percentage of cells in G1 and significant percentage of cells undergoing apoptosis compared to controls,Results,"The combination treatment results in an increased percentage of cells in G1, and a significant percentage of cells undergoing apoptosis, compared to the control cultures",0.9
PMID:18367665,10.1124/jpet.107.135830,Induction of apoptosis in neurofibromatosis type 1 malignant peripheral nerve sheath tumor cell lines by a combination of novel farnesyl transferase inhibitors and lovastatin.,NF90-8,cell_line,Mechanistic,High amounts of active DEVDase (caspases-3 and -7) were observed following treatment with 500 nM FTI compounds and 500 nM lovastatin,Results,"However, high amounts of active DEVDase were observed in NF90-8 cells (Fig. 7C-D), and moderate amounts in ST88-14 (Fig. 7A-B) cells, following treatment with 500 nM 1 or 2 and 500 nM lovastatin",0.9
PMID:18367665,10.1124/jpet.107.135830,Induction of apoptosis in neurofibromatosis type 1 malignant peripheral nerve sheath tumor cell lines by a combination of novel farnesyl transferase inhibitors and lovastatin.,ST88-14,cell_line,Mechanistic,Moderate reduction of Ras prenylation observed in FTI/lovastatin combination treated cells compared to single treatments,Results,"Ras prenylation was also reduced in ST88-14 FTI/lovastatin combination treated cells compared to the single treatments of 1, 2, or lovastatin. The observed reduction of Ras prenylation in ST88-14 cells was moderate",0.85
PMID:18367665,10.1124/jpet.107.135830,Induction of apoptosis in neurofibromatosis type 1 malignant peripheral nerve sheath tumor cell lines by a combination of novel farnesyl transferase inhibitors and lovastatin.,ST88-14,cell_line,Efficacy,Reduction of proliferation observed when 500 nM FTI compounds were used in combination with 500 nM lovastatin,Results,"However, when 500 nM 1 or 2 were used in combination with 500 nM lovastatin, we observed a reduction of ST88-14 proliferation",0.9
PMID:18367665,10.1124/jpet.107.135830,Induction of apoptosis in neurofibromatosis type 1 malignant peripheral nerve sheath tumor cell lines by a combination of novel farnesyl transferase inhibitors and lovastatin.,ST88-14,cell_line,Mechanistic,"Moderate G1 cell cycle arrest at 24 hours maintained at 48 hours following FTI/lovastatin combination treatment, with modest increase in apoptotic cells",Results,"We observed a moderate G1 cell cycle arrest at 24 hours that was maintained at 48 hours following FTI/lovastatin combination treatment. Although we observed an increased percentage of apoptotic cells at 48 hours, the effect was more modest",0.85
PMID:18367665,10.1124/jpet.107.135830,Induction of apoptosis in neurofibromatosis type 1 malignant peripheral nerve sheath tumor cell lines by a combination of novel farnesyl transferase inhibitors and lovastatin.,Primary normal rat Schwann cells,cell_line,Safety,Combination treatments of 500 nM FTI compounds with 500 nM lovastatin had no observable toxicity on normal primary Schwann cells,Results,"However, in a stark contrast to the effect on MPNST cells, combination treatments of 500 nM 1 or 2 with 500 nM lovastatin had no observable toxicity on normal primary Schwann cells",0.95
PMID:18367665,10.1124/jpet.107.135830,Induction of apoptosis in neurofibromatosis type 1 malignant peripheral nerve sheath tumor cell lines by a combination of novel farnesyl transferase inhibitors and lovastatin.,iSC,cell_line,Safety,Combination treatments of 500 nM FTI compounds with 500 nM lovastatin did not significantly reduce proliferation of immortalized Schwann cells,Results,Combination treatments of 500 nM 1 or 2 with 500 nM lovastatin also did not significantly reduce proliferation of iSC cells,0.9
PMID:40723243,10.3390/cancers17142359,The Combination of HSP90 Inhibitors and Selumetinib Reinforces the Inhibitory Effects on Plexiform Neurofibromas.,ipNF05.5 Mixed Clones,cell_line,Efficacy,"Showed modest dose-dependent responses to selumetinib alone, with significantly improved inhibition when combined with lowest concentrations of HSP90i",Results,treatment with selumetinib alone (the left column) resulted in modest dose-dependent responses in pNF cell lines. The administration of the lowest concentrations of HSP90i...yielded significantly improved inhibition,0.9
PMID:40723243,10.3390/cancers17142359,The Combination of HSP90 Inhibitors and Selumetinib Reinforces the Inhibitory Effects on Plexiform Neurofibromas.,ipNF05.5 Single Clone,cell_line,Efficacy,Demonstrated synergistic effects with mean synergy scores above cutoff (>10) for HSP90i and selumetinib combinations,Results,"the means of synergy scores for the ipNF05.5 Mixed Clones, ipNF05.5 Single Clone, and ipNF95.11bC are all above the cutoff for the combinations",0.95
PMID:40723243,10.3390/cancers17142359,The Combination of HSP90 Inhibitors and Selumetinib Reinforces the Inhibitory Effects on Plexiform Neurofibromas.,ipNF95.11bC,cell_line,Efficacy,"Achieved synergy scores above cutoff (>10) with HSP90i and selumetinib combinations, with highest synergy scores at low concentrations of both agents",Results,"the means of synergy scores for the ipNF05.5 Mixed Clones, ipNF05.5 Single Clone, and ipNF95.11bC are all above the cutoff...highest synergy scores were commonly observed within the combination therapy",0.95
PMID:40723243,10.3390/cancers17142359,The Combination of HSP90 Inhibitors and Selumetinib Reinforces the Inhibitory Effects on Plexiform Neurofibromas.,ipnNF95.11c,cell_line,Safety,Non-tumor Schwann cell line showed only mild inhibitory effects when treated with selumetinib and HSP90i combinations,Results,"Meanwhile, the combinations exhibited mild inhibitory effects on non-tumor Schwann cell lines, ipnNF95.11c",0.9
PMID:40723243,10.3390/cancers17142359,The Combination of HSP90 Inhibitors and Selumetinib Reinforces the Inhibitory Effects on Plexiform Neurofibromas.,DhhCre;Nf1f/f;Luciferase,animal_model,Efficacy,Combination treatment (selumetinib 40 mg/kg + SNX-2112 30 mg/kg) showed much stronger tumor growth inhibition compared to selumetinib alone (50 mg/kg) and vehicle control,Results,The growth rate of tumors demonstrated a much stronger inhibitory effect of the combination compared to both selumetinib alone and vehicle control,0.95
PMID:40723243,10.3390/cancers17142359,The Combination of HSP90 Inhibitors and Selumetinib Reinforces the Inhibitory Effects on Plexiform Neurofibromas.,DhhCre;Nf1f/f;Luciferase,animal_model,Safety,No significant toxicity reflected by body weight loss in any treatment cohort,Results,with no significant toxicity reflected by body weight loss,0.9
PMID:15240917,10.1155/S1110724304308107,Survival of Human Neurofibroma in Immunodeficient Mice and Initial Results of Therapy With Pirfenidone.,human neurofibroma xenografts,patient_derived_model,Efficacy,Survival rates ranged from 84.6% to 100% across various implantation locations without treatment over 6 weeks,Results,The survival of the neurofibroma xenografts in the various locations ranged from 84.6% to 100% ( Table 1 ).,0.95
PMID:15240917,10.1155/S1110724304308107,Survival of Human Neurofibroma in Immunodeficient Mice and Initial Results of Therapy With Pirfenidone.,human neurofibroma xenografts,patient_derived_model,Efficacy,"Subcutaneous implants had 77/91 survival rate, epineurium implants had 13/15 survival rate",Results,Subcutaneously implanted tumors had similar survival rates (77/91) as tumors implanted into epineurium of the sciatic nerve (13/15),0.95
PMID:15240917,10.1155/S1110724304308107,Survival of Human Neurofibroma in Immunodeficient Mice and Initial Results of Therapy With Pirfenidone.,human neurofibroma xenografts,patient_derived_model,Efficacy,Xenotransplants in ear remained stable in appearance and size for 12 months post-implantation (P = .41),Results,Neurofibroma xenotransplants in the ear were stable in appearance and size for twelve months postimplantation ( P = .41 Figure 1b ).,0.9
PMID:15240917,10.1155/S1110724304308107,Survival of Human Neurofibroma in Immunodeficient Mice and Initial Results of Therapy With Pirfenidone.,human neurofibroma xenografts,patient_derived_model,Efficacy,"Survival of neurofibromas was lower in pirfenidone-treated animals compared to controls, irrespective of implantation location",Results,"Survival of neurofibromas in animals treated with pirfenidone was lower than in control animals, irrespective of the location of implanted tumor",0.85
PMID:15240917,10.1155/S1110724304308107,Survival of Human Neurofibroma in Immunodeficient Mice and Initial Results of Therapy With Pirfenidone.,human neurofibroma xenografts,patient_derived_model,Biomarker,"Retained histologic characteristics of original tumors over 6 weeks, with no significant change in cellularity or collagen content except appearing more dense in 6-week-old implants",Results,"Over the 6 weeks of monitoring, human neurofibroma implants retained the histologic characteristics of the original tumors...No significant change in cellularity or collagen content was observed, except that tumors appeared more dense in 6-week-old implants",0.9
PMID:21963652,10.1016/j.expneurol.2011.09.005,PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice.,Nf1+/− GFAP CKO mice,animal_model,Biomarker,10% reduction in number of tyrosine hydroxylase (TH)-positive neurons innervating the striatum in vivo,Results,Our previous experiments using Nf1 CKO mice revealed a 10% reduction in the number of Nf1 +/− tyrosine hydroxylase (TH)-positive neurons innervating the striatum in vivo,0.95
PMID:21963652,10.1016/j.expneurol.2011.09.005,PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice.,Nf1+/− GFAP CKO mice,animal_model,Biomarker,50% decrease in neurite length in vitro,Results,"as well as a cell-autonomous 50% decrease in neurite length in vitro, suggesting a presynaptic defect",0.95
PMID:21963652,10.1016/j.expneurol.2011.09.005,PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice.,Nf1+/− GFAP CKO mice,animal_model,Biomarker,"10% reduction in expression of presynaptic VMAT2 and DAT transporters (p=.03, p=.0004; N=6)",Results,"we demonstrate a 10% reduction in the expression of presynaptic (VMAT2 and DAT) DA transporters, but normal expression of postsynaptic D1, D2, and D3 receptors",0.95
PMID:21963652,10.1016/j.expneurol.2011.09.005,PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice.,Nf1+/− GFAP CKO mice,animal_model,Biomarker,"Normal expression of postsynaptic D1, D2, and D3 receptors",Results,"but normal expression of postsynaptic D1, D2, and D3 receptors ( Fig. 1C–D ) (p=.03, p=.0004; N=6)",0.9
PMID:39415595,10.1242/dmm.050862,Generation of a zebrafish neurofibromatosis model via inducible knockout of nf2a/b.,Tg(U6x:nf2a/b-4sgRNA),genetic_reagent,Efficacy,All four gRNAs elicited mutations in vivo at 80-95% efficiency using T7 endonuclease assay,Results,we observed that all four gRNAs could elicit mutations in vivo at almost 80-95% efficiency,0.9
PMID:39415595,10.1242/dmm.050862,Generation of a zebrafish neurofibromatosis model via inducible knockout of nf2a/b.,Tg(U6x:nf2a/b-4sgRNA),genetic_reagent,Efficacy,CRISPR-Cas9-induced modifications observed in 70-95% of sequencing reads for nf2a and nf2b target regions,Results,We performed PCR sequencing for the nf2a and nf2b target regions and observed CRISPR-Cas9-induced modifications in 70-95% of the reads,0.9
PMID:25043591,10.1002/jbmr.2316,Combined MEK inhibition and BMP2 treatment promotes osteoblast differentiation and bone healing in Nf1Osx -/- mice.,Nf1flox/flox bone marrow stromal cells,cell_line,Biomarker,Ex vivo Nf1 ablation induced significant reduction in CFU-Ap and CFU-Ob colonies following 14 days of differentiation,Results,ex vivoNf1 ablation in Nf1 flox/flox BMSCs induces a significant reduction in the number of CFU-Ap and CFU-Ob colonies following 14 days of differentiation,0.9
PMID:23071067,10.1158/0008-5472.CAN-12-1728,Genetically mediated Nf1 loss in mice promotes diverse radiation-induced tumors modeling second malignant neoplasms.,Nf1+/- mice,animal_model,Safety,"High dose abdominal irradiation (15 and 30 Gy) reduced overall survival in a dose-dependent manner (log-rank test p<0.0001), with median survivals of 469 and 410 days respectively compared to 583 days for unirradiated controls",Results,"radiation-exposure reduced the overall survival of Nf1+/− mice in a dose-dependent manner (log-rank test p<0.0001, Figure 1B) at higher dose levels (15 and 30 Gy). The median survivals of Nf1+/− mice receiving 0, 3, 15, and 30 Gy were 583, 652, 469 and 410 days, respectively.",0.95
PMID:23071067,10.1158/0008-5472.CAN-12-1728,Genetically mediated Nf1 loss in mice promotes diverse radiation-induced tumors modeling second malignant neoplasms.,Nf1+/- mice,animal_model,Efficacy,"Tumor incidence increased with increasing radiation dose (p < 0.0001 by χ2 analysis), demonstrating enhanced radiation-induced tumorigenesis compared to wildtype mice",Results,"Tumors were more common in Nf1+/− mice than WT mice, and for Nf1+/− mice tumor incidence increased with increasing radiation dose (p < 0.0001 by χ2 analysis, Figure 2)",0.95
PMID:23071067,10.1158/0008-5472.CAN-12-1728,Genetically mediated Nf1 loss in mice promotes diverse radiation-induced tumors modeling second malignant neoplasms.,Nf1+/- mice,animal_model,Efficacy,"Sarcomas were significantly more common in irradiated Nf1+/- mice than irradiated wildtype mice (p = 0.0175, log-rank)",Results,"sarcomas are well recognized SMNs after high-dose radiation therapy (21–23), and were significantly more common in irradiated Nf1+/− mice than irradiated WT mice (p = 0.0175, log-rank)",0.95
PMID:23071067,10.1158/0008-5472.CAN-12-1728,Genetically mediated Nf1 loss in mice promotes diverse radiation-induced tumors modeling second malignant neoplasms.,Nf1+/- mice,animal_model,Safety,"Solid tumor free survival and hematologic disease free survival were both reduced in a dose-dependent manner (log rank test, p<0.0001 for solid tumor free survival and p=0.0001 for hematologic disease free survival)",Results,"solid tumor free survival and hematologic disease free survival were both reduced in a dose-dependent manner in Nf1+/− mice but not WT mice (Figure 3, log rank test, p<0.0001 for solid tumor free survival in Nf1+/− mice and p=0.0001 for hematologic disease free survival in Nf1+/− mice)",0.95
PMID:23071067,10.1158/0008-5472.CAN-12-1728,Genetically mediated Nf1 loss in mice promotes diverse radiation-induced tumors modeling second malignant neoplasms.,Nf1+/- mice,animal_model,Biomarker,Significantly increased mean terminal splenic weight compared to wildtype mice in unirradiated controls,Results,found significantly increased mean terminal splenic weight in unirradiated Nf1+/− mice as compared to WT mice (Supplementary Figure 2A),0.9
PMID:23071067,10.1158/0008-5472.CAN-12-1728,Genetically mediated Nf1 loss in mice promotes diverse radiation-induced tumors modeling second malignant neoplasms.,Nf1+/- mice,animal_model,Mechanistic,"Loss of heterozygosity was a common event in tumors, with LOH of Nf1 accompanied by LOH of at least one microsatellite in 87% of all tumors",Results,"Microsatellite and SNP sequencing analysis revealed that loss of heterozygosity was a common event in tumors isolated from Nf1+/− mutant mice (Figure 5), and the frequency of LOH at rs13481119 was similar across the three major classes of solid malignancies... LOH of Nf1 was accompanied by LOH of at least one of the microsatellites in 87% percent of all tumors",0.95
PMID:16835260,10.1093/hmg/ddl165,Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling.,Nf1+/- mice,animal_model,Efficacy,TGF-β and Nf1+/- MCCM mediated increased recruitment of Nf1+/- fibroblasts into matrigel plugs compared to WT mice,Results,"Consistent with in vitro studies, TGF-β and Nf1+/− MCCM mediates an increase in the recruitment of Nf1+/− fibroblasts into the matrigel plug.",0.85
PMID:16835260,10.1093/hmg/ddl165,Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling.,Nf1+/- mice,animal_model,Efficacy,Treatment with 6 μM imatinib mesylate daily for 1 week reduced fibroblast recruitment into matrigel plugs,Results,"Further, treatment of Nf1+/− mice with imatinib mesylate reduces this process.",0.8
PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,Neural stem cells,cell_line,Efficacy,"NF-1 knockout NSCs showed 1.8-fold greater NF-200-positive cells, 2.1-fold greater MAP2-positive cells, and 2.2-fold greater β3-Tubulin-positive cells compared to vector control",Results,"the counts of NF-200-, MAP2- and β3-Tubulin-positive cells in the SCI+LV-NF-1 NSC group were 1.8-, 2.1-, and 2.2-fold greater, respectively",0.9
PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,Neural stem cells,cell_line,Efficacy,GFAP-positive cells reduced to 28.3% in NF-1 knockout NSCs compared to vector control,Results,while the count of GFAP-positive cells was reduced to 28.3%,0.9
PMID:24817309,10.1371/journal.pone.0097320,Nf2/Merlin controls spinal cord neural progenitor function in a Rac1/ErbB2-dependent manner.,Nf2flox/flox mice,animal_model,Mechanistic,Primary embryonic spinal cord NPCs from Nf2flox/flox mice used for conditional Nf2 inactivation via adenoviral Cre delivery,Results,we chose to employ primary embryonic spinal cord (SC) NPC cultures from Nf2 floxed mice (Nf2flox/flox; [13]) in which merlin expression could be eliminated following adenoviral delivery of Cre recombinase,0.95
PMID:24817309,10.1371/journal.pone.0097320,Nf2/Merlin controls spinal cord neural progenitor function in a Rac1/ErbB2-dependent manner.,Nf2-deficient spinal cord neural progenitor cells,advanced_cellular_model,Mechanistic,"Showed 1.8-fold increase in neurosphere diameter, 3.6-fold increase in cell number, 1.7-fold increase in clonogenic expansion, and altered differentiation patterns",Results,Nf2 inactivation results in increased NPC growth (1.8-fold increase in neurosphere diameter...3.6-fold increase in cell number at day 8...1.7-fold increase in clonogenic expansion,0.95
PMID:40507334,10.3390/cancers17111852,Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs.,MCF7,cell_line,Mechanistic,"Used for PRIMAB validation in FFPE IHC format, showed disruption of pro-survival protein-BIM complexes when treated with specific BH3-mimetics",Results,"...untreated MCF-7 cells or those treated with BCL-2-targeting ABT-199/Venetoclax, BCL-XL-targeting A1155463, or MCL-1-targeting AZD5991 were prepared as FFPE slides, and the pro-survival protein–BIM complexes were stained using PRIMABs...",0.9
PMID:40507334,10.3390/cancers17111852,Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs.,MCF7,cell_line,Mechanistic,"BIM knockout resulted in fourfold reduction in HSMCB signal by flow cytometry, confirming BIM requirement for PRIMAB binding",Results,"...we fixed, permeabilized, and stained MCF7 wild type (WT) and BIM KO clone 2E9 cells with HSMCB and found a fourfold reduction in signal in the KO cell by flow cytometry...",0.95
PMID:26190969,10.3389/fncel.2015.00234,"In vivo synaptic transmission and morphology in mouse models of Tuberous sclerosis, Fragile X syndrome, Neurofibromatosis type 1, and Costello syndrome.",Nf1 (+/-),animal_model,Mechanistic,Some evidence that EPSP-AP coupling was stronger in the NF1 mice,Discussion,"We found some evidence that EPSP-AP coupling was stronger in the NF1 mice, but this was not observed in the CS mouse",0.7
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,S462TY,cell_line,Biomarker,Significant increase in ROS levels after 24h treatment with 10 μM FT895,Results,"Further analysis to determine the mean fluorescent intensity revealed a significant increase in ROS levels in S462TY, STS26T, and T265 cells",0.9
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,S462TY,cell_line,Biomarker,Significant reduction in mtDNA-CN levels based on both ND2 and ND4L genes after 24h exposure to 10 μM FT895,Results,"Following a 24 h exposure to 10 μM FT895, the levels of mtDNA-CN based on both ND2 and ND4L genes exhibited a significant reduction in all four different MPNST cells",0.9
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,S462TY,cell_line,Mechanistic,"Reduced activities of mitochondrial respiration and no reaction to ATP synthase inhibitor, oxidative phosphorylation uncoupler, and complex I/III inhibitors after 24h FT895 treatment",Results,"kinetic measurements showed the reduced activities of mitochondrial respiration when FT895 was administered to S462TY, T265, and ST8814 cell lines...Furthermore, S462TY and T265 displayed no reaction to the treatment",0.9
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,S462TY,cell_line,Mechanistic,"Significant decrease in basal respiration, maximal respiration, and ATP-production-coupled respiration compared to DMSO group",Results,"the FT895 group exhibited a significant decrease in basal respiration, maximal respiration, and ATP-production-coupled respiration in four cell lines",0.9
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,S462TY,cell_line,Mechanistic,6-hour exposure to 10 and 20 μM FT895 suppressed mitochondrial respiration in dose-dependent manner with significant reductions in basal and maximal respiration,Results,"A six-hour exposure to 10 and 20 μM FT895 suppressed mitochondrial respiration in a dose-dependent manner, resulting in significant reductions in both basal and maximal respiration",0.9
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,S462TY,cell_line,Mechanistic,Upward shift in side scatter (SSC) indicating increase in cellular granularity after FT895 treatment,Results,"we observed an upward shift in side scatter (SSC), particularly in S462TY cells, indicating an increase in cellular granularity",0.9
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,S462TY,cell_line,Mechanistic,Decrease in PINK1 and Parkin protein levels following FT895 treatment,Results,"Our experiment revealed a decrease in PINK1 and Parkin protein levels in S462TY, STS26T, T265, and STS8814 cells following FT895 treatment",0.9
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,S462TY,cell_line,Mechanistic,Decrease in XBP1s level after FT895 treatment while XBP1u level remained constant,Results,"The results revealed a constant XBP1u level in MPNST cells and a decrease in the XBP1s level in S462TY, T265, and ST8814 cells after FT895 treatment",0.9
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,S462TY,cell_line,Mechanistic,"XBP1s-mediated transcriptional activities for MPV17L2, POLG, TFAM, PINK1, and Parkin notably decreased after FT895 treatment",Results,"the XBP1s-mediated transcriptional activities for MPV17L2, POLG, TFAM, PINK1, and Parkin notably decreased in S462TY, STS26T, and T265 cells after FT895 treatment",0.9
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,S462TY,cell_line,Biomarker,"Significantly decreased mRNA expression levels of Parkin, PINK1, POLG, MPV17L2, and PGC1α after FT895 treatment",Results,"The levels of Parkin, PINK1, POLG, and MPV17L2 were significantly decreased in all four MPNST cell lines...albeit a significant decrease in the levels in S462TY and STS26T cells",0.9
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,S462TY,cell_line,Biomarker,Increased GLUT1 mRNA and protein expression after FT895 treatment,Results,"Further investigation of the mRNA expression of GLUT1 in MPNST cells showed increased expression in S462TY, T265, and ST8814...The changes in GLUT1 protein levels in MPNST cells were consistent with the mRNA expression",0.9
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,STS26T,cell_line,Biomarker,Significant increase in ROS levels after 24h treatment with 10 μM FT895,Results,"Further analysis to determine the mean fluorescent intensity revealed a significant increase in ROS levels in S462TY, STS26T, and T265 cells",0.9
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,STS26T,cell_line,Biomarker,Significant reduction in mtDNA-CN levels based on both ND2 and ND4L genes after 24h exposure to 10 μM FT895,Results,"Following a 24 h exposure to 10 μM FT895, the levels of mtDNA-CN based on both ND2 and ND4L genes exhibited a significant reduction in all four different MPNST cells",0.9
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,STS26T,cell_line,Mechanistic,"Modest alteration in mitochondrial respiration activities and partial response to ATP synthase inhibitor, oxidative phosphorylation uncoupler, and complex I/III inhibitors",Results,while STS26T showed a modest alteration...whereas STS26T and ST8814 exhibited only a partial response,0.9
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,STS26T,cell_line,Mechanistic,Became more energetically active based on extracellular acidification (ECAR) measurements after FT895 treatment,Results,"we noted that FT895 induced a relatively less active state in S462TY and T265 cells, whereas STS26T cells became more energetically active",0.9
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,T265,cell_line,Biomarker,Significant increase in ROS levels after 24h treatment with 10 μM FT895,Results,"Further analysis to determine the mean fluorescent intensity revealed a significant increase in ROS levels in S462TY, STS26T, and T265 cells",0.9
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,T265,cell_line,Biomarker,Significant reduction in mtDNA-CN levels based on both ND2 and ND4L genes after 24h exposure to 10 μM FT895,Results,"Following a 24 h exposure to 10 μM FT895, the levels of mtDNA-CN based on both ND2 and ND4L genes exhibited a significant reduction in all four different MPNST cells",0.9
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,T265,cell_line,Mechanistic,"Reduced activities of mitochondrial respiration and no reaction to ATP synthase inhibitor, oxidative phosphorylation uncoupler, and complex I/III inhibitors after 24h FT895 treatment",Results,"kinetic measurements showed the reduced activities of mitochondrial respiration when FT895 was administered to S462TY, T265, and ST8814 cell lines...Furthermore, S462TY and T265 displayed no reaction to the treatment",0.9
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,T265,cell_line,Biomarker,Increased GLUT1 mRNA and protein expression after FT895 treatment,Results,"Further investigation of the mRNA expression of GLUT1 in MPNST cells showed increased expression in S462TY, T265, and ST8814",0.9
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,ST8814,cell_line,Biomarker,Modest elevation of ROS after 24h treatment with 10 μM FT895,Results,while a modest elevation of ROS in ST8814 cells after treatment,0.9
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,ST8814,cell_line,Biomarker,Significant reduction in mtDNA-CN levels based on both ND2 and ND4L genes after 24h exposure to 10 μM FT895,Results,"Following a 24 h exposure to 10 μM FT895, the levels of mtDNA-CN based on both ND2 and ND4L genes exhibited a significant reduction in all four different MPNST cells",0.9
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,ST8814,cell_line,Mechanistic,Showed preference for glycolytic pathway as energy source following FT895 treatment,Results,"Furthermore, STS8814 cells appeared to show a preference for the glycolytic pathway as their energy source following FT895 treatment",0.9
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,ST8814,cell_line,Biomarker,Increased GLUT1 mRNA and protein expression after FT895 treatment,Results,"Further investigation of the mRNA expression of GLUT1 in MPNST cells showed increased expression in S462TY, T265, and ST8814",0.9
PMID:32948135,10.1186/s12885-020-07397-w,Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model.,S462,cell_line,Efficacy,Most responsive MPNST cell line to 3-BrPA treatment with significant viability reduction at 20-120 μM (p ≤ 0.031),Results,S462 cells were most responsive... viability decreases of S462 cells were significant in an agent concentration range of 20 to 120 μM (p ≤ 0.031),0.95
PMID:32948135,10.1186/s12885-020-07397-w,Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model.,S462,cell_line,Biomarker,Showed highest Ki67 expression (nearly 100%) and p53 expression (about 80%) among MPNST cell lines,Results,MPNST showed a moderate to high labelling for Ki67 (highest in S462 with nearly 100%) and for p53 (highest in S462 with about 80%),0.95
PMID:32948135,10.1186/s12885-020-07397-w,Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model.,S462,cell_line,Efficacy,"Under starvation conditions, showed significant viability reduction with 3-BrPA at 0-20 μM range (p = 0.029)",Results,significant differences in a range of 20 to 80 μM: 0 to 20 μM in S462 cells (p = 0.029),0.92
PMID:32948135,10.1186/s12885-020-07397-w,Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model.,NSF1,cell_line,Efficacy,Showed significant viability reduction at 40-120 μM 3-BrPA concentration range (p ≤ 0.017),Results,The corresponding concentration range for the NSF1 cells was 40 to 120 μM (p ≤ 0.017),0.95
PMID:32948135,10.1186/s12885-020-07397-w,Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model.,NSF1,cell_line,Efficacy,"Under starvation, showed enhanced dose response with significant differences at 0-40 μM range (p ≤ 0.015) and slope change from -40.3%/10 μM to -12.6%/10 μM",Results,0 to 40 μM in NSF1 cells (p ≤ 0.015)... slopes of the regression lines for the cell line NSF1 without and NSF1* with starvation were quite different: − 40.3%/10 μM versus − 12.6%/10 μM,0.93
PMID:32948135,10.1186/s12885-020-07397-w,Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model.,T265,cell_line,Efficacy,Showed no significant decreases in viability with 3-BrPA treatment (p ≥ 0.605),Results,We found no significant decreases in the viability of T265 cells (p ≥ 0.605),0.95
PMID:32948135,10.1186/s12885-020-07397-w,Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model.,T265,cell_line,Efficacy,"Under starvation conditions, showed significant viability reduction with 3-BrPA at 0-80 μM range (p ≤ 0.029)",Results,significant differences in a range of 20 to 80 μM... 0 to 80 μM in T265 cells (p ≤ 0.029),0.92
PMID:32948135,10.1186/s12885-020-07397-w,Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model.,B8 fibroblasts,cell_line,Efficacy,"PA28γ overexpressing B8γ cells showed partial resistance to 3-BrPA treatment, with viability reduction only at concentrations >80 μM",Results,B8γ cells treated with 3-BrPA displayed a reduction of viability only at higher concentrations > 80 μM... PA28y overexpressing cells are partially resistant to 3-BrPA treatment,0.93
PMID:32948135,10.1186/s12885-020-07397-w,Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model.,B8 fibroblasts,cell_line,Mechanistic,PA28γ overexpressing cells showed higher NADH dehydrogenase activity and less sensitivity to 3-BrPA treatment compared to controls,Results,NADH dehydrogenase activity in untreated B8y cells was higher compared to controls... differences indicating that PA28 overexpression is associated with a higher enzyme activity and less sensitivity to treatment,0.88
PMID:32948135,10.1186/s12885-020-07397-w,Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model.,B8 fibroblasts,cell_line,Mechanistic,Control B8vc cells showed significant viability reduction at 100-120 μM 3-BrPA (p = 0.003) and much higher ROS reduction at 80-120 μM (p ≤ 0.036),Results,Viability of control B8vc cells was reduced significantly and pronounced at 100 and 120 μM of 3-BrPA probably indicating higher cytotoxicity (p = 0.003)... p values were ≤ 0.036 in the concentration range of 80 to 120 μM,0.94
PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",STS26T,cell_line,Efficacy,Relatively resistant to MEK inhibition with high IC50s and treatment failing to achieve maximal efficacy,Results,both 26T and S462 cells were relatively resistant to MEK inhibition with high IC50s and treatment failing to achieve maximal efficacy,0.85
PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",STS26T,cell_line,Efficacy,Low dose combination of mirdametinib with palbociclib yielded highly synergistic anti-proliferative activity,Results,low dose combination of mirdametinib with palbociclib yielded highly synergistic anti-proliferative activity,0.9
PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",STS26T,cell_line,Efficacy,Combination therapy significantly increased cell death and senescence relative to vehicle or either monotherapy,Results,Combination therapy significantly increased MPNST cell death and senescence in both 26T and S462 cells relative to vehicle or either monotherapy,0.9
PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",STS26T,cell_line,Efficacy,Combination therapy greatly reduced clonogenic survival compared to each drug alone,Results,combination therapy greatly reduced MPNST cell clonogenic survival compared to each drug alone,0.9
PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",S462,cell_line,Efficacy,Relatively resistant to MEK inhibition with high IC50s and treatment failing to achieve maximal efficacy,Results,both 26T and S462 cells were relatively resistant to MEK inhibition with high IC50s and treatment failing to achieve maximal efficacy,0.85
PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",S462,cell_line,Efficacy,Low dose combination of mirdametinib with palbociclib yielded highly synergistic anti-proliferative activity,Results,low dose combination of mirdametinib with palbociclib yielded highly synergistic anti-proliferative activity,0.9
PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",S462,cell_line,Efficacy,Combination therapy significantly increased cell death and senescence relative to vehicle or either monotherapy,Results,Combination therapy significantly increased MPNST cell death and senescence in both 26T and S462 cells relative to vehicle or either monotherapy,0.9
PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",S462,cell_line,Efficacy,Daily oral therapy with palbociclib plus mirdametinib significantly slowed tumor growth in orthotopic xenografts compared to vehicle or either monotherapy,Results,Daily oral therapy with palbociclib plus mirdametinib significantly slowed tumor growth compared to vehicle or either monotherapy,0.9
PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,ST88-14,cell_line,Efficacy,APX3330 treatment resulted in 40-50% decrease in cell migration in wound closure assay,Results,Wound closure assay indicated a 40–50% decrease in migration in ST88-14 and S462 cells after treatment with APX3330,0.95
PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,S462,cell_line,Efficacy,APX3330 treatment resulted in 40-50% decrease in cell migration in wound closure assay,Results,Wound closure assay indicated a 40–50% decrease in migration in ST88-14 and S462 cells after treatment with APX3330,0.95
PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,NF90-8,cell_line,Biomarker,17-300-fold increase in Y705 phosphorylation in response to IL-6 stimulation,Results,"NF90-8, ST88-14 and RHT-92 all responded to IL-6 stimulation as seen by the 17–300-fold increase in Y705 phosphorylation",0.95
PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,ST88-14,cell_line,Biomarker,17-300-fold increase in Y705 phosphorylation in response to IL-6 stimulation,Results,"NF90-8, ST88-14 and RHT-92 all responded to IL-6 stimulation as seen by the 17–300-fold increase in Y705 phosphorylation",0.95
PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,RHT-92,cell_line,Biomarker,17-300-fold increase in Y705 phosphorylation in response to IL-6 stimulation,Results,"NF90-8, ST88-14 and RHT-92 all responded to IL-6 stimulation as seen by the 17–300-fold increase in Y705 phosphorylation",0.95
PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,S462,cell_line,Biomarker,Did not activate STAT3 in response to IL-6 and had lower levels of total STAT3 compared to ST88-14 and NF90-8 cells,Results,"However, S462 cells did not activate STAT3 in response to IL-6 and had lower levels of total STAT3 in comparison to ST88-14 and NF90-8 cells",0.95
PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,Nf1-Arf flox/flox ;Postn-Cre,animal_model,Biomarker,"Malignant transformation was associated with significant upregulation of p-STAT3 and Ref-1, with p-STAT3 increase correlating with disease progression",Results,malignant transformation of plexiform neurofibroma and ANNUBP precursor tumours to MPNST was associated with significant upregulation of p-STAT3 and Ref-1...The increase in expression of p-STAT3 appeared to correlate with disease progression,0.95
PMID:33085177,10.1002/mgg3.1530,The development of the PlexiQoL: A patient-reported outcome measure for adults with neurofibromatosis type 1-associated plexiform neurofibromas.,PlexiQoL,clinical_assessment_tool,Behavioral,"Completion time ranged from 2 to 7 minutes (mean = 4.4, SD = 1.3)",Results,"The time taken to complete the PlexiQoL ranged from 2 to 7 (mean =4.4, SD =1.3) minutes.",0.95
PMID:33085177,10.1002/mgg3.1530,The development of the PlexiQoL: A patient-reported outcome measure for adults with neurofibromatosis type 1-associated plexiform neurofibromas.,PlexiQoL,clinical_assessment_tool,Other,Internal reliability was good with Person-Separation Index (PSI) = 0.84,Results,All items fit the Rasch model and internal reliability was good (PSI = 0.84).,0.95
PMID:33085177,10.1002/mgg3.1530,The development of the PlexiQoL: A patient-reported outcome measure for adults with neurofibromatosis type 1-associated plexiform neurofibromas.,PlexiQoL,clinical_assessment_tool,Other,Cronbach's α coefficients were 0.90 at both time points,Results,"Cronbach's α coefficients for the PlexiQoL were 0.90 at both time points, confirming that the items had a good level of association.",0.95
PMID:33085177,10.1002/mgg3.1530,The development of the PlexiQoL: A patient-reported outcome measure for adults with neurofibromatosis type 1-associated plexiform neurofibromas.,PlexiQoL,clinical_assessment_tool,Other,"Test-retest reliability was 0.90, demonstrating excellent reproducibility",Results,"Test‐retest reliability was 0.90, demonstrating excellent reproducibility, indicating that the PlexiQoL produces low levels of measurement error.",0.95
PMID:33085177,10.1002/mgg3.1530,The development of the PlexiQoL: A patient-reported outcome measure for adults with neurofibromatosis type 1-associated plexiform neurofibromas.,PlexiQoL,clinical_assessment_tool,Behavioral,97.4% of respondents obtained valid scores on the measure,Discussion,The PlexiQoL has a wide measurement range with 97.4% of respondents obtaining valid scores on the measure.,0.95
PMID:33085177,10.1002/mgg3.1530,The development of the PlexiQoL: A patient-reported outcome measure for adults with neurofibromatosis type 1-associated plexiform neurofibromas.,PlexiQoL,clinical_assessment_tool,Other,"Minimal floor and ceiling effects found (7.3% scoring minimum, 2.1% scoring maximum at Time 1)",Results,"In contrast, minimal floor and ceiling effects were found for the PlexiQoL.",0.9
